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ABSTRACT
Prostate cancer (PCa) has become a major public health issue; it is the second 
most common cause of cancer-related death in the UK. PCa preferentially 
metastasises to the bone. Semaphorins are an important family of membrane 
bound or secreted signalling proteins, which control cell movement (or 
chemotaxis). They have a role in the nervous, immune and vascular systems, but 
have not previously been studied in prostate. To determine if semaphorins and 
their receptors are expressed in normal and pathological prostate, profiling 
experiments were performed by (q)RT-PCR in prostate cell lines and tissues. 
Results show that semaphorins and receptors are ubiquitously expressed, 
suggesting autocrine and paracrine regulation of semaphorin signalling in 
prostate; particularly an autocrine signalling of Semaphorin3A in bone metastasis 
derived cells. Results also show that expression of secreted semaphorins is 
regulated by hypoxia; which strongly downregulates semaphorin 3e in primary 
tum our derived cells, whereas semaphorin 3c is strongly upregulated. Particular 
focus was brought on semaphorin 3e, whose expression is strongly increased in 
epithelial cells derived from benign prostate hyperplasia, non-neoplastic tissue, 
and bone metastasis derived cells. A Semaphorin3E expression construct was 
made and the protein produced in mammalian cells to study its effects on cell 
morphology and adhesion by im mu nocytochemistry and adhesion assays. Results 
show that Semaphorin3E inhibits integrin-mediated cell adhesion while it initiates 
vinculin-mediated focal adhesion formation, which suggest that Semaphorin3E 
may play important regulatory roles in prostate cancer metastasis. The effects on 
cell movement o f frequent missense mutations of PlexinBl receptor, associated 
with prostate primary tumours and metastases, was studied by migration assays. 
Results show that the three mutations of PlexinBl increase cell migration in 
absence of ligand Semaphorin4D, and further increase migration in its presence. 
Together these results suggest that semaphorin signalling has a key role in 
prostate cancer progression.
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INTRODUCTION
The following thesis is divided into four chapters: (1 )  literature review, (2 )  
materials and methods, (3 )  results and discussions, (4 )  conclusion and future 
work.
(1 )  The 'literature review' chapter comprises three sections, (a )  The prostate and 
its pathologies, with emphasis on prostate adenocarcinoma, the second most 
common cause of death due to cancer in the UK. (b ) The theories of cancer 
progression, summarising the molecular-based theory of cancer, which describes 
nine cancer gene pathways, eventually all leading to activation of the 
hypoxia/HIFl pathway, which promotes angiogenesis and survival of the cancer 
cells, (c ) The sema domain containing superfamily describes three family 
members with common and specific features, details the HGF and MET, and 
Semaphorin4D and PlexinBl signalling pathways, and summarise their roles in 
cell guidance and migration, invasive growth, and tumour angiogenesis.
(2 )  The 'materials and methods' chapter is divided into two sections, (a )  
materials and (b ) methods.
(3 )  The 'results and discussions' chapter contains three sections, (a )  The first 
section resumes the results of expression profiling experiments under normoxic 
and hypoxic conditions in 10 prostate cell lines. Results show that semaphorins 
and their receptors are largely expressed in prostate cell lines, and that the 
expression of secreted semaphorins is strongly regulated by hypoxia, (b ) The 
second section summarises the study of three mutations of PlexinBl receptor, 
associated with prostate tumours and metastases. The mutations modulate cell 
migration in presence or absence of Semaphorin4D ligand, (c ) The last section 
describes the production of Semaphorin3E protein and its effects on cell 
phenotype and behaviour. Semaphorin3E inhibits pl-integrin-mediated cell 
adhesion and initiates vinculin-mediated cell m otility, spreading.
(4 )  Finally, the 'conclusions and future work' chapter summarises all findings and 
suggests further studies.
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P14ARF: pl6INK4
pl6INK4A: cyclin-dependent kinase inhibitor 2A
p27KIPl: cyclin-dependent kinase inhibitor IB
p53: tumour protein 53
PAGE: polyacrylamide gel
PAK: p21-activated kinase
PBS: phosphate buffer
PCa: prostate cancer
PI3K: phosphoinositlde 3 kinase
PIN: prostate intraepithelial neoplasia
PLC-y: phospholipase C-gamma
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Plx: Plexin
PNS: peripheral nervous system
POT1: protection of telomere 1 homolog
pRB: retinoblastoma protein
PRGF: plasminogen-related growth factor
P5I: domain found in plexlns, semaphorin
and Integrins
pT: tumour stage
PTB: phosphotyrosine binding
PTEN: phosphate and tensin homolog
PYK2: proline-rich tyrosine kinase 2
R: recurrence
RNA: ribonucleic acid
Rndl: Rho family GTPase 1
RON: macrophage stimulating 1 receptor
rpm: rotation per minute
RTK: receptor tyrosine kinase
S: serine
SDS: sodium dodecyl sulfate 
SEM: standard error of the mean 
Sema: semaphorin domain 
Sema3: semaphorin class 3 
Semaphorin 3e: gene 
Semaphorin3E: protein 
SemaH: Semaphorin3E 
SF: scatter factor
SH2/SH3: Src-homolgy 2 and 3 domains 
She: (Src homology 2 domain containing) 
transforming protein
SHP2: Src homology 2-containing tyrosine 
phosphatase
SMT: somatic mutation theory
SP: sex and plexin domain
Src: v-src sarcoma viral oncogene homolog
STAT: signal transducer and activator of
transcription
TCF4: Transcription factor 4 
TEMED: N,N,N',N'-tetramethylenediamine 
TGFp: transforming growth facto beta 
TIN2: TRFl-interacting nuclear factor 2 
TNFa: tumour necrosis factor alpha 
TNFR-1: tumour necrosis factor receptor 1 
TOFT: tissue organization theory 
tPA: plasminogen activator, tissue 
TPP1: tripeptidyl peptidase telomere 
TRF1/2: telomeric repeat binding factor Vi 
TRITC: tetramethyl rhodamine iso- 
thyociante
TSP-1: thrombospondin 1
UK: united kingdom
uPA: plasminogen activator, urokinase
UTR: untranslated region
VEGF: vascular endothelial growth factor
VEGFR: vascular endothelial growth factor
receptor
VSV: vesicular somatitis virus 
WT: wild type 
Y: tyrosine
REMARKS:
Names of genes are written in lower 
case: plexin b l, semaphorin 3e
Names of proteins are written in caps:
PlexinBl, Semaphorin3E
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Expression, regulation and roles of 
semaphorins and their receptors in prostate 
and prostate cancer
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CHAPTER 1: LITERATURE REVIEW
Section 1: The Prostate and its pathologies
1. Role and s tru c tu re  o f th e  p rostate
Prostate is a gland of the male reproductive system that makes and stores 
seminal fluid, which nourishes sperm. The gland has the size of a walnut, and is 
located below the bladder and in front of the rectum (Figure 1). I t  surrounds the 
upper part of the urethra that empties urine from the bladder. The prostate gland 
is made of acini and ducts and comprises three anatomical zones: the peripheral 
zone, the transition zone, and the central zone (McNeal, 1981a). The peripheral 
zone, approximately 65% of the prostate volume, is characterised by small, 
simple, acinar spaces lined by tall columnar secretory epithelial cells. The central 
zone, approximately 25% of normal prostatic volume, is made of large acini with 
irregular contours tha t are lined by low columnar cuboidal epithelium. This central 
zone surrounds the ejaculatory ducts. The transition zone, 5 to 10% of the 
prostate volume, is separated from the other two zones by a narrow band of 
fibromuscular stroma. The ducts of this transition zone empty bilaterally into the 
urethra.
2. Patho log ies o f th e  p rostate
The three most common problems occurring in the prostate are inflammation 
(prostatitis), enlargement (BPH), and cancer (PCa). The symptoms of an 
unhealthy prostate (a simple inflammation, a BPH or a cancer) are a need to 
urinate frequently, especially at night; difficulty starting urination or holding back
111 adder
Urethra
Vas defer ens
Testicle
Figure 1 : Anatom y of th e  m ale reproductive system  (p icture from
). The prostateh ttp ://w w w .liv .a c .
gland is located below the bladder and in front o f the rectum.
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urine; inability to urinate; weak or interrupted flow of urine; painful or burning 
urination, and difficulty in having an erection; painful ejaculation; blood in urine 
or semen or frequent pain and stiffness in the lower back, hips, or upper thighs. 
Prostatitis is an inflammation of the prostate gland that may or may not be 
caused by an acute or recurrent infection. Benign prostatic hyperplasia (BPH) is 
an abnormal growth of normal prostate cells ending in an enlargement of the 
gland, squeezing the urethra, which may gradually lead to bladder and/or kidney 
damage. BPH is not cancerous and does not increase the risk of prostate cancer. 
Prostate cancers are classical adenocarcinomas, made up of epithelial cells with 
varying degrees of glandular architecture. High grade prostate intraepithelial 
neoplasia (PIN) is considered the precursor of a majority of invasive prostate 
adenocarcinomas (Haggman et al., 1997). BPH and PCa have different origins 
within the gland, the peripheral zone is the most frequent site of cancer and the 
transition zone is the almost exclusive site of BPH (McNeal, 1981b; Colombo et 
al., 2001).
3. Prostate cancer: risk factors, treatm ents, staging and grading
Prostate cancer has become a major public health issue. I t  is the third 
commonest cancer in men worldwide and the most common non-cutaneous 
malignancy in the United States. In the UK, 32.000 cases of prostate cancer are 
diagnosed per year and 10.000 men die from PCa each year. Prostate cancer is 
the second commonest cause of death due to cancer in the UK, after lung cancer. 
(Cancer Research UK website: http://info.cancerresearchuk.orQ/cancerstats). The 
risk factors commonly associated with prostate cancer are an age over 50, a 
family history of prostate cancer, the ethnicity (more frequent in African than 
white Americans, and the diet (Hsing and Devesa, 2001). A diet high in animal fat 
may increase the risk of prostate cancer, whereas a diet high in fru it and 
vegetables may decrease the risk. The treatments available for early stage 
prostate cancer patients are radical prostatectomy, radiotherapy or watchful 
waiting. For late stage prostate cancer, i.e. PCa that has started invading other 
organs (metastases), the treatments available are androgen ablation therapy and 
chemotherapy. The majority of advanced stage PCa patients have developed bone 
lesions, causing morbidity (Jacobs, 1983; Lange and Vessela, 1998). Localised 
prostate cancer detected at an early stage is curable, whereas treatments for 
advanced prostate cancer are not curative.
An accurate assessment of the clinical stage and grade of prostate tumours is 
crucial for patients outcome. The stage refers to the extent and spread of the
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disease, while the grade refers to the nature (aggressiveness) of the particular 
tumour (table 1). The currently used TNM staging system (UICC 1997) for 
prostate cancer is based on the old system proposed by Schroder in 1992 
(Schroder et al., 1992). There are 4 different stages of prostate cancer, pT l 
(organ confined, not palpable), pT2 (organ confined, palpable), pT3 
(extracapsular spread), and pT4 (local organs invaded). The presence of regional 
lymph nodes (N) and distant metastases (M) are also assessed. The grading 
system currently used for prostate cancer had first been proposed in 1966 by 
Donald F. Gleason, hence its name (Gleason, 1966). The Gleason score (GSC) is a 
pathologic classification only, based on the premise that poorly differentiated 
tumours are more aggressive and unpredictable than well-differentiated tumours. 
Pathologists look fo r a primary predominant pattern, and a secondary or lesser 
pattern (Gleason grades), and each is given a score from 1 to 5. Scores for 
primary and secondary patterns are added together to achieve the Gleason score 
for the tumour. Scores can range from 2 (uniformly well differentiated 1 + 1) to 10 
(diffusely anaplastic 5+5). The higher the Gleason score, the more aggressive is 
the tum our and the worse is the prognosis (Gleason, 1992).
■
PT2 Organ confined MX Presence of distant metastases cannot be]
T2a Unilateral assessed 1
T2b Bilateral MO No distant metastases
PT3 Extra prostatic extension Ml Distant metastases
T3a Extraprostatic extension Mia Non regional lymph nodes metastases
T3b Seminal vesicle invasion Mlb Bone metastases
pT4 Invasion of bladder, and rectum Mlc Other sites metastases■ ■■ ■
NX Regional lymph nodes cannot 2-4 2.1% risk of developing metastases
be assessed 5.4% risk of developing metastases
NO No regional lymph nodes 4-5 13.5% risk of developing metastases
N1 Metastasis in regional lymph 7-10 More aggressive neoplasms with seminal
1 nodes | vesicles extension, and/or metastases spread |
Table 1 : Staging and grading o f prostate tumours. The stage o f the tum our (pT) refers to  the  e x te n t and spread 
o f the disease, w hile the grade refers to the nature (aggressiveness) o f the  pa rticu lar tum our. The presence o f 
regional lym ph nodes (N ) and d is tan t metastases (M) is also assessed.
4. Molecular biology and genetics of prostate cancer
Prostate cancer develops from a lesion in the epithelial layer of the peripheral 
zone of the gland to become an invasive tumour that spreads within the prostate
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and subsequently acquires the potential to metastasise to distant sites, most 
often the lymph node and bone. The molecular biology of PCa and its progression 
is characterised by aberrant activity of several regulatory pathways (for a review 
see Quinn et al, 2005), which can be grouped broadly into androgen receptor 
signalling (AR mutation and/or amplification), signal transduction (family of EGF 
receptors), cell cycle regulation (c-Myc amplification, increased p l6 INK4A, 
decreased p27KIP1, decrease or loss of pRb, increased proliferation index), 
apoptosis (increased apoptotic index, p53 and Bcl-2), cell adhesion and cohesion 
(reduced E-cadherin and catenins, increased metalloproteinases and chondroitin 
sulphate), and angiogenesis (increased VEGF, VEGF receptors, nitric oxid).
Moreover, chromosomal alterations are commonly observed in PCa, and the 
characteristic patterns of chromosome abnormalities can be considered as 
indicative of stages of PCa progression (for a review see Bova and Isaacs, 1996; 
Bate-Shen and Shen, 2000). Prostate cancer lesions are heterogeneous and of 
multifocal nature. Allelic losses on chromosomes 1, 3, 7q, 8p, lOq, 11, 13q, 16q, 
17q, and 18q have been commonly reported. Despite their significance for 
prostate carcinogenesis, no single candidate tumour suppressor gene has been 
definitely assigned a role in cancer progression. Several candidate have been 
implicated, such as proteins RB, p53, PTEN, NKX3.1, KLF6 (Narla et al., 2001), 
and ETS transcription factors (ERG and ETV1) (Tomlins et al., 2005). However, 
none of these has been shown to be mutated in a large percentage of prostate 
cancer specimens and reports are conflicting. In addition, although chromosome 
gains appear to be less frequent than chromosome losses, gains at 3, 8q and 7 
have been reported (Sattler et al., 1999; Alcaraz et al., 1994; Bandyk et al., 
1994; Van Den Berg et al., 1995).
______________ Section 2: T h eo ries  o f can cer progression______________
For the last 50 years, the prevailing explanatory theory for cancer 
transformation has been the somatic mutation theory (SMT), which is a 
molecular-based theory, i.e. a reductionist theory according to which all complex 
cancer phenomena can be reduced to simple molecular events (Curtis HJ., 1965). 
The premise of the molecular-based theory (SMT) is that the default state of all 
cells is quiescence (GO state). The somatic mutation or molecular-based theory of 
cancer defines cancer as a genetic disease of cell proliferation. Tumourigenesis is 
a long multistep process. Each step reflecting a genetic alteration that confers a 
growth advantage to the cell (each step defines a premalignant state). Only when
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a cell has accumulated 4 to 6 genetic alterations (at the minimum) does it 
develop into an invasive cancer (for reviews see Renan, 1993; Tomlinson et al, 
1996; Boland et al., 1999). Another less "in-vogue" and indeed very controversial 
theory (Blagosklonny, 2005) is the original tissue-organisation-field theory 
(TOFT), or tissue-based theory (Soto and Sonneschein, 2005). This theory was 
first suggested at the end of the 19th century by Boll, Conheim, and Ribbert, and 
was subsequently forgotten after the introduction of molecular biology tools. The 
premise of this tissue-based theory is that the default state of all cells is 
proliferation. The tissue-based theory of cancer defines cancer as a problem of 
tissue organisation and communication. Cancer probably arise from a combination 
of both molecular-based mutations and tissue-miscommunications.
In the following chapter, the molecular based theory will be discussed in details 
as most points described here will be referred to in the results and discussions 
chapter.
1. Genetic alterations
a. Oncogenes, tum our suppressor genes and stability genes
The genetic alterations encountered in a cancer cell occur within three 
categories of genes, oncogenes, tumour suppressor genes and stability genes. 
Oncogenes are genes that become constitutively active when they are mutated, 
or active under conditions in which the wild type gene is not. Oncogene activation 
can result from chromosomal translocations, gene amplifications, or subtle 
intragenic mutations affecting crucial residues (regulating the activity of the gene 
product). An activating somatic mutation in one allele of an oncogene is generally 
sufficient to confer a selective growth advantage to the cell bearing it. There are 
more than a hundred oncogenes identified, and they all show a dominant gain-of- 
function mutation. Tumour suppressor genes are genes that show a reduced 
activity when they are mutated. Tumour suppressor gene inactivation can result 
from missense mutations at crucial residues (regulating the activity of the gene 
product), mutations resulting in a truncated protein, deletions or insertions, or 
epigenetic silencing. Mutations in both the maternal and paternal alleles of a 
tumour suppressor gene are generally required to confer a selective advantage to 
the cell. There are more than 30 tumour suppressor genes identified, and they all 
show a recessive loss-of-function mutation. Stability genes are genes involved in 
DNA repair (MMR mismatch repair, NER nucleotide excision repair, and BER base 
excision repair), m itotic recombination, and chromosomal segregation. When they
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are mutated, on both alleles, they become inactivated and mutations in other 
genes (oncogenes, tumour suppressor genes) occur at higher rates. Inactivation 
of stability genes therefore increase genetic instability, which is a tra it found in 
many cancer cells.
b. The nine cancer gene pathways
Interestingly, most cancer-associated mutations are affecting a few limited 
number of cellular regulatory pathways, or cancer gene pathways. Within each 
cancer gene pathway the same exclusivity principle applies. Namely, one and only 
one gene is generally mutated per cancer pathway in any single tumour, as if 
mutating any of the genes of the pathway had similar functional effects and 
therefore gives no selective advantage (for a review see Vogelstein and Kinzler,
2004). Nine cancer gene pathways have thus been described (figure 2). The 
retinoblastoma protein (RB) and p53 tumour suppressor protein (P53) pathways 
are intertwined and regulate cell cycle progression/arrest. The apoptosis pathway 
controls programmed cell death. The receptor tyrosine kinase (RTK) and SMAD 
pathways are mitogenic signalling pathways, which transduce growth factors 
signals into transcriptional activation of genes mainly involved in cell 
growth/proliferation. The phosphoinositide 3 kinase (PI3K) pathway is the 
survival-promoting pathway. The glioma-associated oncogene (GLI) pathway 
induces cell cycle progression. GLI proteins, which are members of the Kruppel 
zinc finger family, are direct effectors of the sonic hedgehog signalling. The 
adenomatous polyposis coil (APC) pathway regulates the Wnt-regulated p-catenin 
degradation, which regulates signal transduction and cadherin mediated cell/cell 
adhesion (Miller et al., 1996). The APC pathway also regulates cytoskeletal 
proteins involved in cell migration, cell adhesion and mitosis (Nathke, 2004, and
2005). The hypoxia inducible factor-1 (HIF1) pathway is activated by oxygen 
deprivation to trigger an overexpression of glycolytic enzymes and angiogenic 
factors. Each o f the cancer gene pathway described eventually leads to activation 
of the HIF1 pathway, which promotes angiogenesis, and therefore survival of the 
cancer cells. All solid tumours (95% of all tumours), among which prostate 
cancer, achieve angiogenesis.
These cancer gene signalling pathways have been thoroughly studied over the 
past decades as detailed in figure 3. Interestingly, the sonic hedgehog signalling 
pathway has recently been linked to prostate cancer abnormal expansion 
(Sanchez et al., PNAS, 2004).
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E-Cad herln
Figure 2 : The nine cancer gene pathw ays (picture from Vogelstein and Kinzler, 
2004). p53: p53 tum our suppressor gene. RB: retinoblastoma. GLI: glioma- 
associated oncogene. APC: adenomatous polyposis coli. RTK: receptor tyrosine 
kinase. PI3K: phosphatidyl-inositol-3 kinase. Apoptosis: programmed cell death, 
HIF1: hypoxia-inducible factor 1.
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Figure 3 : In te g ra te d  circuits of the cell (p icture from Hanahan and Weinberg, 2000). In bold are the genes 
known to be functionally altered in cancer.
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2. The hallmarks of cancer cells
Most cancer cells share a common set of acquired capabilities, namely the 
ability to generate their own mitogenic signals, to resist exogenous growth- 
inhibitory signals, to evade apoptosis, to proliferate without limits (undergo 
immortalisation), to acquire vasculature (undergo angiogenesis), and in more 
advanced cancers, to invade and metastasise (for a review see Hanahan and 
Weinberg, 2000).
a. Acquiring self sufficiency in growth signals
Following the premise of the molecular-based theory, i.e. the default state of 
all cells is quiescence (GO state), it then becomes a requirement for normal 
epithelial cells to be able to respond to mitogenic growth signals in order to 
evolve to an active profilerative state (G1/S-G2/M phases of the cell cycle). 
Mitogenic signals, such as diffusible growth factors (GFs), extracellular matrix 
(ECM) components, and cell-to-cell adhesion/interaction molecules are 
transduced by transmembrane receptors carrying tyrosine kinase activities (RTK) 
(e.g. EGF receptor, MET receptor, etc.). Cancer cells may reach self-sufficiency in 
growth signals (autonomy) by three different routes: alteration of the 
extracellular growth signals, alteration of their receptors, or alteration of the 
intracellular circuits activated by interactions between growth signal and receptor. 
Many cancer cells acquire the ability to synthesise GFs to which they are 
responsive (autocrine stimulation). Others become hyper-responsive to ambient 
levels of GFs (that would normally not trigger proliferation) by overexpressing 
their receptors, which, on the other hand may also lead to ligand-independent 
signalling. Ligand-independent signalling is also achieved by structural alterations 
of the receptors, which lead to constitutively active forms of the receptors. Cancer 
cells may also switch the type of ECM receptors they express to favour those 
transmitting pro-growth signals. Both RTK and pro-growth integrins transduce 
their signals through the SOS-Ras-Raf-MAPK intracellular cascade.
b. Acquiring insensitivity to growth-inhibitory signals
Anti-proliferative signals operate to maintain cellular quiescence (GO state) by 
blocking cell proliferation, either by preventing the transition of quiescent cells 
into the G l/S  phase of the cell cycle, or by inducing cell differentiation, i.e. 
entering the postmitotic phase. Both these events are under the control of the 
retinoblastoma protein (RB), which was the first tumour suppressor identified. 
Protein RB is on the one hand, a negative regulator of the cell cycle that
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Bcl-W) apoptotic proteins. The ultimate effectors of apoptosis include an array of 
intracellular proteases, the cysteine aspartyl-specific proteases or CASPASES, 
which cleave cellular substrates, leading to biochemical and morphological 
changes that are characteristic of apoptosis (Kumar, 2007). Besides these 
proteotypic caspase-dependent apoptosis pathways, there are also less well- 
defined cell death pathways that do not require CASPASES activation (Borner and 
Monney, 1999; Sperandio et al., 2000). Survival signals are conveyed by 
IGF1,2/IGFR-1 (Insulin Growth Factor-1 or -2/Insulin Growth Factor Receptor-1) 
and IL3/IL3R (Interleukin3/Interleukin3 Receptor), whereas death signals are 
conveyed by FAS/FASR (FAS Receptor) and TNFa/TNFR-1 (Tumour Necrosis 
Factor alpha/Tumour Necrosis Factor Receptor-1). Abrogation of adherence-based 
survival signals (cell/m atrix and cell/cell interactions) elicits apoptosis. Cancer 
cells may therefore escape apoptosis by modifying their integrin repertoire that 
will also allow them to impair contact with the underlying basement membrane.
d. Acquiring unlimited proliferative potential (resistance to  
senescence)
The acquired disruptions of cell-to-cell signalling (independence to growth 
signals, insensitivity to anti-growth signals, and resistance to apoptosis) are not 
sufficient to ensure expansive tumour growth. Mammalian cells are indeed 
governed by yet another program, called senescence that limits their aberrant 
multiplication (for reviews see Hayflick, 1997 and 2003; Stewart and Weinberg,
2006). Cells that have reached their finite replicative potential enter senescence. 
Replicative generations are counted by the 50 to 100 base pair (bp) loss of 
telomeric DNA from the ends of each chromosome. The telomeres, protective 
ends of chromosomes, are composed of several thousand repeats of a short 6bp 
sequence element (TTAGGG). To ensure chromosomal stability, telomeres are 
protected from homologous recombinations and from the DNA repair machinerie 
by shelterin. Shelterin is a complex of six telomere-specific proteins (TRF1/2, 
TIN2, TPP1, POT1 and Rapl) that determine the structure of telomeres terminus 
(T-loops allowing distinction from sites of DNA damage) and control the synthesis 
of telomeric DNA by the telomerase enzyme (for a review see De Lange, 2005). 
The telomerase enzyme adds hexanucleotide repeats onto the ends of telomeric 
DNA to maintain a certain length. In normal cells, the telomerase enzyme is 
inactive and a progressive erosion of telomeres naturally occurs through 
successive cycles of replication, which is attributed to the inability of DNA 
polymerases to completely replicate the 3'ends of chromosomal DNA during each 
S phase. The loss of telomeres is translated into a loss of ability to protect
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chromosomes from end-to-end fusions. Telomeres erosion below a certain length 
trigger the crisis state, which is characterised by a strong chromosomal instability 
(karyotypic disarray) inevitably resulting in cell death. Ongoing maintenance of 
telomeres is therefore a prerequisite for cell immortalisation (indefinite 
proliferation), which permits unlimited multiplication of descendant cells 
(replicative immortality), a hallmark of cancer. Cancer cells may avoid 
senescence by maintaining telomeres at a length above the critical threshold. 
Telomeres maintenance is mainly achieved by reactivating (upregulating the 
expression of) the telomerase enzyme. Telomere maintenance may also be 
achieved by a telomerase-independent mechanism, termed alternative 
lengthening of telomeres or ALT (Bryan et al., 1995; Henson et al., 2002).
e. Acquiring sustained angiogenesis (VEGF secretion)
Tumours cannot grow to a size greater than 2mm in diameter unless they 
succeed in acquiring access to the circulatory system. Indeed, oxygen and 
nutrients supplied by the vasculature are crucial for cell function and survival, 
obligating virtually all cells in a tissue to reside within 100pm of a capillary blood 
vessel. Initially, proliferating cancer cells lack angiogenic ability, therefore they 
cannot promote the growth of new blood vessels (neoangiogenesis). Tumour cells 
acquire access to the circulatory system by achieving the angiogenic switch from 
vascular quiescence, by secreting pro-angiogenic factors and by down-regulating 
the expression of anti-angiogenic factors (Bergers et al., 2003). Pro-angiogenic 
factors secreted by cancer cells are mainly vascular endothelial growth factors 
(VEGFs) and fibroblast growth factors (FGFs), while anti-angiogenic factors would 
be represented by thrombospondin-1 (TSP-1) and (3-interferon (J3-IFN). 
Angiogenic factors receptors, which are tyrosine kinase receptors, are displayed 
by endothelial cells. H IFla, which plays a major role in the response of tumours 
to hypoxia, is mainly responsible for the angiogenic switch (Semenza, 2000; 
Diaz-Gonzalez et al., 2005). Integrin signalling also contributes to acquiring 
sustained angiogenesis. Quiescent vessels express one class of integrins, whereas 
sprouting capillaries express another (aVp3, and pl-integrins, Sheppard, 2002). 
Thus, there are pro- and anti-angiogenic integrins, like there are pro- and anti­
growth integrins, and pro- and anti-apoptotic integrins.
The process of new blood vessel formation (neo-angiogenesis) is thus essential 
for the growth and metastatic propagation of cancer and is therefore a feature of 
many cancers, including prostate cancer, where quantification of microvessel 
density correlates with disease stage and outcome (Weidner et al., 1993; Jackson
27
et al., 1997). In prostate cancer, gene expression of angiogenic factors, such as 
VEGF, correlates with the metastatic potential of prostate cancer cells (Aalinkeel 
et al., 2004).
3. Metastasis, and the invasive growth program
Cancer cells have thus to reach the circulation to eventually metastasise new 
sites (figure 4). Metastatic dissemination occurs when the cancer cells spread 
from the primary tumour site (figure 4.1), invade the surrounding tissue (figure 
4.2), and reach the circulation for intravasation (figure 4.3). As a primary tumour 
grows, it needs to develop a blood supply that can support its metabolic needs. 
The new blood vessels can provide an escape route by which cancer cells leave 
the primary tumour site and enter the circulation. Cancer cells are also able to 
enter existing blood vessels and lymphatic vessels. The cells need to survive in 
the circulation (apoptosis-resistance, change of integrins repertoire) until they 
can extravasate at a new site (figure 4.4). Once in the new site, the cancer cells 
must initiate and maintain growth to form micrometastases (figure 4.4). This 
growth must be sustained by the development of new blood vessels in order for a 
macroscopic tumour to form (figure 4.5).
The first step in metastasis is the detachment of cancer cells from the primary 
tumour and the gain of motility, i.e. acquiring invasive capabilities. The invasive 
growth program is a complex biological program that instruct cells to dissociate, 
migrate, degrade the surrounding matrix, proliferate and survive (for reviews see 
Trusolino and Comoglio, 2002; Comoglio and Trusolino, 2002; Gentile and 
Comoglio, 2004). This program is an essential mechanism for embryonic 
development, tissue morphogenesis, and wound healing, that is aberrantly 
implemented for cancer dissemination and metastasis. The hepatocyte growth 
factor (or scatter factor) HGF, through its specific receptor MET, fully controls the 
coordinated regulation of the invasive growth program. Other cytokines and 
growth factors can be responsible for parts of the program. For example, HGF can 
down-regulate the transcription of E-cadherins, as shown in the prostate cancer 
cell line derived from a brain metastasis DU145 (Miura et al., 2001), or stimulate 
their proteolytic cleavage by matrix metalloproteinases (MMP), as shown in the 
prostate cancer cell line derived from a lymph node metastasis LNCaP (Davies et 
al., 2001), which triggers the destabilisation of the adherens junctions 
maintaining the normal attachment of epithelial cells within a tissue (scattering). 
Intercellular adhesions are held by cadherins, which are connected to the 
cytoskeleton by catenins. Additionally, HGF can disrupt the structural integrity of
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adherens junctions by increasing (J-catenins phosphorylation (Davies et al.,
1999). In all cases, HGF weakens carcinoma cells aggregation and facilitates their 
dissociation and scattering.
Macnometastflsls
Primary tum our
Invasive Growth Intravasation
Extravasation/
Micrometastasis
Figure 4 : Stages o f tu m o u r m etastasis (picture from Mol e t al., 2007). 1. Stage o f prim ary tum our (cancer 
cells are highlighted in red). 2. Invasive growth: cancer cells detach from the prim ary tum our and start to invade 
the surrounding tissue. 2. Intravasation: migratory cancer cells reach the nearest blood vessel and Intravasate 
in to the blood stream. 4. Extravasation: travelling cancer cells escape the vessel and start to invade secondary 
tissues and m icrometastasis o f single cells develops. 5. Macrometastasis: a secondary tum our develops from  the 
micrometastasis.
Stromal invasion by cancer cells is another crucial step for metastasis. Cancer 
cells that have spread from the primary tum our site have to start to recognise 
ECM molecules that are present in the stromal compartment through which they 
invade. HGF can also strongly influence apoptosis resistance and adaptation to a 
new environment, both by up regulating the transcription of certain integrins and 
by stimulating the ir aggregation at actin-rich adhesive sites, w ithout modifying 
the number of integrin molecules at the membrane (Trusolino et al., 1998 and
2000). Such positive regulation of integrin synthesis allows survival of cancer 
cells and migration within stroma. HGF can also enhance the expression of a large 
number of matrix metalloproteinases (MMPs) and stimulate the conversion of 
the ir precursors into active enzymes (Rosenthal et al., 1998; Monvoisin et al., 
2002; Park et al., 2003). At the leading edge of migrating cells, MMPs interact 
with integrins to localise and concentrate the extracellular matrix digestion 
(Brooks et al., 1996; Hofmann et al., 2000). Additionally, some MMPs can 
selectively cleave ECM ligands to reveal cryptic domains tha t display chemotactic 
properties and facilitate cell migration (Giannelli et al., 1997). Matrix 
metalloproteinases can also have a significant effect on the ability of cancer cells 
to grow in a secondary site (for a review see Chambers and Matrisian, 1997).
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Overexpression of MMPs has been reported in prostate cancer (Aalinkeel et al., 
2004; Morgia et al., 2005).
Metastases can show an organ-specific pattern of spread. For example, breast 
and prostate tumours preferentially metastasise to the bone. The ability of cancer 
cells to grow in a specific site depends on features that are inherent to the cancer 
cell, factors peculiar to the metastatic site, and the active interplay between these 
factors ('seed' and 'soil' theory) (for a review see Langley and Fidler, 2007).
Section 3: T h e  sem a dom ain  co n ta in in g  s u p e rfa m ily
1. Three fam ilies sharing common extracellular structural features
The sema domain containing superfamily includes three families of proteins, 
the scatter factor receptor family, the plexin family, and the semaphorin family 
(figure 5). All three protein families share similar extracellular structural features, 
namely a sema domain, one or more copies of a small cystin-rich domain (CRD) 
located immediately C-terminal of the sema domain, and at least one 
immunoglobulin-like domain (Ig-like domain). Those three extracellular domains 
have been involved in protein/protein or protein/ligand interactions.
a. The sema domain
The sema domain was first described by Kolodkin and colleagues in 1993 
(Kolodkin et al., 1993). I t  is a conserved extracellular stretch of approximately 
500 amino acids (aa), whose three-dimensional crystal structure is a variant of 
the seven blade |3-propeller fold (figure 6) (Antipenko et al., 2003; Love et al., 
2003; Gherardi et al., 2003; Stamos et al., 2004). The (3-propeller is a very 
widely used protein fold topology that consists of multiple (4 to 8, typically 7) 
four-stranded, twisted (3 sheets, formed sequentially and packed face to face 
around a central axis. The sema domain is the largest known variant of the p- 
propeller fold with 500aa. Most seven blade p-propellers contain approximately 
400aa, 438aa in the larger propeller of aV-integrin. The extra sequence found in 
the sema domain produces several long loops and a long insertion (shown in red 
on figure 6) (Gherardi et al., 2004). Throughout evolution, the p-propeller fold 
has been extensively adapted to protein/ligand binding and catalysis.
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Extracellular i ,m s in .:m |v .ine reg ion  Intracellular
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= PSI domain = MRS m o tif ^ ------ (50-80 rt9idu«>
Figure 5 : The sem a dom ain containing superfam ily contains th ree  m em bers: sem aphorins, plexins, and  
scatte r facto r receptors. They are characterized by the presence of am ino-term inal special features, such as the 
sema domain (a stretch o f 500 amino acids approxim ately), cystin-rich regions (CRD), and im m unoglobulin-like 
m otifs (Ig ).
Seven blade (S-propeller structure 
3
a V - Integrin
MET receptor
S e m a p lio r lt i3 A
Semaphorin4D
Figure 6 : S tructure o f the sem a dom ain (p icture from 
Gherardi et al., 2004). Ribbon diagram s o f the seven-blade p- 
propellers o f aV-integrin (in grey) (PD8 code H5g), MET 
receptor (in green) (PDB code ls h y ) , Semaphorin3A protein 
(in yellow) (PDB code lq 4 7 ), and Semaphorin4D protein (in 
blue) (PDB code lo lz ). The left panels show views o f the 
domains along the pseudo-sevenfold axes. Right panels show 
the same domains tilted by 908 degrees around the horizontal 
axis to show the top and bottom faces o f the domains. The 
insertion/extrusion typical o f the sema domains of 
Semaphorins 3A, 4D and MET is shown in red
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b. The cystin -rich  dom ain  (CRD)
The CRD was previously known as MRS (Met-related sequence) m otif or PSI 
domain (a domain found in Plexins, Semaphorins and Integrins), whose minimal 
consensus is C-X(5-6)-C-X(2)-C-X(6-8)-C-X(2)-C-X(3-5)-C . The cystin-rich 
domain, located immediately C-terminal of the sema domain, is a large group of 
cysteine rich modules tha t can either be present as a single copy or as multiple 
copies. These cosine-rich domains comprise three to four highly conserved 
disulfide bonds over approximately 50 amino acids, whose formation is essential 
for structural stabilisation. Two out of the three highly conserved disulfide bonds 
keep the structural core of the CRD domain together. The third highly conserved 
bond links the C-terminal cysteine to the core, thus defining the distance between 
the N and C term in i of the domain, and also orientating the neighbouring domains 
(p-propeller, Ig-like domain, figure 7). In semaphorins, the CRD domain is 
providing a link between the p-propeller ligand recognition domain and the stalk 
(Kozlov et al., 2004). Hence the importance of the CRD domains for the biological 
function of the sema domain. Mutations in these regions modulate the sema 
domain biological activity (Behar et al., 1999).
Figure 7 : S tructure o f th e  CRD dom ain of Sem aphorin4D
(p icture from Kozlov et al., 2004). The CRD domain (in blue) likely 
orients the adjacent domains for proper ligand binding The CRD 
domain links the Im m unoglobulin-like domain (in purple) with the 
propeller-shaped sema domain (in cyan). Variable part of the CRD 
domain is shown in yellow.
c. The im m u n o g lo b u lin -like  dom ain  ( Ig - l ik e  d o m a in )
The Ig-like domain was previously known as IPT repeat or TIG domain (repeats 
found within immunoglobulins, plexins and transcription factors). The 
immunoglobulin-like domain is one of the most widespread domains among 
animals. Proteins containing one or more Ig-like domains are part of a wider 
heterogeneous group, the immunoglobulin superfamily, built on a common fold, 
the immunoglobulin fold (Ig fold), whose structural characteristic is this of a
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Greek-key p-barrel or a sandwich of two p-sheets (Figure 8) (fo r a review see 
Halaby and Mornon, 1998). The superfamily can be divided into discrete 
structural sets by the number and length of the p-strands. The two major types of 
Ig-like domains are the constant C type (subtypes C l to C4, Fn3, and H) and the 
variable V type, containing an extra loop (for reviews see Bork et al., 1994; 
Halaby et al., 1999). The I type is an intermediate between the C l and V types 
(Gerstein and Altman, 1995). Proteins containing domains of the C l and V sets 
are mostly molecules of the vertebrate immune system, whereas those from the I 
set are mainly cell surface-adhesion proteins, as well as intracellular muscle 
proteins. The Ig-like domain of MET is of the E type, which is found earlier in 
bacterial enzymes, as well as in transcription factors of the NF-xB/REL/dorsal 
family. Preliminary analyses (unpublished data) suggest that the Ig-like domain 
of class 3 semaphorins is of the I type (Gherardi et al., 2003). Proteins with Ig- 
like domains are mostly involved in cell adhesion and pattern recognition.
Figure 8 : S tructure of the im m unoglobulin-like  
( Ig - l ik e )  dom ain (from  the protein data bank 
website: h ttp ://w w w .rcsb .org /pdb/hom e/hom e.do).
Ig-like  domain o f the muscle protein Titin , module 
m5 (PDB code ln cu ), I set.
d. Three fam ilies  sharing  a com m on function  o f cell gu idance
Because of their structural homology, scatter factor receptors, plexins and 
semaphorins share a common role in mediating cell guidance cues (Artigiani et 
al., 1999). Semaphorins belongs to the larger fam ily of neuronal guidance 
factors, also comprising the ephrins, netrins and slits families (fo r a review see 
Dickson, 2002). Indeed, the formation of a functional neuronal network requires 
proper targeting of axons, which is accomplished by sensing a variety of 
extracellular cues (guidance factors) in the local environment. Neuronal growth 
cones, located at the tip of the growing axons, are highly motile structures that 
respond to guidance cues by selectively altering the stability of the actin 
cytoskeleton and microtubules. Guidance receptors transduce the ir signal through 
activation of Rho guanosine triphosphatases or Rho GTPases in order to mediate
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axonal retraction or attraction (for reviews see Huber et al., 2003). Plexins, as 
semaphorin receptors, mediate axon and cell guidance. Stimulation of plexin 
receptors by their ligands, semaphorins, also leads to a cascade of small 
cytoplasmic GTPases activation, including pl90-Rho-GAP and PDZ-Rho-GEF, 
resulting in the reorganisation of cytoskeletal structures and therefore neurons 
and cell migration or motility. Scatter factor HGF also activates Rho GTPases, 
such as Racl, RhoA, and cdc42, to induce scattering, as shown in the prostate 
cancer cell line derived from a brain metastasis DU145 (Wells et al., 2005) and in 
other cell types (Royal et al., 2000; Miao et al., 2003). HGF triggers a variety of 
cellular responses ranging from cell scattering (motility) and proliferation to 
branching morphogenesis, invasive growth, and angiogenesis, through the 
specific receptor MET, which is a tyrosine-kinase receptor (for reviews see Vande 
Woude et al., 1997, Zhang and Vande Woude, 2003, Gao and Vande Woude, 
2005, Furge et al, 2000, Tamagnone and Comoglio, 1997, Comoglio et al., 1999, 
Comoglio and Boccaccio, 2001). Additionally, those signalling pathways are able 
to interplay, as when plexin receptors interact with scatter factor receptors to 
induce invasive growth (Giordano et al., 2002, Conrotto et al., 2004). For 
example, scatter factor receptor MET interacts with all three class B plexins, but 
not A or D plexins. PlexinBl and MET interaction is ligand-independent, but 
activation of PlexinBl upon ligand binding then stimulates the tyrosine kinase 
activity of MET, which enhances invasive growth (Giordano et al., 2002).
In the following section, focus will mainly be brought on the prototypes for 
each family (scatter factor receptors; plexins; and semaphorins); looking at their 
structures, signalling pathways, biological effects in vitro and in vivo, at 
physiological and pathological levels.
2. The scatter factor receptor fam ily
a. General features
The proto-oncogenes c-Met, Ron and c-Sea are the three members of the 
scatter factor receptor family (figure 9). These proto-oncogenes respectively 
encode the single-pass cell membrane glycoproteins MET, RON and SEA, which 
are receptors for scatter factors (SFs) also called Plasminogen-Related Growth 
Factors (PRGFs) (for a review see Comoglio et al., 1999). Scatter factor 1 (SF1), 
or PRGF-1, is the hepatocyte growth factor HGF that specifically binds the scatter 
factor receptor MET. Scatter factor 2 (SF2), or PRGF-2, is the macrophage 
stimulating protein MSP that specifically binds the scatter factor receptor RON.
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HGF and MET are the prototypes of the scatter factor and scatter factor receptor 
families.
Met homologues are found in vertebrates, including mice, rats, chicks, frogs 
and puffer fish, but none were found in invertebrates (neither in Drosophila 
melanogaster nor in Caenorhabditis elegans). HGF and MET expression starts 
during embryogenesis predominantly in developing epithelial organs (lung, 
pancreas, kidney, intestine, and salivary gland), and transiently in skeletal muscle 
and neuronal cells. Particularly, MET receptor is expressed at the surface of 
epithelial cells while HGF is secreted by mesenchymal cells in close vicinity 
(Sonnenberg et al., 1993). This specific distribution between HGF and its receptor 
indicates a paracrine mode of action.
Extracellular Intracellular
MET and RON
Figure 9 : Dom ain arch itecture o f the scatter factor receptor fam ily  m em bers
(p icture from  Gherardi et al., 2004). The N-term inal sema domain is in purple, followed 
by one CRD repeat (cystin-rich domains) in blue, and four im m unoglobulin-llke domains 
in grey. The C-term inal moiety is intracellular and contains a tyrosine kinase domain (in 
orange). The cellular membrane is in pink.
b. S tru c tu re  o f sca tte r fac to r HGF
The human gene encoding HGF spans approximately 70kDa on chromosome 
7 q l l . l - 2 1  and consists of 18 exons (Saccone et al., 1992; Seki et al., 1991). 
HGF is a large molecule (approximately lOOkDa) that shares structural homology 
(approximately 40% ) with plasminogen, an enzyme of the blood coagulation 
cascade, and has a sim ilar mechanism of activation (Donate et al., 1994). HGF is 
secreted as a single chain precursor (pro-HGF) that is activated in the 
extracellular environment by specific proteases (e.g. uPA and tPA) releasing two 
subunits (a and p), joined by disulfide bonds. The a chain (heavy) of HGF has a 
molecular mass around 60kDa and contains four typical Kringle domains, which 
are cysteine-rich double-looped structures presenting protein/protein interaction 
properties, a receptor binding site, short sequence folded in a hairpin loop and 
located at the N-terminal extrem ity, and a heparin binding site. The p chain 
(light) of HGF weighs approximately 30kDa and is closely related to the catalytic 
domain of serine proteases. However, HGF has lost the catalytic serine protease 
activity during evolution, when the serine residue that forms the catalytic triad 
necessary for the catalytic activity of serine proteases was substituted with a 
tyrosine (Lokker et al., 1992). Although HGF is a soluble molecule normally found 
in serum, it also naturally accumulates, bound to sulphated glycosaminoglycans
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(GAGs) such as heparan-sulphate, in the extracellular matrix and in basement 
membranes (Kobayashi et al., 1994).
c. Structure of scatter factor receptor MET
The human Met gene spans more than 120kb on chromosome 7q21-q31 and 
consists of 21 exons (Liu, 1998). The primary Met transcript produces a 150kDa 
polypeptide that is partially glycosylated into a 170kDa-precursor protein. After 
further glycosylation, MET precursor is cleaved by furin protease into a SOkDa 
extracellular a-chain and a 140kDa transmembrane p-chain, linked via disulfide 
bonds (Komada et al., 1993). The a-chain of MET receptor is extracellular, heavily 
glycosylated and spans approximately 310 residues. The a-chain and the first 212 
extracellular residues of the p-chain represent the ligand binding (sema domain) 
and the heparin binding sites of the MET receptor (Gherardi et al., 2003). The 
sema domain of MET receptor adopts a seven-bladed p-propeller 3D structure 
(Stamos et al, 2004) similar to those of Semaphorin3A and 4D proteins 
(Antipenko et al., 2003 and Love et al., 2003). The sema domain of MET receptor 
is a ligand binding domain, which also plays a critical role in ligand dependent and 
independent receptor dimerisation and activation (autophosphorylation and 
transducers phosphorylation) (Kong-Beltran, 2004). The intracellular part of the 
p-chain of MET receptor tyrosine kinase comprises a tyrosine kinase domain, 
whose crystal structure has been published (Schiering et al., 2003, Bolanos- 
Garcia, 2005), a tyrosine autophosphorylation site and a multifunctional docking 
site, whose consensus sequence is Y1349VHVNATY1356VNV (Ponzetto et al., 1994). 
The multisubstrate-docking site is responsible for much of MET receptor signal 
transduction (Komada and Kitamura, 1993; Zhu et al., 1994).
d. HGF/MET signalling pathways
Upon ligand binding, MET receptor undergoes dimerisation and 
autophosphorylation of two specific tyrosine residues, Y1234 and Y1235 located 
within the activation loop of the tyrosine kinase domain (figure 10). This 
autophosphorylation activates the intrinsic kinase activity of MET receptor leading 
to transphosphorylation of the two tyrosine residues Y1349 and Y1356 located within 
the multisubstrate docking site, thus allowing binding and phosphorylation of 
adapter proteins and signal transducers that contain Src homology 2 and 3 
domains (SH2 and SH3), phosphotyrosine binding domains (PTB) and MET 
binding domains (MBD). Mutational analysis shows that Y1349 and Y1356 mediate 
the interaction with She, Src and G abl, while Y1356 alone mediates recruitment of
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Grb2, PI3K, PLC-y, SHP2 (for reviews see Furge et al., 2000; Bolanos-Garcia, 
2005).
M E T M E T
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Transducers* and 
adapters
m ullifunelional
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Signal transduction
Fioure 1 0 : HGF/M ET signalling pathw ay (picture from Trusolino and Comoglio, 2002). The p-chain o f MET 
receptor contains a sema domain (not represented here) in its extracellular moiety, and in the intracellular
moiety a tyrosine kinase domain, a tyrosine autophosphorylation site and a m ultifunctional docking site, which 
consensus sequence is Y1349VNVXXXY1356VHV. When bound to its specific ligand HGF, MET receptor 
undergoes dimerisation and autophosphorylation o f two specific tyrosines of the tyrosine kinase domain. Once 
activated by phosphorylation, the tyrosine kinase domain o f each monomer phosphorylates the two tyrosines of 
the m ultifunctional docking site o f each other monomer (transphosphorylation). The activated docking site 
subsequently binds several transducers and/or adapters
e. H G F/M E T biological effects
HGF/MET signalling induces mitogenic (growth/proliferation, protection against 
apoptosis), motogenic (dissociation/scattering, m otility/m igration, acquisition of 
polarity, ECM invasion) and morphogenic (branching morphogenesis, tubule 
formation) responses in vitro, and during embryonal development (figure 11). In  
vivo, HGF/MET signalling plays a role in growth, wound healing, tissue 
regeneration, invasion and tum our metastasis, and finally angiogenesis (for a 
review see Maulik et al., 2002).
HGF is the only growth factor able to elicit the full complex genetic programs of 
branching morphogenesis and invasive growth (for a review see Zhang and Vande 
Woude, 2003). The morphogenetic branching program is a differentiation 
program in which groups of cells proliferate, migrate and differentiate to form a 
connected series of tubules arranged like the branches of a tree. Such paracrine
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represses the expression of genes essential for cell growth/proliferation (for 
reviews see Giacinti and Giordano, 2006; Macaluso et al., 2006), and on the other 
hand, a positive regulator of cell differentiation that counteracts differentiation 
inhibitors (for a review see Khidr and Chen, 2006). Anti-growth signals, such as 
TGFp (transforming growth factor-p), act on the protein RB pathway to block 
advance through the G1 phase (by keeping RB activated by preventing Its 
phosphorylation). Proliferative cells, or cells that have already entered the G l/S  
(DNA synthesis and replication) or G2/M phase (cell growth and division) of the 
cell cycle are insensitive to anti-growth signals. Cancer cells may gain 
insensitivity to anti-growth signals by disrupting the protein RB pathway. 
Disruption of the protein RB pathway, found in the majority of cancer cells, is 
achieved by various mechanisms (mutation, sequestration by viruses, 
phosphorylation) that control protein RB levels and/or phosphorylation status, all 
leading to inactivation of the protein RB. Cell differentiation signals are mediated 
by complexes of transcription factors Mad/Max (Myc associated factor X). Cancer 
cells may avoid getting into the terminal differentiation process, i.e. postmitotic 
or G2/M phase, by disrupting the c-MYC pathway. Disruption of the c-MYC 
pathway is achieved by various mechanisms, such as mutations, overexpression, 
rearrangement and translocation of the proto-oncogene c-myc gene (8q24.12- 
q24.13). Many cancer cells, like in prostate cancer, overexpress c-MYC 
oncoprotein (Jenkins et al., 1997), which impairs cell differentiation by shifting 
the balance of transcription factors back to Myc/Max complexes, thus promoting 
cell growth. Integrins and other cell adhesion molecules also send anti-growth 
signals to the cells. However, it is very likely that these adherence-based anti­
growth signals impinge on the protein RB circuit.
c. Acquiring resistance to programmed cell death (apoptosis)
Cells have an intrinsic mechanism of self destruction called programmed cell 
death or apoptosis. Normally, an excessive proliferation/growth at inappropriate 
sites induces apoptosis in the affected cells. The ability of cancer cells to expand 
in number is therefore determined not only by the rate of proliferation but also by 
their ability to acquire resistance to apoptosis. The apoptotic program is a 
multistep program that leads to cellular membrane disruption, cytosol extrusion, 
chromosome fragmentation, and degradation of the nucleus. Many of the signals 
that elicit apoptosis converge on the mitochondria (for a review see Gogvadze 
and Orrenius, 2006), which respond by releasing cytochrome C (Cyt-C), and 
other pro-apoptotic proteins. This release is controlled by members of the Bcl-2 
family, which includes both pro- (Bax, Bak, Bid, Bim) and anti- (Bcl-2, Bcl-XL,
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signalling between epithelial cells and mesenchymal cells is vital to 
embryogenesis and contributes to kidney and mammary gland formation, 
migration and development of muscle and neuronal precursors, and liver and 
placenta development (Bladt et al., 1995; Schmidt et al., 1995; Niemann et al., 
1998). The invasive growth program (as mentioned in the previous section, 3. 
Metastasis) is a complex biological program that instruct cells to dissociate, 
migrate, degrade the surrounding matrix, proliferate and survive (for reviews see 
Trusolino and Comoglio, 2002; Comoglio and Trusolino, 2002; Gentile and 
Comoglio, 2004). The invasive growth program is an essential mechanism for 
embryonic development, tissue morphogenesis, and wound healing.
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Figure 11 : HGF/M ET biological effects (picture from Trusolino and Comoglio, 2002). Upon ligand 
stimulation, MET receptor acts via a two-phospbotyrosine docking site to activate multip le intracellular 
transducers and signalling pathways. Phosphatidylinositol 3 kinase (PI3K)-dependent signals result in 
promotion o f cell m otility  and survival. The superactivation o f the Grb2-SOS-Ras cascade leads to uncontrolled 
proliferation and oncogenic transformation. Sustained recruitm ent of the phospholipase C-y (PLC-y) and the 
protein tyrosine phosphatase SHP2, as well as the in tegrity o f the signal transducers and activators of 
transcription (STAT) pathway, are required for MET receptor's morphogenetic activity
In normal prostate, HGF is secreted by stromal cells while epithelial cells 
express the receptor MET (Humphrey et al., 1995). Scatter factor receptor MET 
has been reported to be overexpressed in PIN, carcinoma and metastasis (Pisters 
et al., 1995). However, attempts to link HGF/MET signalling pathway to the 
metastatic abilities of prostate tumour cells have not yet been successful in vivo. 
Nevertheless, inhibition of HGF/MET signalling pathway reduces in vitro  invasion
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and migration of two prostate cancer cell lines derived from a brain (DU145) and 
bone (PC3) metastases (Davies et al., 2004).
3. The p lex in  fam ily
a. G eneral fea tu res
The plexin fam ily is a homogenous fam ily of at least nine members, which 
have been subdivided into four classes on the basis of sequence sim ilarity, 
namely class A plexins (A l to A4), class B plexins (B1 to B3), PlexinCl and 
PlexinDl (see nomenclature table below). Plexin genes encode single 
transmembrane glycoproteins that function as receptors for semaphorins (figure 
12) (for a review see Tamagnone et al., 1999). P lexinBl, which is the prototype 
of class B plexins, is a functional receptor for Semaphorin4D/CD100, the immune 
semaphorin (prototype of class 4 semaphorins). P lexinAl, which is the prototype 
of class A plexins, is a functional receptor for Semaphorin3A, the neuronal 
semaphorin (prototype of class 3 semaphorins). Not all plexins, however, have 
been assigned ligands, plexins A4 is still an orphan receptor.
Plexins homologues are found in vertebrates, including mice, rats, chicks, dogs 
and zebrafish, and in invertebrates, in Drosophila melanogaster and in 
Caenorhabditis elegans. Plexins expression starts during embryogenesis 
predominantly in neural tissues and developing epithelia (brain, kidney, ovary, 
and testis) (Maestrini et al., 1996). In the adult, they are ubiquitously expressed 
by epithelial cells (although expression has not been shown in all cell types). In 
the normal or pathological prostate, plexins expression levels have not been 
assessed.
Extracellular Intracellular
Figure 1 2 : Dom ain arch itec ture of the plexin fam ily  m em bers (p icture from  Gherardi 
et al., 2004) The N-term inal sema domain is in purple, followed by three CRD repeats 
(cystin-rich domains) in blue, and four im m unoglobulin-like domains in grey. The C- 
term inal moiety is in tracellu lar and contains two highly conserved sex and plexin (SP) 
domains (in  orange) tha t lack a cata lytic activ ity  (represented here in one domain). The 
cellu lar membrane is in pink.
b. P lexin  nom en c la tu re
Plexin nomenclature is summarised in table 2.
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Accepted denomination Other known denomination chromosomal location (in humans)
In -/Vertebrates Human Clones
PlexinAl Plexin a l PLEXIN A l
PLEXIN 1 
PLXN1
NOV 3q21-qter
PlexinA2 Plexin a2 PLEXIN A2
PLEXIN 2 
PLXN2 OCT Chr 1
PlexinA3 Plexin a3 PLEXIN A3
PLEXIN 4 
PLXN4 SEX Xq28
PlexinA4 Plexin a4 PLEXIN A4 Chr 7
PlexinBl Plexin b l PLEXIN Bl
PLEXIN 5 
PLXN5 SEP KIAA0407 3p21.31
PlexinB2 Plexin b2 PLEXIN B2
MM1
KIAA0315 22ql3.31-ql3.33
PlexlnB3 Plexin b3 PLEXIN B3
PLEXIN 6 
PLXN6 Xq28
PlexinDl Plexin d l PLEXIN D l Chr 3
Viral Vaccinia Virus (VV)
PlexinCl
Plexin cl 
PLEXIN Cl 
VESPR
A39R Chrl2
Table 2 : Plexin nom enclature and chromosomal location in humans.
c. S tructu re  o f P lex in B l receptor
Class B plexins (at least, PlexinBl and B2) are the closest homologues to 
scatter factor receptors, i.e. MET, the prototype of the scatter factor receptor 
family. PlexinBl is the prototype of class B plexins. The human plexin b l gene 
spans approximately 26kb on chromosome 3p21.31 and consists of 32 exons. The 
primary plexin b l transcript produces a 300kDa polypeptide that is partially 
glycosylated. PlexinBl precursor, like MET precursor, is cleaved by furin protease 
into a 200kDa extracellular a-chain and a lOOkDa transmembrane p-chain 
(Artigiani et al., 2003). The a-chain of PlexinBl receptor is extracellular, spans 
approximately 1500 residues, and contains the sema domain, three cystin-rich 
domains (compared to only one in MET receptor extracellular moiety), and three 
immunoglobulin-like domains. The p-chain of PlexinBl receptor spans 
approximately 620aa, with a transmembrane domain of approximately 18aa. The 
cytoplasmic moiety of the p-chain of PlexinBl exhibits two well-conserved 
domains among plexin receptors. Those two domains were formerly known as SP 
domains (Sex and Plexin domains), as they were first identified in the SEX 
proteins family, now the plexin family (see nomenclature table). Those two SP 
domains, now known as C l and C2 domains (Castellani and Rougon, 2002), were 
first defined as two homologous regions of approximately 320 and 150 amino 
acids, separated by a divergent insert of approximately 70 residues, showing no
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kinase activity (Maestrini et al., 1996). The C l and C2 domains share sequence 
similarity with the GAP domain of the Ras family-specific GTPase activating 
proteins, especially R-Ras-GAP (Rohm et al., 2000a). However, in plexins 
intracellular region, this GAP homology domain is divided into two by an unrelated 
linker region, which shows a CRIB (Cdc42/Rac-Interactive Binding)-like motif. The 
CRIB-like motif is a small GTPase binding motif, therefore mainly binding the 
small GTPases Cdc42 and Rac, but also binding other small GTPases, such as Rho 
and Rndl (Kruger et al., 2005; Oinuma et al., 2004a).
d. P lexinB l/Sem aphorin4D  signalling pathway
Stimulation of PlexinBl by its ligand Semaphorin4D regulates the activity of 
small cytoplasmic GTPases, such as R-Ras, Rac and Rho (figure 13). The 
cytoplasmic domain of plexins has two highly conserved domains denoted C l and 
C2, which have weak homology to Ras-GAPs (GTPase activating proteins). The C l 
and C2 domains of PlexinBl interact to form an inactive conformation (figure 
13a). Rndl binds to the linker region between these domains and disrupts this 
inactive conformation (figure 13b). R-Ras can then bind to regions of both 
domains of PlexinBl (Oinuma et al., 2003 and 2004b). The binding of R-RasGTP 
is dependent on Rndl binding and disruption of the closed conformation. In the 
absence of receptor clustering by Semaphorin4D, binding of R-RasGTP to 
PlexinBl suppresses the basal GTPase activity of R-Ras and traps it in its active 
form (figure 13c). The R-Ras-GAP activity of PlexinBl is activated upon receptor 
clustering resulting in inactivation of R-Ras (figure 13d) (Oinuma et al., 2004a). 
PlexinBl also binds RacGTP and sequesters it from its downstream signalling 
partners such as PAK (Vikis et al., 2002). PlexinBl controls the activation state of 
Rho via PDZ-Rho-GEF and LARG which bind to the C-terminal end of PlexinBl 
(Swiercz et al., 2002), and by activating pl90-Rho-GAP (Barberis et al., 2005).
Stimulation of PlexinBl by its ligand Semaphorin4D also activates tyrosine 
kinase cascades through interaction with receptor tyrosine kinases MET (Giordano 
et al., 2002; Conrotto et al., 2004) and ErbB2 (Swiercz et al., 2004). PlexinBl 
interacts with these receptors via its extracellular domain (figure 14). Activation 
of PlexinBl results in activation of the tyrosine kinase activity of both MET and 
ErbB2, resulting in the phosphorylation of PlexinBl and MET or ErbB2. PlexinBl 
also promotes the activation of tyrosine kinase cascades in endothelial cells via 
PYK2 and Src (Basile et al., 2005), resulting in phosphorylation of PlexinBl and 
the p85 regulatory subunit of phosphoinositide 3 kinase (PI3K).
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p l9 0 R h o G A P
Figure 1 3 : P le x in B l/S e m a p h o rin 4 D  signalling pathw ay via sm all GTPases (p icture from M. W illiamson), a. In 
the absence of ligand binding or receptor clustering the C l and C2 domains o f the cytoplasmic domains o f P lexinBl 
in teract to form  a closed inactive conform ation, b. The closed secondary structure is disrupted upon R ndl binding, c. 
This allows the binding o f R-RasGTP to regions in the C l and C2 domains. RacGTP also binds to a region between the 
C l and C2 domains and PDZ-Rho-GEF binds to the C-terminal end o f the cytoplasmic domain (the dependence of 
RacGTP or PDZ-Rho-GEF on Rndl binding has not been shown). At th is stage the basal GTPase activity o f R-Ras is 
inhib ited by P lexinB l binding and so R-Ras remains in its active state, d. Upon receptor clustering as a result of 
ligand binding or overexpression, the R-RasGAP activity of P lexinBl is activated resulting in the conversion of R- 
RasGTP to R-RasGDP. PDZ-Rho-GEF is also activated resulting in RhoA activation and MAPK pathway activation. 
pl90-Rho-GAP is also activated, which inactivates RhoA.
a b
PlexinBl
PYK2 - Src ' > PI3K/Akt
Figure 1 4 : P lex in B l/S em ap h o rin 4 D  signalling pathw ay via tyrosine kinases (p icture from M. W illiamson), a. 
Met and ErbB2 interact w ith PlexinB l via the cytoplasmic domain o f both receptors, b. Upon receptor clustering as a 
result of ligand binding (Semaphorin4D) or overexpression, Met/ErbB2 is activated, resulting in activation o f the 
tyrosine kinase activity o f c-Met/ErbB2 and tyrosine phosphorylation o f both Met/ErbB2 and P lexinB l. PI3K is also 
activated via PYK2 and Src upon P lexinB l activation.
e. P le x in B l/S e m a p h o rin 4 D  biological effects
Activation of plexins, either by ligand binding or overexpression, regulates the 
activity of small cytoplasmic GTPases and tyrosine kinases, resulting in the 
reorganisation of cytoskeletal structures and subsequent cell adhesion, migration, 
and motility, and invasive growth (for a review see Kumanogoh and Kikutani, 
2004).
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4. The sem aphorin  fam ily
a. General fea tu res
Semaphorins are a large family of signalling proteins. Semaphorin derives from 
the Greek word "semaphore", meaning to convey information by a signalling 
system. Since the discovery of the first semaphorin in 1992, more than 30 
members have been identified. These were subsequently sub-divided into eight 
classes according to the ir species of origin and their structure (Kolodkin et al., 
1993). Semaphorins exist either as secreted, membrane-bound or 
transmembrane proteins (figure 15). Class 1 semaphorins are transmembrane 
invertebrate semaphorins, class 2 are secreted invertebrate semaphorins, class 3 
are secreted vertebrate semaphorins, class 4 to 6 are transmembrane vertebrate 
semaphorins, class 7 are membrane-bound vertebrate semaphorins, and class 8 
are secreted viral semaphorins.
Semaphorins 1 
Semaphorins 2 
Semaphorins 3 
Semaphorins 4  
Semaphorins 5 
Semaphorins 6 
Semaphorins 7
Figure 1 5 : Dom ain arch itecture and classes of the  semaphorin fam ily  m em bers
(picture from Gherardi et al., 2004). Semaphorins are classified into eight classes, namely the 
animal (1 -7 ) and viral semaphorins. The viral semaphorin shown in the figure only contains 
the sema domain, and corresponds to the product o f reading frames present in vaccinia and 
variola viruses. Other viral semaphorins, such as tha t o f the fowlpox virus (UniProt accession 
code Q9J5F6), contain the CRD repeat (cystin-rich domain). The Sema domain is in purple, 
the CRD repeat in blue, the Ig-like domain in grey, the thrombospondin repeats in dark red, 
the basic m o tif in bright ref, the GPI anchor in green, and the cellular membrane in pink.
Semaphorins homologues are found in vertebrates, including mice, rats, 
chicks, dogs and zebrafish, and in invertebrates, such as Grasshopper, Drosophila 
Melanogaster and Caenorhabditis Elegans. Semaphorins expression starts during 
embryogenesis, predominantly in neural and vascular tissues. In the normal or 
pathological prostate, expression profiles of semaphorins have not been assessed.
Viral Semaphorins
Extracellular Intracellular
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Accepted
denomination Other known denomination
Human
Chromosomal
Location
Invertebrates Grasshopper(SAM)
D ro s o p h ila  
M e la n o g a s te r f  D M E )
C a e n o rh a b d b it is .  
E le g a n s  (C E L )
Sema-la G-Sema I D-Sema I
Ce-Sema I 
Ce-Sema-la 
Smp-1
T-Sema I 
Fasciculln 
IV
2L (29E2-29E3)
Sema-lb D-Sema III Ce-Sema-lbSmp-2 Sema I I I 2R (54D4-54D5)
Sema-2a G-Sema II D-Sema II Ce-Sema II Sema II 2R (53C6-53C7)
Vertebrates Human (H -, HSA)
Chick 
(C-, GGA) Mouse (M-, MMU)
Rat 
(RNO, R-) 
Zebrafish
(Z )
SEMA3A
Sema 3 
H-Sema I 
SEMA I II  
SEMA1 
SEMAL 
SEMAD
C-Collapsln-1
Collapsin-1
Coll-1
COLL-1
M-SemD
R-Sema III 
Sema-Zla 7pl2.1
SEMA3B
H-Sema V 
H-Sema A 
SEMAA
M-SemA SemaS ? LUCA-1 ? 3p21.3
SEMA3C H-Sema E SEMAE
COLL-3
C-Coll-3 M-SemE 7q21-q31
SEMA3D COLL-2C-Coll-2 Sema-Z2 7q21.11
SEMA3E SEMAH COLL-5 C-Coll-5
M-Sema H 
M-Sema K KIAA0331 7q21.11
SEMA3F
H-Sema IV 
Sema III/F  
H-Sema3F
M-Sema IV
SemaK 
Sema4 
Sema IV
3p21.3
SEMA3G Sem2 3p21.1
SEMA4A SEMAB M-SemB lq22
SEMA4B SEMAC M-SemC KIAA1745 15q25
SEMA4C SEMAISEMAF M-Sema F
Sema f 
S em acll 
KIAA1739
2q 11.2
SEMA4D SEMAJCD100
COLL-4
C-Coll-4 M-Sema G 9q22-q31
SEMA4E Sema-Z7 ?
SEMA4F SEMAM SEMAW H-Sema W
m-Sema M 
M-Sema W R-Sema W 2pl3.1
SEMA4G KIAA1619 10q24.32
SEMA5A SEMAF M-SemF 5pl5.2
SEMA5B SEMAG M-SemGM-SemB KIAA1445 3q21.1
SEMA5C D-Sema5C ?
SEMA6A SEMAQ M-Sema Via KIAA1368 5q23.1
SEMA6B SEMAZSEMAN M-Sema VIb R-Sema Z 19pl3.3
SEMA6C SEMAY M-Sema Y R-Sema Y lq21.2
SEMA6D KIAA1479 15021.1
SEMA7A
SEMAL 
H-Sema L 
H-Sema K1 
CD108
M-Sema L 
M-Sema K1 CDwl08 15q22.3-q23
Viral Vaccinia Virus (VV)
SEMAVA Vaccinia sema Variola sema
SEMAVB AHVsema
Table 3 : Sem aphorin nom enclature and chrom osom al location in hum ans (according to the Semaphorin 
Nomenclature Comm ittee).
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b. Sem aphorin  nom encla tu re
Semaphorin nomenclature is complex and confusing. Table 3 gives a summary 
of the current denomination of semaphorins in various species, as well as their 
chromosomic location when known.
c. Class 3 o f secreted  sem aphorins and Sem aphorin3E
There are 7 members in the human class 3 semaphorin fam ily of secreted 
proteins, namely Semaphorin3A to 3G. They contain an average of about 750 
amino-acids and weigh approximately 85 KDa. They exhibit an N-terminal sema 
domain, an immunoglobulin-like domain, and a C-terminal basic domain (figure 
16). Although secreted semaphorins are diffusible signals, they are probably 
tethered to the cell surface and extracellular matrix by the basic charged 
sequence of the ir C-terminal moiety, which exhibits binding properties. The 
amino-term inal extrem ity of class 3 semaphorins is involved in the receptor 
specificity and biological activity of semaphorins (Feiner et al., 1997; Koppel et 
al., 1997). Semaphorin3A is the prototype of this fam ily of secreted proteins.
Binding p ro pertiesBiological activ ity  and  
recep to r specificity
Figure 1 6 : Secreted semaphorins structure and function. Secreted semaphorins 
(class 3) contain an N-terminal extrem ity, a sema domain (Sema, in purple), a CRD 
domain (in grey), an immunoglobulin-like domain (Ig , in blue), and a basic ( + ) C-term inal 
ex trem ity  (in red). The Sema domain confers biological ac tiv ity  and receptor specificity, 
while the C-term inal extrem ity confers binding properties to secreted semaphorins.
Class 3 semaphorins exist in monomeric, dimeric and processed forms. Indeed, 
class 3 semaphorins (3A, 3B, 3C, and 3E) are known to dimerise and undergo 
proteolytic processing by furin and furin-like convertase (Adams et al., 1997; 
Klosterman et al., 1998; Koppel et al., 1998). The furin-dependent proteolytic 
processing of Semaphorin3A, 3B and 3C has been shown to determine their 
repulsive potency (Adams et al., 1997), and this of Semaphorin3E converts its 
repelling signal into an inducer of invasive growth (Christensen et al., 2005). The 
semaphorin 3e gene spans more than 285kb on chromosome 7q21.11 and 
consists of 17 exons. Its mRNA is 6474bp long and encodes a protein of 775aa. 
The KIAA0331 clone of semaphorin 3e gene encodes a protein of 814 aa and
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weigh approximately 90KDa. Semaphorin3E protein is also known as SemaH, or 
Collapsin-5 in chicks, and m-Sema-H or m-Sema-K in mice.
d. Class 4 of transm em brane semaphorins and Semaphorin4D
Class 4 semaphorins are transmembrane proteins exhibiting an N-terminal 
sema domain, an immunoglobulin-like domain, and a single-pass domain. There 
are 7 members in the human class 4 semaphorin family, namely Semaphorin4A 
to 4G. Semaphorin4D, also known as CD100, is the prototype of this yet 
uncharacterised family. Semaphorin4D/CD100 protein is known as the immune 
semaphorin because of its role in controlling immune and inflammatory responses 
(for reviews see Kumanogoh and Kikutani, 2003; Takegahara et al., 2005). 
Semaphorin4D can be found either as a membrane bound or as a soluble protein, 
suggesting that it might also function as a receptor to induce a bi-directional 
signalling (Tamagnone et al., 1999). The semaphorin 4d gene spans more than 
102kb on chromosome 9q22-q31 and consists of 14 exons. Its mRNA is 4675bp 
long and encodes a protein of 862aa. The transmembrane form of Semaphorin4D 
weighs approximately 150kDa, while the soluble version weighs 120kDa.
e. Semaphorin receptors
The functional receptors for secreted semaphorins (class 3) are complexes 
including a dimer of neuropilins and a monomer of one of the four class A plexins. 
Neuropilins function as the semaphorin binding subunits, whereas plexins serve 
as signal transducing subunits (Takahashi et al., 1999; Tamagnone et al., 1999). 
Neuropilins are considered essential co-receptors for secreted semaphorins, as 
these would not directly bind plexins (Kolodkin et al, 1997; Chen et al., 1998). 
The growth repelling activities of class 3 semaphorins are associated with the 
neuropilin-binding capacity of their full-length, dimeric forms (Miao et al., 1999; 
Kessler et al., 2004; Bielenberg et al., 2004). For example, the active receptor for 
Semaphorin3A is a complex made of a dimer of Neuropilinl and a monomer of 
PlexinAl (Takahashi et al., 1999). Semaphorin3A binds Neuropilinl but not 
Neuropilin2 (Chen et al., 1997; He and Tessier-Lavigne, 1997; Kolodkin et a!., 
1997), whereas Semaphorin3B, 3C and 3F bind to both neuropilins (1 and 2) 
(Takahashi et al., 1998). Semaphorin3C binds to PlexinA2 and PlexinDl (Kolodkin 
et al., 1997; Gitler et al., 2004). Although, it had previously been shown that the 
chick Semaphorin3E was able to bind Neuropilinl (Feiner et al., 1997), a more 
recent study has shown that Semaphorin3E directly binds to PlexinDl (class D 
plexin), independently of neuropilins (Gu et al., 2005).
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Sem aphorins Receptors
S e m a -la  
S e m a -lb  
Sem a-2a  
SEMA3A
SEMA3B
SEMA3C
SEMA3D
Plexin A 
Plexin A
7
NP1 & PlexinAl or PlexinA2 or PlexlnA3
NP1-NP2 & VEGFR2
NP1- NP2 & Plexin A l  
or PlexinA2 or PlexinDl or PlexinBl
NP1
SEMA3E NP1?PlexinDl
SEMA3F NP1- NP2 & PlexinAl or PlexinA3
SEMA4A Tim -2
SEMA4B 7
SEMA4C PlexinB2
SEMA4D PlexinBl
SEMA4E 7
SEMA4F 7
SEMA5A Plexin B3
SEMA5B 7
SEMA5C 7
SEMA6A Plexin?
SEMA6B 7
SEMA6C ?
SEMA6D Plexin A l & VEGFR-2 & OTK
SEMA7A PlexinCl
SEMAVA PlexinCl
SEMAVB PlexinCl
Table 4 : Sem aphorins and receptors, plexins and neuropilins.
NP (1 /2 ): N europ ilin l/2 . VEGFR-2: vascular endothelial growth 
factor receptor-2. OTK: o ff track receptor.
In contrast, membrane-associated semaphorins (class 4 to 7 semaphorins) 
bind directly to  plexin receptors, and do not interact with neuropilins. Their 
functional receptor is a monomere of plexin. For example, PlexinBl is the 
functional receptor for Semaphorin4D in non-lymphoid tissues (Giordano et al., 
2002), Semaphorin6D binds to PlexinAl (Toyofuku et al., 2004), and 
Semaphorin7A to PlexinCl (Tamagnone et al., 1999). A soluble version of 
Semaphorin4D has been found in various cellular types. This soluble 
Semaphorin4D protein acts through PlexinCl on human monocytes and through 
PlexinBl on imm ature dendritic cells (Chabbert-de Ponnat et al., 2005). The 
functional receptor for Semaphorin4D in lymphoid tissues is CD72 (Kumanogoh et 
al., 2000).
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f. N europilins s tru ctu re  and functions
At least eight members have been characterised in the neuropilin family. 
Neuropilins are single spanning transmembrane proteins. Their extracellular 
moiety contains two N-terminal domains similar to complement binding domains 
called CUB domains, two coagulation factor V /V III homology domains, and a MAM 
(Meprin/A5/Mu-phosphatase) domain (figure 17). The intracellular moiety of 
neuropilins is a short cytoplasmic tail of about 40 amino acids that contains a PDZ 
domain-binding motif.
Neuropilins are widely expressed in all phyla, except in flies. Particularly, they 
are expressed at the surface of neuronal cells, endothelial cells of capillaries and 
blood vessels, and in mesenchymal cells surrounding blood vessels.
I igaiKl b ind ing  site Signal transduction?
Sema dom ain b ind ing s ite O ligom erisa tion s ite
Ig-basic b ind ing s ite M em brane localisation 
and c luste ring
Figure 1 7 : N europilins structure and function. The C-terminal moiety o f neuropilins contains the ligand binding 
domain and a site tha t triggers oligomerisation. The intracellular moiety o f neuropilins is very short but the presence 
o f a PDZ domain may confer neuropilins a role in signal transduction. CUB: complement binding domain, MAM: 
m eprin/A5/M u-phosphatase domain, Ig : immunoglobulin.
Neuropilin 1 and 2 genes span respectively 120kb on chromosome 10p l2  and 
112 kb on chromosome 2q34 (Rossignol et al., 1999). Neuropilin 1 consists of 17 
exons and weighs approximately 140KDa, whereas neuropilin 2 contains 18 exons 
or 17 exons if alternatively spliced (Rossignol et al., 2000). Despite similar 
domain structures, the overall homology between these two neuropilins is only 
44%. In fact, both neuropilins are expressed in several tissue-specific splice 
forms that d iffer by their C-terminal moiety. At least three isoforms of Neuropilinl 
(N p l, s l2 N p l, and s l lN p l )  and five isoforms of Neuropilin2 (Np2a(17), 
Np2a(22), Np2b(0), Np2b(5), and s9Np2) are generated by alternative splicing. 
The alternative splicing occurs in the linker regions, which are located between 
the coagulation factor-homology and MAM domains as well as between the MAM 
and transmembrane domains. Some neuropilin isoforms are soluble. They 
correspond to truncated N-terminal neuropilin regions, lacking the 
transmembrane and cytoplasmic domains. The soluble neuropilin isoforms may
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play a role of natural inhibitors (Rossignol et al., 2000). In fact, transmembrane 
neuropilins and soluble neuropilins perform opposite functions, the first acting as 
receptors and the latter as receptor antagonists (Gagnon et al., 2000).
The CUB domain, of approximately 110 residues, contains four conserved 
cysteines that form two disulfide bridges. The structure of the CUB domain has 
been predicted to be a p-barrel similar to that of immunoglobulins. The CUB and 
coagulation factor homology domains represent the ligand-binding site. CUB binds 
to the sema domain and the coagulation factor homology domain binds to the 
immunoglobulin-like domain and the basic C-terminal tail of secreted 
semaphorins. The MAM domain, of approximately 170 amino acids, also contains 
four cysteines that probably form disulfide bridges. This domain is thought to 
have an adhesive function, and is involved in the oligomerisation process of 
neuropilins (Roskies, 1998), and for the interaction with other membrane 
receptors (He and Tessier-Lavigne, 1997). The PDZ domain is also called DHR 
(Dig homologous region) or GLGF (relatively well conserved tetrapeptide in these 
domains) and possesses different binding properties and is found in several 
signalling proteins. PDZ domain-containing molecules serve to anchor proteins at 
specific subcellular locations and organise intracellular signal transduction 
components. Three C-terminal amino acids S (Serine), E (Glutamate), and A 
(Alanine) represent the PDZ domain-binding site. These three amino acids allow 
neuropilins to bind PDZ domain-containing proteins, such as NIP (Neuropilin 
Interacting Protein). NIP protein might participate in the regulation of neuropilin 
signalling as a molecular adapter that couples neuropilins to membrane trafficking 
machinery, as is the case in dynamic axon growth cones (Kornau et al., 1997). 
Soluble neuropilins, missing the last three SEA-COOH amino acids, might not 
interact with NIP but with other adapters. Also, NIP protein could act positively to 
link neuropilins to signalling molecules or to the cytoskeleton in order to permit 
clustering, and/or it could act as an inhibitory protein to mask critical regions of 
neuropilins that interact with other signalling molecules or receptors. Therefore, 
PDZ domain-binding sites are responsible for neuropilins localisation and 
clustering, and eventually signal transduction (Cai and Reed, 1999).
Neuropilins are functionally active when they form either homodimers or 
heterodimers. They are co-receptors for class 3 semaphorins and for selected 
isoforms of the angiogenic vascular endothelial growth factor, those containing a 
heparin-binding domain (VEGFi65, i45) (Serini et al., 2003; Torres-Vasquez, 2004; 
Soker et al., 1998). Neuropilins form complexes with plexins, VEGFs receptors 
and with adhesion molecules such as Ll-CAM (Castellani et al., 2000).
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Consequently, neuropilins are involved in many biological processes, such as 
axonal guidance (via semaphorin interactions), angiogenesis (via VEGF 
interactions), cell adhesion (via the coagulation factor domains and Ll-CAM 
interactions), tumourigenesis and tumour progression (for a review see 
Guttmann-Raviv et al., 2006).
g. Semaphorins functions
Semaphorins are chemotactic guidance cues playing crucial roles orchestrating 
cellular movement. Semaphorins were first identified in the nervous system for 
their role in neuronal cell migration and axon guidance. Since their first 
identification in the early 90s' in the developing nervous system, semaphorins 
have been reported to be expressed in many other tissues and organs, including 
the immune and vascular systems, where they play major roles (for reviews see 
Bismuth and Boumsell, 2002; Moretti et al., 2006; Eichmann et al., 2005).
Class 3 of secreted semaphorins are known to act on nerves as repulsive or 
attractive cues. For example, Semaphorin3A, which is essential for the correct 
wiring of the peripheral nervous system (PNS), functions as an axonal repellent 
for motoneurons, sympathetic ganglion neurons, and a subset of sensory 
neurons. Semaphorin3B and 3C repel sympathetic ganglion neurons, but not DRG 
(dorsal root ganglion) neurons, unlike Semaphorin3A (Takahashi et al., 1998). 
Additionally, Semaphorin3C attracts cortical axons (Pascual et al., 2005; Bagnard 
et al., 2000). Semaphorin3E inhibits growing retinal axons (Steinbach et al., 
2002) while it stimulates neurite outgrowth of PC12 cells, to the same extent as 
NGF (Sakai et al., 1999). A Semaphorin3E mutation (S703L) has been found in a 
patient with CHARGE syndrome, which is characterised by nerve dysfunction, 
cardiac defects, and growth retardation (Lalani et al., 2004).
Class 3 of secreted semaphorins are known to act on endothelial cells as 
repulsive or attractive cues. For example, Semaphorin3A inhibits endothelial cell 
adhesion and migration through integrin inhibition, thus controlling vascular 
morphogenesis (Serini et al., 2003). Semaphorin3F is also an inhibitor of 
angiogenesis inhibiting VEGF165- and bFGF-induced angiogenesis (Kessler et al.,
2004). Semaphorin3C, which is required for normal cardiovascular patterning, 
stimulates endothelial cell proliferation and survival and enhances their adhesion 
by increasing integrin activity, to the same extent as VEGF-A. Semaphorin3C also 
induces endothelial cell directional migration by stimulating integrin 
phosphorylation, and tube formation by stimulating VEGFi 20 secretion via 
neuropilin/plexin signalling, like VEGF-A, and contrary to Semaphorin3A (Banu et
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al., 2006). Interestingly, Semaphorin3A and VEGFi65 compete for Neuropilinl 
binding (Bachelder et al., 2003). Semaphorin3E, through its specific PlexinDl 
receptor, restricts vessel growth and branching to intersomitic regions, thus 
controlling endothelial cells positioning and the patterning of developing 
vasculature during embryogenesis (Gu et al., 2005). PlexinDl is a receptor for 
secreted Semaphorin3C and 3E that is expressed by endothelial cells and is 
critical for vascular development (Gitler et al., 2004; Torres-Vasquez, 2004).
Some semaphorins play major roles in the immune system, such as 
transmembrane Semaphorin4D protein (CD100), Semaphorin7A, and secreted 
Semaphorin3A, by regulating humoral and cellular immune responses, as well as 
the inflammatory response (Shi et al., 2000; Czopik et al., 2006; Suzuki et al., 
2007; Lepelletier et al., 2006). The soluble version of the transmembrane 
Semaphorin4D protein inhibits immune cell migration (Delaire et al., 2001).
Recently, semaphorins have been implicated in tumourigenesis, tumour cell 
migration, invasive growth, and angiogenesis (Neufeld et al., 2005; Pan et al., 
2007; Serini et al., 2003; for reviews see Hinck, 2004; Chedotal et al., 2005 and 
2007; Suchting et al., 2006). Semaphorin3B and 3F are tumour suppressors, 
whose genes are located on chromosome 3p21.3, which is frequently lost (LOH) 
in prostate cancer (Dahiya et al., 1997). Semaphorin3F is also a potent 
metastasis inhibitor that is markedly down regulated in highly metastatic 
melanoma tum our cells (Kessler et al., 2004; Bielenberg et al., 2004). 
Particularly, Semaphorin3F inhibits the formation of metastases in the lymph 
node and lung. Semaphorin3C is overexpressed in ovarian tumour cell lines with 
invasive and metastatic behaviour (Yamada et al., 1997; Christensen et al., 
1998; Neufeld et al., 2005). Semaphorin3E expression positively correlates with 
the metastatic ability of breast cancer cells, and its paracrine stimulation 
promotes metastasis growth in the lung (Christensen et al., 1998 and 2005). 
Semaphorin3E, when truncated at its C-terminal moiety by furin(-like) 
convertase, mediates tumour-endothelial cells interaction, stimulating lung 
endothelial cells migration via E rk l/2  activation and thus contributing to a local 
angiogenic response, which contributes to metastasis to the lung (Christensen et 
al., 2005). Semaphorin4D is also able to control invasive growth and tumour 
angiogenesis, because of the association of its receptor PlexinBl with the MET 
receptor, which when stimulated by its ligand HGF controls invasive growth, and 
because Semaphorin4D stimulates endothelial cell migration (Giordano et al., 
2002; Conrotto et al., 2004; Basile et al., 2006).
51
A IM S  and OBJECTIVES
Semaphorins control the migration of nerve, immune, and endothelial cells, 
and are increasingly implicated in tumour cell migration and invasion. The aims of 
this thesis were therefore to investigate whether semaphorins also play a role in 
normal and/or tumour cell migration in prostate and whether semaphorin 
signalling is involved in the development of diseases of the prostate (BPH, PCa, 
metastasis) by influencing cellular movement.
Because the expression of semaphorins and their receptors, plexins and 
neuropilins, had not been assessed in normal or diseased prostate before, we first 
needed to establish whether semaphorins and their receptors were synthesised 
by prostate cells. To study their expression profiles, 10 prostate cel! lines were 
grown to approximately 80% confluence, and total RNA was extracted at three 
consecutive passages for each cell line. The presence of semaphorins, plexins, 
and neuropilins genes was detected by RT-PCRs using specific primers.
After establishing that normal and diseased prostate cell lines express 
semaphorins and receptors, we needed to understand what could regulate their 
expression in diseased prostate. We hypothesised that semaphorin expression is 
switched on in cancer in response to hypoxia. Expression of semaphorins in 
response to regions of hypoxia in a tumour may activate plexin receptors on 
endothelial cells promoting their migration and enhancing angiogenesis. Regions 
of hypoxia are frequent in cancers and HIFla, a transcription factor whose 
degradation is inhibited as a response to hypoxia, is overexpressed in prostate 
primary tumours and regional and distant lymph node and bone metastases, 
compared to normal prostate tissue (Du et al., 2003; Hao et al., 2004). H IF la is 
mainly responsible for the angiogenic switch (Semenza, 2000; Diaz-Gonzalez et 
al., 2005) thus promoting an increase in VEGF expression and angiogenesis, the 
formation of new blood vessels bringing oxygen and nutrients that are essential 
for the survival of the cancer cells and for the growth and metastatic propagation 
of cancer. In prostate cancer, the quantification of microvessel density and the 
gene expression of angiogenic factors (such as VEGF) have been correlated with 
the metastatic potential of prostate cancer cells (Weidner et al., 1993; Jackson et 
al., 1997; Aalinkeel et al., 2004).
The regulation of semaphorins expression by oxygen deprivation had not been 
investigated before. In order to investigate the expression profiles of semaphorins 
following hypoxic conditions, normal and primary tumour prostate cell lines as
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well as one colon carcinoma cell line were cultured in hypoxic incubators. After 
24h and 48h, total RNA was extracted and RT-PCRs were performed using specific 
primers for secreted semaphorins.
The expression of the semaphorin 3e gene/ one of the least studied secreted 
semaphorins at the time (2001), had been positively correlated with the 
metastatic ability of breast cancer cells (Christensen et al., 1998). Four years 
later, the same group confirmed their results and showed that semaphorin 3e 
paracrine stimulation promoted metastasis growth in the lung (Christensen et al.,
2005). Moreover, RT-PCR experiments from results chapter 1 of this thesis 
showed that semaphorin 3e expression was ubiquitous in all the prostate cell lines 
tested, with variation in expression according to the cell type. To quantify 
semaphorin 3e expression in normal and diseased prostate, real-time RT-PCR 
experiments using specific primers and probes were performed. To understand 
the role of Semaphorin3E in normal and diseased prostate, the protein had to be 
produced in vitro, as it is not commercially available (unlike Semaphorin3A). To 
produce Semaphorin3E protein, its complete cDNA sequence was amplified by 
PCR using primers with specific sites for 2 restriction enzymes, and ligated into a 
mammalian expression vector. The recombinant vector containing the transgene 
was subsequently used to transform Cos-7 cells. After 72h, the medium was 
collected, concentrated, and the amount of secreted Semaphorin3E protein was 
measured. The secreted Semaphorin3E protein was thus available for further 
experiments.
Prior to investigating the roles of Semaphorin3E on cell migration in prostate 
cells which are not easily transfectable, preliminary experiments about its role at 
large were performed in easily transfectable cellular systems (Cos, NIH and HEK 
cells). Results published by other groups showed that Semaphorin3A and 3F 
inhibited pi-integrin-mediated adhesion of endothelial cell and tumour cell on 
fibronectin respectively, while Semaphorin3C stimulated endothelial cell adhesion 
by increasing p l-in tegrin  activity, suggesting a role for secreted semaphorins in 
regulating integrin-mediated cell adhesion (Serini et al., 2003; Bielenberg et al., 
2004; Banu et al., 2006). Cell adhesion is a phenotype involved in cell migration 
and metastasis and the role of Semaphorin3E in cell adhesion had not previously 
been determined. To determine if Semaphorin3E protein has an affect on cell 
adhesion, adhesion assays were performed in the presence of Semaphorin3E. In 
addition the effect of Semaphorin3E protein on pl-integrin activity and focal 
adhesion formation was determined using immunocytochemistry. I t  is only with 
the publication of Semaphorin3E functional receptor, PlexinDl (Gu et al., 2005),
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that it was possible to elucidate the role of Semaphorin3E with these preliminary 
experiments. Further experiments using prostate cells are needed to investigate 
the role of Semaphorin3E specifically in the prostate and prostate cancer.
In parallel, Dr. Williamson (my supervisor) discovered that the plexin b l gene 
is mutated in prostate cancer and metastasis (Wong et al., 2007). In an attempt 
to understand the biological effects of these mutations on cell movement, 
migration assay experiments were performed, in presence or absence of ligand, 
Semaphorin4D.
The aims of the thesis were therefore to:
1. Determine if semaphorins and their receptors are expressed in prostate 
cell lines and tissue.
2. Determine if expression of semaphorins is regulated by hypoxia in 
normal and cancer prostate cell lines.
3. Determine the effect of Semaphorin3E protein on cell adhesion and p i-  
integrin activity.
4. Determine the effect of mutations found in the plexin b l gene in prostate 
cancer on cell motility.
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CHAPTER 2: MATERIALS AND METHODS
LIST OF MANUFACTURERS CONTACT DETAILS
Applied Biosystems: http://www3.appliedbiosvstem s.com /AB H om e/index.htm . 850
Lincoln Centre Drive, Foster City, CA 94404, USA.
ATCC: http://www.lQCProm ochem -atcc.com /. LGC Standards, Queens Road, Teddington, 
Middlesex, TW11 OLY, UK.
Autogen Biodear: http://www.autOQenbioclear.com /. Holly Ditch Farm, Mile Elm, Caine, 
Wiltshire, SN11 OPY, UK.
Billups Rothenberg: http://w w w .brincubator.com /. PO Box 977, Del Mar, CA 9 2 0 1 4 -0977 , 
USA.
Biogene Ltd: http://w ww .bioQene.com /index.cfm , BioGene House, 6 The Business Centre, 
Harvard Way, Kimbolton, Cambs PE28 ONJ, United Kingdom
Cambrex: www.cambrex.com.Cam brex Corporation, 1 Meadowlands Plaza, East
Rutherford, New Jersey 07073.
Chemicon International: www.chemicon.com. 28820  Single OAk Drive, Temecula, CA 
92590.
Clontech: www.clontech.com, Clontech Laboratories, Inc., 1290 Terra Bella Ave., Mountain 
View, CA 94043 , USA.
Costar/Corning Incorporated: http://www.scienceproducts.cornina.com. Corning, NY
144831, USA.
Eppendorf: h ttp ://w w w .eppendorf.co .uk /in t/7N 3, Endurance House, Vision Park, Chivers 
W ay, Histon, Cambridge, CB24 9ZR, UK.
Gibco, Invitrogen: http://w w w .invitrogen.com /site /us/en/hom e.htm l. Invitrogen Ltd, 3 
Fountain Drive, Inchinnan Business Park, Paisley, UK, PA4 9RF.
Jackson Im munoResearch Laboratories, Inc.: www.iacksonimm uno.com, 872W . Baltimore 
Pike, P.O. Box 9 , W est Grove, PA 19390.
Labtech international: h ttp ://w w w .labtech.co .uk/. 1 Acorn house, The Broyle Ringmer, 
East Sussex, BN8 5NN.
Leec Ltd: http://w w w .leec.co.uk/w eb/LEEC /index.cfm . Private road 7, Colwick Industrial 
Estate, Nottingham, NG42AJ, UK.
Millipore: h ttp ://w w w .m illipore .com /, Suite 3 & 5, Building 6, Croxley Green Business Park, 
W atford, Hertfordshire. W D18 8YH.
New Brunswick Scientific: h ttp://w w w .nbsc.com /. PO Box 4005 , Edison, NJ 0881 8 -4 0 0 5 , 
USA.
Nunc: http://w w w .nuncbrand.com /en/default.aspx. 75 Panorama, Creek Drive, Rochester, 
NY, 14625-2385 .
Pierce: h ttp ://w w w .p iercenet.com /. PO Box 117, Rockford, IL  61105 , USA.
Qiagen: http://w w w l.Q iaqen.com /D efault.aspx?, QIAGEN House, Fleming W ay, Crawley, 
West Sussex, RH10 9NQ.
Pierce: h ttp ://w w w .p iercenet.com /. PO Box 117, Rockford, IL 61105  USA.
R&D Systems: h ttp ://w w w .rndsvstem s.com /. 19 Barton Lane, Abingdon Science Park, 
Abingdon, 0 X 14  3NB, UK.
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Santa Cruz Biotechnology: h ttp ://w w w .scbt.com /. Santa Cruz Biotechnology, Inc. 2145  
Delaware Avenue Santa Cruz, CA. 95050  U.S.A.
Sigma: www.siam a.com . 3050 Spruce Street, Saint Louis, Missouri 63103  USA.
Sorvall : h ttp ://w w w .therm o.com /com /cda/hom e/1 ...0 0 .htm l. hermo Fisher Scientific Inc., 
81 Wyman Street, Waltham , MA 02454 , USA.
Stratagene: h ttp ://w w w .strataaene.com /hom epaae/default.aspx, 11011 N. Torrey Pines 
Road, La Jolla, CA 92037 , USA.
Vector Labs: h ttp://w w w .vectorlabs.com /uk/default.asp. 3 Accent Park, Bakewell Road 
Orton Southgate, Peterborough, PE2 6XS, England
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Section 1: M a te ria ls
1. Cellular biology materials
All the cell lines cited below were genotyped, maintained and catalogued by 
Professor Masters (email: jmasters@ucl.ac.uld. Cells were typed by short tandem 
repeat profiling (Masters et al., 2001). Only stocks that had been genotyped were 
used for experiments. All prostate cell lines were maintained in culture in a 
humidified incubator at 36.5°C, 21% 0 2, 5% C02 (LEEC). The cells were cultured 
in flasks (Nunc). When confluency was reached, the cells were rinsed with PBS 
(Gibco), and trypsinised for re-seeding at a 1/5 density (Trypsin 2.5g/L, Gibco). 
The culture medium was typically changed every two-three days.
a. Prostate cell lines
The matched non-neoplastic ("normal") and primary tumour derived cell lines 
were isolated from a patient with localised prostate carcinoma and were 
subsequently immortalised by the HPV virus (Bright et al., 1997). From patient 
number 1542 were isolated non-neoplastic ("normal") epithelial cells 1542NPTX 
(abbreviated 42N), non-neoplastic ("normal") stromal cells 1542FTX (42F) and 
primary tumour cells 1542CPTX (42C). From patient number 1532 were isolated 
non-neoplastic ("normal") epithelial cells 1542NPTX (32N), non-neoplastic 
("normal") stromal cells 1532FTX (32F) and primary tumour cells 1532CPTX 
(32C). Matched non-neoplastic ("normal") and primary tumour derived cell lines 
were grown in keratinocyte-SFM medium (Gibco), supplemented by 2.5jig of 
recombinant epidermal growth factor (rEGF), 15mg of bovine pituitary extract 
(BPE), and 8% foetal calf serum (FCS, Gibco).
The BPH derived cell lines were isolated from a patient diagnosed with benign 
prostate hyperplasia and are of epithelial (Pre2.8) or stromal (S2.13) origins 
(Daly-Burns et al., 2007). They were immortalised by a temperature sensitive 
SV40 virus construct. BPH-derived epithelial cells were grown in PREGM medium 
(Cambrex), with supplements. BPH-derived stromal cells were grown in 
RPMU640 medium (Gibco), supplemented by 8% FCS (Gibco).
The PCa metastasis derived cell lines, which spontaneously immortalised, were 
isolated from metastases to the brain (DU145), the lymph nodes (LNCaP), or the 
bone (PC3). They were grown in RPMI1640 medium (Gibco), supplemented by 
8% FCS and L-Glutamine (2mM, Gibco). Among the three metastases derived cell 
lines, PC3 and DU145 are able to form tumours when injected to immuno- 
suppressed animals. LNCaP cells do not form tumours in nude mice, unless co-
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injected with fibroblasts or a matrix containing adhesion factors. LNCaP cell line 
was isolated from lymph node metastasis of a patient diagnosed with prostate 
cancer (Horoszewicz et al., 1980 and 1983). LNCaP cells are androgen-sensitive 
cells, although they do express a mutated version of the androgen receptor (AR). 
LNCaP cells are tumourigenic in mice, but not metastatic. DU145 cell line was 
isolated from brain metastasis of a 69-year-old patient with moderately 
differentiated prostate cancer (Stone et al., 1978 and Mickey et al., 1980). DU145 
cells are androgen-insensitive cells, as they do not express the androgen 
receptor. DU145 cells are tumourigenic in mice but not metastatic. PC3 cell line 
was isolated from bone metastasis of a 62-year-old patient with undifferentiated 
prostate cancer (Kaighn et al., 1978 and 1979). PC3 cells are androgen- 
insensitive cells since they do not express the androgen receptor. They are highly 
tumourigenic and metastatic in mice.
Cell lines Passages
LNCaP 26 /  27 /  28
DU145 7 4 / 7 5  /  76
PC3 29 /  3 0 /  31
1542CPTX (42C ) 67 /  68 /  69
1542NPTX (42N ) 49 /  50 /  51
1542FTX (42F) 23 /  24 /  25
Pre2.8 52 /  54 /  57
S2.13 62 /  63 /  64
Table S: Prostate cell lines passages at 
which total RNA was extracted for RT- 
PCR.
b. Other cells in culture
The colon carcinoma cell line HT29 (obtained from ATCC) was grown in 
McCoy's medium (Gibco) with 8% FCS (Gibco).
The monkey kidney Cos-1 and Cos-7 cells (obtained from ATCC) were grown in 
RPMI1640 medium (Gibco) supplemented by 8% FCS and L-Glutamine (2mM, 
Gibco).
The mouse fibroblast NIH3T3 cells (obtained from ATCC) were grown in DMEM 
medium (Gibco), supplemented by 8% FCS and L-Glutamine (2mM, Gibco).
The human embryonic kidney HEK293 cells (obtained from ATCC) were grown 
in DMEM medium supplemented by 8% NCS (Labtech International) and L- 
Glutamine (2mM, Gibco).
59
c. Paired no n -n eo p las tic  and carcinom a p ro sta te  tissu e  sam ples
Paired clinical samples from 6 patients with prostate cancer were kindly 
provided by Helmut Klocker from the University of Innsbruck, Austria (table 6). 
For each patient, they provided us with a malignant and non-neoplastic sample 
(total RNA extracts, extracted from laser capture microdissected fresh frozen 
prostate tissue). Patients presented no regional lymph node metastasis (NO), 
clinical stages ranging from confined tum ours (pT2) to tum ours tha t have 
extended through the prostatic capsule (pT3a); i.e. tumours confined within the 
prostate but involving both lobes (2c) and tumours with extra capsular extension 
(3a), Gleason scores (GSC) between 5 and 7. Unfortunately, distant metastasis 
could not be assessed (MX) (table 6). The Gleason grade defines the grade of the 
malignancy (ranges from 2 to 10) and illustrates the architectural changes of the 
cancer. The Gleason score is the sum of the 2 highest grades. A Gleason score 
between 5-7 defines well-moderately differentiated tumours. The higher the 
Gleason score the more severe and less differentiated the cancer is. Poorly 
differentiated tum ours have lost the ir ability to form gland-like structures. These 
tumours are the most aggressive and are most likely associated with capsular 
in filtra tion, seminal vesicles extension, and/or metastatic spread.
Sample number Prostate weight (g) PT N M R GSP GSC
1-2 37 3a 0 X 0 3+2 5
3-4 40 2c 0 X 1 3+3 6
5-6 47 2c 0 X 0 3+3 6
7-8 34 3a 0 X 1 3+3 6
9-10 20 2c 0 X 1 3+2 5
11-12 45 2c 0 X 0 3+4 7
Table 6 : H istological data of the  paired no n-neo plastic /carc in om a pros ta te  tissue  
sam ples (H . K locker). The 6 paired carcinom a/non-neoplastic tissue samples are 
orig inating from  patients w ith well or m oderately d ifferentiated tum ours (GSC 5-7), 
confined w ith in  the prostate, e ither involving both lobes (2c) or w ith extra capsular 
extension (3 a ), presenting however no regional lymph node metastases (N :0 ), and whose 
d istant metastases could not be assessed (M :X). pT: tum our stage, R: recurrence, GSP: 
Gleason grade, GSC: Gleason score.
2. M o lecu lar b io logy m ateria ls
a. P lasm id DNAs
KIAA0331/pBLUESCRIPT I I  SK(+) phagemid was kindly provided by Tanaka 
(KIAA0331 clone DKFZp566H0824 in pAMPl from RZPD). This phagemid contains 
the complete coding sequence of semaphorin 3e gene with the 5' and 3' 
untranslated regions (UTR). Semaphorin 3e insert was amplified from this
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plasmid using specific primers containing restriction enzyme sites (5'KpnI-forward 
primer and 3'NotI-reverse primer, refer to page 63).
The expression vector pEF6/Myc-His-version B (Invitrogen) contains the T7 
primer, the restriction enzyme sites 5'KpnI and 3'NotI, a Myc epitope and a 
6xHis-Tag (figure 18). This expression vector was used for the cloning of 
semaphorin 3e insert.
PlexinAl/VSV and Neuropilinl/HA plasmids DNA were kindly provided by S. 
Strittmaker in pcDNA3.1 vectors (Takahashi and Strittmatter, 2001). These 
plasmids were used to transfect cells that were subsequently used in 
immunohistochemistry experiments and adhesion assays in presence or absence 
of Semaphorin 3A or 3E proteins.
PlexinBl plasmid DNA was kindly provided by A. Hall (Driessens et al., 2001) 
in a pCDNA3 vector.
AP-Semaphorin4D-GST plasmid was kindly provided by L.Tamagnone 
(Tamagnone et al., 1999) in an APtag-1 vector.
PlexinDl/pBKVSV plasmid was kindly provided by A. Puschel (Rohm et al., 
2000b). This phagemid vector pBK (Stratagene, Kanamycinr) contains plexin d l 
cDNA and a VSV-Tag that has been introduced between the signal peptide and 
the plexin d l coding sequence. This plasmid was used to transfect cells that were 
subsequently used for immunohistochemistry experiments and adhesion assays in 
presence or absence of Semaphorin3A or 3E proteins.
All the above cited plasmids were amplified in Max Efficiency® DH5a™- 
competent cells (refer to page 65), and purified using the Maxi Purification kit 
(refer to page 65). Mammalian cells were transfected with each plasmid using 
Lipofectamine™2000 (refer to page 67).
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Figure 1 8 : Plasmid pEF6/M yc-H is (version B, In v itro g en ).
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b. P rim ers  and probes
• Primers for RT-PCR
All PCR primers were designed manually and synthesised by Invitrogen. 
Primers were used at a concentration of 10pmol/|iL.
> Semaphorins RT-PCR primers:
Gene Forward primer Reverse primer
Semaphorin 3a ACTGGCTATTTCAGCAATGGAGC AACTTGTTCACAGAACTCATCC
Semaphorin 3b GACTTTCAGCCTGGAGCGAAC CTCTGTTCGGAGACTTGGACG
Semaphorin 3c CAAGACCT CT GAAT ACTT CAGCC GTACCATCTGGGATGACATGTGC
Semaphorin 3e GGGCACATT AT CACCTT GCTCC CTCATCGTCATGCTCAGTGCGG
Semaphorin 3f CTCCGTGTTCCGAGGCTCTGC T AGCGCCCGT CGCCT GCAT CC
Semaphorin 4d GGTCTTCGCTGTGAACGCAC AAGTAGACCCTGTCATCCTC
> Plexins RT-PCR primers:
Gene Forward primer Reverse primer
Plexin a l GGGACGCCAGCTCCGTGCGTGC CTT CAGCT CC AACAGGCCAGT GG
Plexin a2 GT GT ATT GGCGAGT GT AAGCCAG AGCTGGGTCTCAGATACGGTGAC
Plexin a3 CGGCAGCGTGGCCTCGCTCAC GGAGGATGATGCGAGTCATGCG
Plexin b l GCTGGGCTGTCTGCAAGTGGCAG GGGAAGATATGGAGCCAGAACCTG
Plexin b3 CAGTGGCAGTCACCTCTATGTCC GACCTGCCAGGCCTT CGACCTG
62
> Neuropilins RT-PCR primers:
Gene Forward primer Reverse primer
Neuropilin 1 C CTCCTGTTGTGTCTTCAGGGC G AGCGCTCTGCAGACCAGTTGG
Neuropilin 2 CTACATCAAGTTCACACTCCGAC CCATTGTCATCACCATGGAGCC
> GAPDH RT-PCR primers:
Gene Primer Sens Primer Anti-Sens
GAPDH CCACCCATGGCAAATTCCATGGCA TCTAG ACGGCAGGTCAGT CCAC
The glycerol 3 phosphate dehydrogenase gene is a housekeeping gene used as 
a control for DNA levels.
> VEGF RT-PCR primers:
The primers for the three isoforms of vascular endothelial growth factor A 
(VEGFA) were available from R&D systems (human VEGF primer pair™). The 
three isoforms amplified are VEGF2oe (567bp), VEGF189 (516bp) and VEGF165 
(444bp). The isoforms VEGFi2i and VEGF145 are not amplified by these primers 
because they lack the lower target site. The positive control 2 (340bp) of 
unknown origin was supplied by the manufacturer (+ve Ctr).
• Quantitative RT-PCR primers
Quantitative PCR primers were designed using Primer Express® software and 
synthesised by Invitrogen. Primers and probes were chosen on two consecutive 
exons (in order to selectively amplify the cDNA and not contaminating genomic 
DNA), which do not show any alternative splicing. The probes are overlapping the 
two exons.
> Semaphorin 3e qRT-PCR primers and probe:
Semaphorin 3e qene Sequence
Forward primer-Exon 16 CAGAAAGGACGTGAGACAAGAAA
Reverse primer-Exon 17 ACCA AGGT CCAT CTTA ACCACTCT
Probe/FAM dye TCATCTGTCTTCACCTCCT
> Plexin b l qRT-PCR primers and probe:
Plexin b l qene Sequence
Forward primer-Exon 30 CAAGGCCATCCCTGAGATCTAC
Reverse primer-Exon 31 AACAGGTCATCCACGAACTTCTG
Probe/FAM dye CCATGAAGGGCACCC
• Sequencing and cloning primers
The same PCR primers than those used for RT-PCR were used for sequencing 
purposes at a concentration of 4pmol/jiL. The sequencing primers used for the
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cloning of semaphorin 3e gene were designed manually and synthesised by 
Invitrogen.
> Semaphorin 3e cloning and sequencing primers:
Semaphorin 3e Sequence
5'Kpn I-forward primer CGCGCGGGTACCGCATGGCATCCGCGGGC
3'NotI-reverse primer CGCGCGGCGGCCGCGAGGAGTCCAGCGTGT
pEF6-Sema3e-Myc/His Sequence
P1-T7 promoter/priminq site TAATACGACTCACTATAGGG
P2-Sema3e-Exon 1-reverse primer CATCCAGCAGCATTGTATGG
P3-Sema3e-Exon 17-forward primer A A7TCTTGCAGCTGATCG GT
P4-BGH-Reverse priming site TAGAAGGCACAGTCGAGG
c. Antibodies and Semaphorin3A protein
The conditions used for each antibody (concentration and dilution) have 
previously been optimised by me or other people in the laboratory. The dilutions 
cited below are optimal for each antibody.
The ICa2 antibody is an in-house rabbit anti-PlexinBl antibody, which was 
kindly provided by S. Giordano (Giordano et al., 2002). This antibody was used 
for western blotting at a 1/500 dilution, using a secondary mouse anti-rabbit 
antibody HRP (horseradish peroxidase)-conjugated at a 1/1500 dilution 
(Autogen). The size of the expected band is lOOkDa.
The c-Myc antibody (9E10: sc-40) is a mouse anti-Myc antibody (Santa Cruz 
Biotechnology, Inc), which was used for western blotting at a dilution 1/600 to 
detect the Myc epitope of the recombinant Semaphorin3E protein produced. The 
secondary antibody, a goat anti-mouse antibody HRP-conjugated was used at a 
1/1000 dilution (Autogen). The size of the expected band is approximately 
90KDa.
The MAB2079Z antibody is a mouse monoclonal anti-human pl-integrins 
antibody, which is specific for active conformations of human pl-integrins 
(Chemicon International). This antibody was used for indirect 
immunofluorescence at a 1/200 dilution.
The V9131 antibody is a mouse monoclonal anti-vinculin antibody (Sigma), 
which was used for indirect immunofluorescence at a 1/400 dilution.
The V4888 antibody is a rabbit anti-VSV antibody (Sigma), which was used for 
indirect immunofluorescence at a 1/00 dilution.
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The HA-probe (Y -ll:sc805 ) is a rabbit polyclonal anti-HA IgG antibody (Santa 
Cruz Biotechnology, Inc), which was used for indirect immunofluorescence at a 
1/00 dilution.
All the other secondary antibodies used are from Jackson ImmunoResearch 
Laboratories, Inc.: fluorescein (FITC)-conjugated polyclonal rabbit anti-mouse 
antibody, rhodamine (TRITC)-conjugated donkey anti-mouse antibody, TRITC- 
conjugated goat anti-rabbit antibody, fluorescein (FITC)-conjugated donkey anti­
goat antibody, and fluorescein (FITC)-conjugated donkey anti-rabbit antibody. All 
secondary antibodies were used at a 1/100 dilution for indirect 
i m m u n of I u orescence.
Phalloidin TRITC-conjugated (Sigma) to stain actin microfilaments in red 
(8.3pL/2.3mL). The mounting medium with DAPI (Vector labs) was used to stain 
nuclei in blue.
Recombinant human semaphorin-3A/Fc chimera (R&D systems) is the 
Semaphorin3A protein used for biological assays such as adhesion assays. A 
working stock solution of lOO^g/mL in 0.1% BSA was prepared.
Section 2:  M ethods
1. General methods
a. Bacterial transformation and plasmid DNA (m axi, m ini) preparations
Competent E.Coli strains, Max Efficiency DH5a™ (Invitrogen), were 
transformed by heat-shock with double-stranded circular plasmid DNA: 50nL of 
competent cells and an aliquot of plasmid DNA (e.g. Semaphorin3E, PlexinBl, 
PlexinAl, Neuropilinl, PlexinDl, Semaphorin4D expression vectors) were thawed 
on ice for few minutes. ljaL of plasmid DNA (lOng/mL) was added to the 50^L of 
competent cells, and incubated on ice for 30 minutes. Cells were then heat- 
shocked in a water bath at 42°C for 45 seconds and immediately placed on ice for 
2 minutes before adding 450nL of S.O.C medium (S.O.C medium: S.O.B. 
medium, 1M MgCI2, 20mL Glucose 1M. S.O.B medium: 20g bacto-tryptone, 5g 
bacto-yeast extract, 0.5g NaCI, 2.5mL KCI 1M, deionised H20 to IL, pH adjusted 
to 7 with NaOH lOO^L, autoclave.). Transformed cells were incubated in a shaking 
incubator at 225rpm for lh  at 37°C to allow expression of antibiotic resistance. 
Transformed cells were then diluted 1:10 and 1:100 with S.O.C medium and
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spread on LB (Luria Bertani broth: lOg tryptone, 5g yeast extract, lOg NaCI, 
deionised H20 to IL, adjust pH to 7 with 5N NaOH, autoclave) /Ampicillin (final 
concentration lOO^ig/mL) plates for incubation overnight at 37°C (turned upside- 
down).
The following day, single colonies were isolated with a pipette tip and used to 
inoculate a starter culture of 5ml of LB/Ampicillin broth which was incubated for 
approximately 8h in a shaking incubator at 300rpm (Innova 4300, New Brunswick 
Scientific) and 37°C. Glycerol stocks of positively transformed bacteria were 
stored at -80°C (0.85mL starter culture, 0.15mL glycerol). The rest of the starter 
culture was diluted 1/500 and used to inoculate lOOmL of selective LB medium 
(overnight in a shaking incubator at 300rpm) for (low copy) plasmid DNA 
preparations. Bacterial cells were harvested by centrifugation at 6000g in Sorvall 
SuperT21 (SL250T rotor) for 15 minutes at 4°C. Supernatant was removed by 
inverting the tubes and bacterial pellets were resuspended in 4mL of Buffer 
Pl/RNase A by vortexing (Maxi Kit, Qiagen). Then 4mL of Buffer P2 were added 
and mixed by thoroughly inverting the tubes. After 5 minutes incubation at room 
temperature, 4mL of buffer P3 were added and mixed by gently inverting the 
tubes. After 15 minutes incubation on ice, the precipitated material was 
centrifuged at 20000g for 30 minutes at 4°C and the supernatant containing the 
plasmid DNA was recentrifuged for 15 minutes at 4°C at 20000g. Supernatant 
was applied to an equilibrated QIAGEN-tiplOO column, subsequently washed with 
2xl0m L of Buffer QC to eliminate all contaminants (RNA, proteins, and low- 
molecular impurities). The plasmid DNA was eluted with 5 mL Buffer QF. The 
protocol for plasmid DNA preparation is based on a modified alkaline lysis 
procedure (Buffer PI, P2), and on the binding of the plasmid DNA to an anion- 
exchange resin (QIAGEN-tip) under appropriate low salt and pH conditions (Buffer 
QC, QF). Eluted plasmid DNA is then concentrated and desalted by isopropanol 
precipitation, by adding 3.5mL of isopropanol (0.7 volume) to the eluted DNA, 
mixing, and centrifugating at 15000g for 30 minutes at 4°C. DNA pellets were 
washed with 2mL 70% ethanol, and centrifuged at 15000g for 10 minutes. 
Supernatants were carefully removed, the pellets air-dried for 5 minutes, and 
redissolved in 200|A of TE buffer (lOmM Tris-CI, pH7.5, ImM EDTA).
b. Digestion by restriction enzymes, DNA precipitation and purification
The reaction used for enzymatic digestion (Notl, Kpnl) of DNA (e.g. 
semaphorin 3e cloning) was the following:
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Enzyme 
Buffer 10X
DNA 20jag
20U
dH20
Final volume
1/10 final volume 
to final volume 
20nL
The mixture was left 2h at least or overnight at 37°C and heated at 65°C for 5 
minutes to inactivate the enzyme. DNA was precipitated in between 2 digestions 
because the enzymes buffers were not compatibles (enzymes from New England 
Biolabs).
DNA precipitation (e.g. in between two digestions by different restriction 
enzymes) was obtained by adding 0,1 volume of 3M sodium acetate (NaAc), pH 
5.2 and 2 volumes of 95% ethanol to one volume of DNA sample. The mixture 
was left 15 minutes on ice before centrifugation at maximum speed (16100g, 
Eppendorf centrifuge) for 25 minutes. The supernatant was decanted and the 
pelleted DNA washed with ice-cold 70% ethanol before being centrifuged 10 
minutes and decanted. Pelleted DNA was air-dried and resuspended in an 
appropriate volume buffer or deionised water.
DNA purification was performed directly from the agarose gel using the 
QIAquick Gel Extraction Kit (Qiagen). The DNA fragment to purify was excised 
from the agarose gel with a clean scalpel, weighted, and incubated in 3 volumes 
of Buffer QG at 50°C for 10 minutes (until the gel has completely dissolved). After 
adding 1 gel volume of isopropanol, the mixture was applied to the QIAquick 
column and the column centrifuged for 1 minute. The bound DNA was washed by 
adding 0.75mL of Buffer PE to the column and centrifuging 1 minute. Finally, the 
DNA was eluted by adding 50jiL of Buffer EB to the column and centrifuging 1 
minute at maximum speed. Sample concentration was estimated using a 
spectrophotometer.
c. Cell transfection
Cells were transfected using Lipofectamine™ 2000, lm g /m l (Invitrogen). 24h 
prior to the transfection, cells were plated in T80 flasks in growth medium at a 
high density in order to obtain about 90% confluency on the day of transfection. 
To obtain optimal transfection efficiency, plasmid DNA and Lipofectamine™ 2000 
reagent were diluted in Opti-MEM® Reduced Serum Medium (Invitrogen). 24^g of 
plasmid DNA (PlexinAl, Neuropilinl, Semaphorin3E plasmids, etc.) and 60jiL of 
Lipofectamine™ 2000 were diluted in 1.5mL of Opti-MEM® medium respectively. 
After 5 minutes incubation at room temperature the diluted plasmid DNA was
67
combined to the diluted Lipofectamine™ reagent and mixed gently. The solution 
was incubated for 20 minutes at room temperature to allow the formation of 
DNA-Lipofectamine™ 2000 complexes. Finally, the mixture was added to the cells 
in culture. After 48h incubation, the cells were ready to assess for transgene 
expression.
2. Expression profiling of semaphorins, plexins, neuropilins, and VEGFs 
in normoxic and hypoxic conditions in prostate cell lines and tissues
a. Cell culture under normoxic and hypoxic conditions
Cell culture under normoxic conditions was performed in our laboratory using a 
humidified incubator at 36.5°C, 21% 0 2/ 5% C02 (LEEC). Cell culture under 
hypoxic conditions was performed at the Rayne Institute (University College 
London, Shakib et al., 2005), using a specific humidified incubator at 36.5°C, 1% 
0 2, 5% C02, 94%N2 (Billups Rothenberg Modulator Incubator, ICN-Flow). The gas 
was circulated at 2 bar pressure at lOL/min flow for 20 minutes at room 
temperature and the chamber was sealed. The medium p02 fell within 20 minutes 
and was maintained for the duration of the experiment.
Normal and primary tumour prostate cells, as well as colon cancer cells were 
transported on ice to the Rayne Institute. Cells were plated in flasks (Nunc) and 
allowed to grow to 90% confluency in a normoxic incubator. Subsequently, the 
flasks (3 T175 flasks per cell line) were incubated in an adjacent hypoxic 
incubator for 24h and 48h. After 24h under hypoxic conditions, the medium had 
already changed colour (from red to yellow) and many dead cells were in 
suspension. Total RNA from each flask was extracted using the RNAeasy® Mini Kit 
(Qiagen, refer to page 68), and transported on dry ice back to the laboratory, 
where it was stored and used for further experiments.
b. Total RNA extractions
All RNA extractions were carried out using the RNAse-Free DNAse protocol of 
the RNAeasy® Mini Kit (Qiagen). Cells were trypsinised, pelleted, and 
homogenised by adding 600jxL of buffer RLT and vortexing until complete 
homogenisation. The homogenised lysate was directly passed onto the 
QIAshredder column, and centrifuged for 2 minutes at maximum speed 
(16100g=13200rpm, Eppendorf centrifuge 5415D). One volume (600^L) of 70% 
ethanol was added to the homogenised lysate (supernatant), well mixed, and 
applied to an RNAeasy mini spin column to allow total RNA to bind to the column.
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After centrifugating 15 seconds at 8000g (9300rpm), contaminants were washed 
away by adding 700nL of buffer RW1, centrifugating for further 15 seconds at 
8000g (9300rpm), and SOOjaL of buffer RPE, centrifugating for 15 seconds at 
8000g (9300rpm). 500 more nL of buffer RPE were pipetted onto the column, and 
centrifuged for 2 minutes at maximum speed to dry the RNAeasy membrane 
(9300rpm). Total RNA was eluted from the column by adding 30pL of RNase-free 
water directly onto the RNAeasy column, and centrifugating for 1 minute at 
8000g (9300rpm).
c. Reverse Transcriptase Polymerase Chain Reaction: RT-PCR
First strand cDNA was synthesised from total RNA by incubating the following 
mixture at 70°C for 10 minutes and then quick chilling on ice:
Oligo (dT)i2-i8 (500ng/mL) 1^ 1 (Invitrogen)
Total RNA 5^g
dH20  12j.il
The same amount of total RNA was used for each RT-PCR reaction. The 
following components were then added to the mixture and incubated at 42°C for 2 
minutes:
5x first strand buffer 4^ 1
0.1M DTT (dithiothreitol) 2pl 
lOmM dNTP Mix l j L t l
dNTP is deoxy-nucleoside 5'-triphosphate; contains lOmM each of dATP, dGTP, 
dCTP and dTTP. SUPERSCRIPT™ RNAse II H' Reverse Transcriptase (Invitrogen) is 
added to the mixture and incubated at 42°C for 50 minutes, and then heated at 
70°C for 15 minutes to inactivate the reactions.
Control samples with no reverse transcriptase enzyme (control no RT), no DNA 
(control no DNA), as well as GAPDH controls have been performed for each 
experiment. All polymerase chain reactions (PCRs) have been performed on a
Perkin Elmer Thermal Cycler and all products run on an ethidium bromide stained
agarose gel electrophoresis (0.8-2%) and visualised by UV transillumination. 
Controls with no RT enzyme or no DNA were negative, and GAPDH expression 
levels were similar, showing approximately equal levels of total RNA between 
samples (results not always shown). Quantification of each PCR product (band 
intensity) has been performed using GeneTools software. Standard paired T-tests 
statistical analysis has been performed using Excel software (refer page 81).
Normoxic conditions:
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Profiling experiments under normoxic conditions have been performed in 
triplicate, on three consecutive RNA extractions (from three different passages) 
for each of the 10 prostate cell lines. The results presented are normalised means 
with standard errors of the mean (SEM). Normalisation was performed for each 
gene (semaphorins, plexins, neuropilins) against expression values obtained in 
the non-neoplastic "normal" epithelial prostate cell line 1542NPTX, abbreviated 
42N (va lue= l). Example: the value obtained for semaphorin 3e band intensity in 
cell line 42C (1542CPTX) was divided by the value obtained for the same gene in 
ceil line 42N, used as a reference for normal expression. The value obtained for 
the same gene in cell line 42F (1542FT) was also divided by the value obtained in 
cell line 42N, etc. The same applies for the other cell lines and the other genes. 
Standard paired T-tests statistical analysis has been performed using Excel 
software (refer to page 81).
At least one PCR product of each primer pair (refer to page 62) was sequenced 
(University of Dundee). Sequences were compared to the reference sequence for 
each gene on the NCBI website f httD ://www.ncbi.nlm.nih.Qov/T using the BLAST 
tool and each was found to be correct (see Appendix 1, page 179).
VEGFA isoforms:
Each RT-PCR for vascular endothelial growth factor A isoforms has been 
performed twice, giving the same results. The results presented are 
representative. The presence of mRNA for the three VEGF-A isoforms has also 
been assessed in RNA extracted from total prostate (commercially available from 
Clontech). The aim was to determine which isoforms were present for each cell 
type and therefore statistical analysis was not applicable.
Hypoxic conditions:
Each RT-PCR has been performed in triplicate, giving the same results. The 
results presented are representative (means of three repeats, with standard error 
of the mean (SEM). Normalisation was performed for each semaphorins gene 
against expression values obtained in the non-neoplastic "normal" epithelial 
prostate cell line 1542NPTX (42N=1), or against expression values obtained in 
the matched primary tumour prostate cell line 1542CPTX (42C=1), or against 
expression values obtained in the colon cancer cell line HT29 (HT29=1). Standard 
paired T-tests statistical analysis has been performed using Excel software (refer 
to page 81). The hypoxia-induced transcriptional activation of vascular endothelial 
growth factor VEGFA in the colon cancer cell line HT29 (Ellis et al., 1998) was 
used as a positive control. The VEGF primers used are the human VEGF primer 
pair™ (specific for all three VEGFA isoforms: VEGFies, VEGFi89, and VEGF2oe)-
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However, the percentage of agarose gel electrophoresis used here (0.8%) 
prevents visualising all isoforms.
d. Quantitative polymerase chain reaction: real-tim e PCR (qRT-PCR)
Primers and probes have been designed using Primer Express® software 
following manufacturer's instructions. Semaphorin 3e specific primers and probe 
span exons 16 to 17, where no alternative splicing has been detected (data not 
shown). Plexin b l specific primers and probe span exons 31 to 32. Each step has 
been optimised as suggested in the manual. Each qRT-PCR has been performed in 
triplicate, using pl-actin as internal control, with ABI PRISM® 7700 Sequence 
Detection System (Applied Biosystems). The results have been transformed and 
normalised as follows:
1. ACT=Average CT plactin-Average CT sample
2. Relative ACT=40-ACT
3. AACT=2'R8lativeCT
4. Remove baseline=AACT sampie-rAACT plactin
The results presented are normalised means of three independent repeats, 
with standard error of the mean (SEM). Another normalisation has been 
performed for each gene (semaphorin 3e, plexin b l)  against expression values 
obtained in normal epithelial prostate cells (1542NPTX, abbreviated 42N, 
va lue= l). Standard paired T-tests statistical analysis has been performed using 
GraphPad software (refer to page 81).
e. Screening for the presence of HIF-responsive elements (HRE)
The consensus sequence of HIF-responsive elements (HRE) is RCGTG, where R 
is A or G (Wenger et al., 2005). In order to search for the presence of HREs 
within the promoter regions of secreted semaphorin genes, the sequence of their 
promoters (promoter + first intron) was extracted form the NCBI database 
(http://www.ncbi.nlm .nih.aov/) and consensus sequences were screened using 
the word search tool from Word software.
3. P lexinBl mutations, Semaphorin4D production and migration assays
a. P lexinBl mutations: site-directed mutagenesis and stable
transfection (Magali Williamson and John Masters)
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Three of the most frequently found changes of plexin b l gene in prostate 
cancers and metastases were introduced into a cDNA clone of plexin b l by in 
vitro site-directed mutagenesis (experiments performed by my colleagues, Wong 
et al., 2007). The three mutations are single nucleotide changes: mutation 
A5359G, mutation A5653G, and mutation T5714C. NIH3T3 and Cos-1 cells were 
transfected (Lipofectamine™2000, Invitrogen) with wild-type plexin b l expression 
vector pcDNA3-WT-plxbl, with mutant plexin b l expression vectors pcDNA3- 
plxbl-A5359Gf pcDNA3-p!xbl-A5653G, and pcDNA3-plxbl-T5714C, and with the 
expression vector only pcDNA3. The cells were selected for the presence of the 
transgene using geneticin (G418, Gibco). Expression of wild-type and mutants 
forms of PlexinBl was checked by RT-PCR (M. Williamson, personal 
communication). Stable cell lines expressing vector only, wild-type PlexinBl 
protein (WT-PlxBl), and the three mutant forms of PlexinBl protein have thus 
been established in the laboratory and I used them in the following experiments.
b. Migration assays in modified Boyden chambers
Technique optimisation and primary results:
Migration assays were performed in modified Boyden chambers, which are 
polycarbonate filters with pores of 8pm diameter (Transwell®, Costar). The under 
surface of the membrane was coated with fibronectin (50pl at lOpg/ml in PBS 
(0.1% solution, Sigma), left to dry for approximately 2 hours and rinsed in PBS. 
Cells stably transfected with wild type or mutants plexin b l expression vector 
were grown to near confluency, harvested using a non-enzymatic cell dissociation 
solution (Sigma) and counted with a haemocytometer. 4 x l0 4 cells were 
resuspended in medium completed with 0.1% NCS (Labtech International), and 
were added to the upper chamber and allowed to migrate for 3h at 37°C. After 
migration, the inside of each filter was wiped off with a cotton bud. The cells that 
have migrated through the filters adhere to the lower side of the Boyden 
chamber, coated with fibronectin. The attached cells were then rinsed in PBS, 
fixed in paraformaldehyde 4% for 10 minutes, rinsed in PBS, stained with 
haematoxylin 4% for 10 minutes, and rinsed with tap water. Finally, the cells that 
have migrated through the filter were counted (means of 4 to 5 random fields) 
using a microscope (objective x20).
Optimisation of the technique has been performed on the number of 
transfected cells to plate in the upper chamber ( lx lO 4, 4 x l0 4, 1x10s), on the time 
of incubation at 37°C (2h, 3h, 4h, 6h, 12h), on the presence or absence of serum 
in the medium (8% NCS or 0.1% NCS), and finally, on the concentration of
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Semaphorin4D ligand to add in the lower chamber (0-200ng/mL). Experiments 
were performed in triplicate and repeated three times. Results have been 
normalised to the level of migration encountered by the cells transfected by the 
vector only (vector=100%). ANOVA statistical analysis has been performed using 
GraphPad software (refer to page 81).
Effects of PlexinBl mutant forms on cell migration;
Three experiments were performed in triplicate. Four to five random fields 
were counted per Transwell using a microscope. The results presented are the 
number of cells counted per cm2. Results have been normalised to the level of 
migration encountered by the cells transfected by the vector only (vecto r= l). 
ANOVA statistical analysis has been performed using GraphPad software (refer to 
page 81).
c. Production and quantification of Semaphorin4D protein
Cos-1 cells were transfected with the AP-Sema4D-GST plasmid (refer to page 
67). After 72h, the medium was collected, and the concentration of protein was 
assessed using the AP Assay Reagent A 2X (Biogene Ltd.). Five \iL of medium, 
45|nL of water, and SO^L of AP reagent were mixed in a tube and incubated 10 
minutes at 37°C. To stop the reaction, lOOfxL of NaOH 0.5M were added. Prior to 
measuring absorbance at 405nm, 800nL of water were added to obtain a final 
volume of lm L. AP enzyme catalyses the following reaction: PNPPoPNP+P 
(PNPP=p-Nitrophenyl Phosphate). PNP appears yellow at an optical density of 
405nm. The optical density was measured using a spectrophotometer. 
Concentration o f Semaphorin4D protein (Qsema4D in j^g/mL) was calculated as 
follow:
Csema4Din mol/L=OD405nm^-l-c; c=concentration Sema4D; Ncuvette length=lcm
Extinction coefficient of para-nitrophenol at 405nm: 8PNP=18.380M'1cm"1
Csema4D in m o l/m L /m in = c Sem3 4 D^N w ith  N = in c u b a tio n  t im e  (m in ) a t  37°C
Csema4Din mol/min or unit ( U ) = c Sema4D in mol/mL/min-fvolume (mL)=Aenzyme
Qsema4D in ng/mL=Aenzyme^Aspedfic (A= activity of the AP enzyme)
Specific activity of AP enzyme: AspeCjfic =1500U/mg
4. Semaphorin3E cloning, immunocytology, and adhesion assays
a. Semaphorin 3e cloning into pEF6/Myc-His mammalian expression 
vector
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Semaphorin 3e gene was PCR-amplified from the phagemid 
KIAA0331/pBLUESCRIPTIISK(+) using the Pfu DNA polymerase (Stratagene) and 
forward and reverse primers specifically designed to contain Kpnl and Notl 
restriction enzymes sites, respectively (refer to page 63). The PCR reaction was:
Semaphorin 3e DNA 2pg
Buffer 10X 1/10
dNTP Mix (2mM) 5pL
Forward primer 2pL
Reverse primer 2(J.L
dH20 30pL
Pfu enzyme 1U
Final volume 50^L
PCR conditions were 2 minutes at 95°C, 15 cycles at 1 minute at 95°C, 1 
minute at 60°C, and 1.30 minutes at 74°C, and 7 minutes at 74°C and 4°C. PCR 
products were subsequently digested by Kpnl (GGTAC/C) and Notl (GC/GGCCGC) 
restriction enzymes (Invitrogen, refer to page 66). As those two restriction 
enzymes are not diluted in the same reaction buffer, DNA was ethanol 
precipitated in between the two reactions (refer to page 67). The semaphorin 3e 
insert was then purified from an agarose gel electrophoresis using the QIAquick 
Gel Extraction Kit (Qiagen, refer to page 67). The mammalian expression vector 
pEF6/Myc-His-version B (Invitrogen) was also digested by Kpnl and Notl enzymes 
and dephosphorylated by the CIAP enzyme, calf intestinal alkaline phosphatase 
(GibcoBRL). CIAP enzymatic reaction was as follows:
DNA 5' overhang ends Ipmol
Dephosphorylation Buffer 10X 4^L
CIAP enxyme in Dilution Buffer 0.01U
dH20 to 39pL
Incubation was performed at 37°C for 30 minutes, and the CIAP enzyme was 
heat inactivated at 65°C for 15 minutes. The digested semaphorin 3e insert and 
dephosphorylated expression vector were then ligated using the T4-DNA Ligase 
(Invitrogen). Ligation reaction was as follows (3:1 ratio insert:vector):
Vector ends 30fmol
Insert ends 90fmol
Ligase Buffer 5X 4pL
T4 DNA Ligase 0.1U
dH20 to 20nL
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The solution was incubated for an hour at room temperature. The ligation 
reaction was diluted 5 fold prior to transform Escherichia Coli host strains (refer 
to page 65). The presence of the insert was checked in several colonies by PCR 
using semaphorin 3e primers (refer to page 63), which allowed the elimination of 
false positive colonies. Colonies containing the recombinant vector were grown up 
in LB browth and the plasmid DNA purified using the Plasmid Mini Kit (Qiagen, 
refer to page 65). RT-PCRs were performed using the P1-T7 and P4-BGH primers 
located respectively at the 5' and 3' ends of the multiple cloning site of pEF6 
vector, and P2 and P3 primers located respectively within the first and last exons 
of semaphorin 3e gene (refer to page 63).
RT-PCR were performed using sequencing primers (refer to page 63) and PCR 
products were sent to the University of Dundee for sequencing. Sequencing of 
these PCR products (vector-Sema3e) as well as of the whole insert DNA 
(semaphorin 3e) using overlapping primers (Invitrogen) allowed us to confirm 
that semaphorin 3e cDNA had been inserted in frame and with no mutations. 
Expression vectors containing the correct sequence of semaphorin 3e complete 
coding sequence were then transformed into bacteria and grown in LB/Ampicillin 
(final concentration 100^ig/mL) broth and the plasmid DNA purified using the 
Plasmid Maxi kit (Qiagen, refer to page 65).
b. Production and purification of Semaphorin 3E protein
Three T175 flasks of mammalian Cos-7 cells were subsequently transfected 
with the recombinant expression vector pEF6-Sema3e-Myc/His using 
Lipofectamine™2000 (Invitrogen, refer to page 67). After 48h incubation at 37°C, 
150jiL of a cocktail of protease inhibitor (Sigma P8340, containing Apoptinin, 
Bestatin, E-64, Leupeptin, Pepstatin A) was added to the medium to avoid the 
degradation of the recombinant protein, and was also added 20jiL of a furin 
protease inhibitor (Clontech, decanoyl-RVKR-chloromethylketone). After 72h, the 
medium was collected, and concentrated using an Amicon Ultra 15 Centrifugal 
Filter Device Ultracel-PL 30 (Millipore), i.e. up to 15mL of collected medium at a 
time was added to the filter device (regenerated cellulose) and centrifuged at 
4000g for 20 minutes using swinging bucket rotors. The retentate volume 
(~200nL) was immediately removed from the filter and collected. The presence of 
the recombinant protein was checked by western blotting (refer to page 134) 
from the concentrated fraction, which was stored in aliquots at -80°C. 
Semaphorin 3E protein is a secreted protein. Western blotting using the anti-Myc
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antibody allowed its detection in the concentrated collected media (refer to pages 
64 and 76).
Semaphorin3E protein was detected using a nickel column, which specifically 
binds 6xHis-Tags (BD TALON® Resin, Clontech, following manufacturer's 
instructions). Small scale purification under denaturing conditions was initially 
performed (all at 4°C unless stated otherwise). One mL of concentrated 
conditioned medium was centrifuged at 14000rpm for 2 minutes, and the pellet 
was re-suspended in 0.5mL of Denaturing Equilibration (DE) Buffer (pH 8.0). The 
solution was centrifuged for further 5 minutes to pellet insoluble debris and 
transferred to a tube containing 50pL of prewashed TALON®Resin. After 10 
minutes agitation at room temperature, the sample was centrifuged at 14000rpm 
for 1 minute to pellet protein/resin complexes. One mL of DE Buffer was added to 
wash the complexes, and the resin was pelleted at 14000rpm for another minute. 
After a second wash, the 6x-His tagged Semaphorin3E protein was eluted by 
adding 50j^L of Elution Buffer, vortexing and centrifugating briefly. Another 
elution was performed by adding 50jxL of EDTA (pH8.0), which removes bound 
metal from the resin, vortexing and centrifugating briefly. The supernatant 
contains the protein. Protein concentration was measured using the Lowry 
method (Sigma) and estimated by western blotting (results not shown). 
Purification of the recombinant protein under native conditions using the large 
scale purification protocol failed (results not shown). This might be due to an 
inaccessible tag under native conditions, or a protease cleavage, which cuts off 
the tag. However, to test the effects of Semaphorin3E protein, it is not necessary 
to have it purified and it was therefore used as such.
c. Protein extraction and Lowry Protein Assay
One mL of RIPA buffer [150mM NaCI, 10%Nonidet P-40 (NP-40, nonionic 
detergent), 0,5% sodium deoxycholate (DOC, ionic detergent), 0,1% sodium 
dodecylsulfate (SDS, ionic detergent), and tris, pH 8.0, 50mM] containing 100|d_ 
of cocktail of proatease inhibitors [Sigma P8340, Aproptinin 80pM (inhibitor of 
serine proteases), Leupeptin 2mM (inhibitor of serine and cysteine proteases)], 
Bestsatin 4mM (inhibitor of aminopeptidases), Pepstatin A l,5m M  (inhibitor of 
acid proteases), E-64 l,4mM (inhibitor of cysteine proteases)] was used to lyse 
confluent cells in culture (T80 flask) and precipitate proteins (30 minutes on ice 
with occasional rocking of the plate). The lysates obtained were pre-cleared by 
centrifugation at lOOOOrpm for 5 minutes at 4°C. Protein concentrations were 
normalised using the Lowry Protein Assay kit (Sigma). A series of BSA (Bovine
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Serum Albumin) standard was prepared as follows: In tube 1 was added 125pL of 
BSA (2mg/mL) and 375pL of water, which gives a 500pL solution of BSA at 
0.5mg/mL. In tubes 2 to 6, 200pL of water was added. A two fold dilution series 
was made by transferring 200pL from tube 1 into tube 2, mix, and then transfer 
2 0 0 jiL from tube 2 into tube 3, mix, and etc. The test samples were prepared by 
mixing lOpL of cell lysate and 190pL of water. A 200pL water tube was used as a 
blank. One mL of Lowry reagent (Folin-Ciocalteu) was then added to each tube in 
a defined order and at 20 seconds intervals. Solution were mixed well (vortex) 
and after 10 minutes, lOOpL of yellow stop solution (diluted 2 fold in water) was 
added to each tube in the same order and at 20 seconds intervals. After 
vortexing, the solutions were left at room temperature for 30 minutes. The optical 
density of each sample was measured at 750nm, using the water control as a 
blank. A graph was drown of BSA concentration versus OD, and the concentration 
in proteins of test samples were determined using the graph. Cell lysate is 20X 
diluted.
d. W estern blotting
Electrophoresis on denaturing (SDS) polyacrylamide gels (PAGE) is used for 
analytical separation of proteins, based upon molecular weight. Polyacrylamide 
gels were made by the free radical-induced polymerisation of acrylamide and 
N,N'-methyenebisacrylamide The formation of free radicals (obtained from the 
chemical decomposition of ammonium persulfate S20 82‘2S04 ) is catalysed by 
TEMED (N,N,N',N'-tetramethylenediamine). Polymerised gels are porous and the 
size of the pores is controlled by the proportion of polyacrylamide and its degree 
of cross-linking. Higher percentage gels are used to resolve smaller proteins.
Resolving gel:
13% gel 10% gel 8% gel 6% gel
h2o 3mL 3.9mL 4.6mL 5.3mL
30% acrylamide (TOXIC) 4.3mL 3.4mL 2.7mL 2.0mL
1.5M Tris pH8.8 2.5mL 2.5mL 2.5mL 2.5mL
10% SDS IOOjiL lOO^L lOOpL lOOpL
10% ammonium persulphate (APS) lOOpL IOOjiL IOOjiL lOOpL
IM,N,N',N'-Tetramethylethylenediamine (TEMED) 8jiL 8pL 8j.iL 8jiL
Stacking gel:
H20 3mL
30% acrylamide (TOXIC) 670pL
1M Tris pH6.8 250jiL
10% SDS 40mL
10% ammonium persulphate (APS) 40jiL
NjN/N^N’-Tetramethylethylenediamine (TEMED) 6j*L
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The Mini-PROTEAN II  system (Bio-Rad) was used. The glass plates were 
washed and rinsed with ethanol until they are completely clean. The glass plates 
with spacers were assembled and snapped into the casting slot of the casting 
stand. The resolving gel was then prepared using freshly made 10% APS, and 
adding the TEMED just before the pouring as the gel polymerise quickly. 
Approximately 7mL of resolving gel was poured into each glass plate assemblies, 
and overlayed with water to make the top of the gel in a straight line. The water 
was removed once the gel had polymerised. The stacking gel (2mL) was then 
poured and the well formers was inserted between the glass plates and left to 
polymerise before being removed.
Protein samples were denatured in 2X Laemmli buffer [lOOmM Tris-HCI, pH 
8.0, 2% (3-mercaptoethanol, 4% SDS, 0,2% bromophenol blue dye, 20% 
glycerol], and boiled for 10 minutes at 98°C before being resolved by SDS-PAGE. 
Sodium dodecylsulfate (SDS) is an anionic detergent that break disulfide bonds 
and negatively charge proteins. Forty ^g of denatured proteins (in SDS-PAGE 
loading buffer) were loaded per lane, and resolved at 100 Volts in SDS-PAGE 
running buffer for lh  to 2h, depending on protein size.
SDS-PAGE loading buffer (stored at 4°C):
Deionised water 4.0 mL
0.5 M Tris-HCI, pH 6.8 1.0 mL
Glycerol 0.8 mL
10% (w /v) SDS 1.6 mL
2-mercaptoethanol 0.4 mL
1% (w /v) bromophenol blue 0.2 mL
SDS-PAGE running buffer 5X:
Tris base 7.5g
Glycine 36g
SDS 2.5g
Deionised water 500mL
Proteins were then electrophorically transferred from the resolution gel to an 
Immobilon™-P Polyvinylindene Difluoride Membranes (PVDF, Sigma-Aldrich). The 
membrane was pre-wet in 100% methanol for 15 seconds and then IX  transfer 
buffer. Prior to use, Whatmann paper and scouring pads were also soaked in 
transfer buffer IX.
Transfer buffer 10X (stored at 4°C):
Tris base 150g
Glycine 720g
Deionised water 10L
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Glass plates were cleaved leaving the gel on the large plate. The stacking gel 
removed, the gel was briefly rinsed in transfer buffer. The membrane was 
apposed to the gel, excluding air bubbles. The wet Whatmann paper was put on 
the membrane and inverted on the wet scouring pad. The glass was then 
removed and another wet Whatmann paper and scouring pad were apposed to 
the gel. The gel and membrane in sandwich were placed in a cassette and then in 
a tank containing IX  transfer buffer, and a magnetic stirrer. Electrophoresis was 
run at 40V overnight at 4°C (the negative charge on the side of the gel and the 
positive charge on the side of the nitrocellulose membrane).
The membrane (or blot) was blocked for an hour with 5% dry milk (marvel) in 
PBS/Tween-20 0.1% (rocking, room temperature) to saturate non-specific protein 
binding sites in order to diminish the background staining. The blots were then 
incubated rocking for an hour at room temperature or overnight at 4°C with 
specific primary antibodies in 1% marvel/PBS (e.g. anti-Myc antibody 1/600 
dilution, anti-IC2 antibody 1/500 dilution). The blots were then washed 3 times in 
PBS/Tween-20 0.1% and PBS, and incubated an additional hour with HRP- 
conjugated secondary antibodies in 1% marvel/PBS (e.g. HRP-conjugated goat 
anti-mouse antibody 1/1000 dilution, HRP-conjugated mouse anti-rabbit antibody 
1/1500 dilution). After four washes in PBS/Tween-20 0.1% and PBS, the proteins 
were visualised by chemiluminescence (ECL), using super signal west Pico 
chemiluminescence substrate (Pierce). Membranes were then wrapped in Saran 
film, and in a dark room, a hyperfilm was apposed for chromogenic detection. 
Each exposed hyperfilm was immersed in developer, then fixer, for 2 to 3 
minutes, and finally rinsed in water. Each band detected represents a protein.
e. Im m unocytochem istry  and im m unostaining
Cos-7 cells were transfected with PlexinAl and Neuropilin-1, and PlexinDl 
expression vectors using Lipofectamine™2000 (Invitrogen) (refer to page 67). 
Fourty eight hours after transfection, cells were trypsinised and plated on 
coverslips placed in 24 well plates to achieve approximately 60% confluence the 
next day. Transfected cells were incubated for further 30 minutes at 37°C, with or 
without Semaphorin3A protein (4|ig/mL) and Semaphorin3E (~4jag/mL). 
Experiments using Semaphorin3A protein were performed in serum free DMEM 
medium (DMEM/SF), while experiments using Semaphorin3E conditioned medium 
were performed in DMEM medium containing 3.2% FBS (DMEM/3.2%). Cells were 
gently washed with PBS twice (to remove PBS the plates were inverted onto a 
towel), and fixed on ice with paraformaldehyde 4% during 10 minutes. PFA was 
freshly prepared, made in PBS, heated in a water bath at 65°C to dissolve and
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cooled at 4°C. Cells were then washed twice with PBS and immunostained. 
Blocking solution (2% horse serum in PBS) was added and put on a shaker for 20 
minutes. The blocking solution removed, the cells were then incubated for 30 
minutes at room temperature on a shaker with the primary antibody (dilution 
1/100, except when mentioned otherwise). After three washes with PBS for 5 
minutes each, on a shaker, the cells were incubated another 30 minutes with the 
secondary antibody (dilution 1/100) on a shaker at room temperature, covering 
with silver foil. Cells were washed three times in PBS and on a shaker and with 
silver foil cover, on a slide and the coverslips were mounted inverted onto the 
slide where a drop of vectastain DAPI conjugated (VectorLabs) was added. 
Coverslips were secured by putting nail varnish around the edge. Cells were 
observed under a microscope at 40X and 100X objective. Coverslips were done in 
triplicate, and the experiment was repeated twice giving the same results.
Controls with no primary antibody were performed for each condition and each 
experiment (results not always shown). Immunostaining was performed using 
phalloidin-TRITC-conjugated (8.3nL/2.3mL) to stain actin microfilaments in red, 
the primary monoclonal mouse antibody directed against active conformations of 
human (31 integrins (dilution 1/200), or the primary mouse monoclonal anti- 
vinculin antibody (dilution 1/400), or the primary mouse anti-Myc antibody, or 
the primary rabbit anti-VSV antibody, or the primary rabbit anti-HA antibody, and 
the secondary polyclonal rabbit anti-mouse FITC-conjugated antibody to stain in 
green, or the secondary donkey anti-mouse TRITC-conjugated antibody, or the 
secondary goat anti-rabbit TRITC-conjugated antibody to stain in red (refer to 
page 64).
f. Adhesion assay
Human embryonic kidney cells (HEK293 cells) were transfected with PlexinAl 
and Neuropilinl expression vectors, PlexinDl expression vector, and sterile water 
(mock transfection) using Lipofectamine™2000 (Invitrogen) (refer to page 67). 
Adhesion assays were performed using the lid of a 96 well plate (Nunc), on which 
three different substrates (matrices) were coated (final concentration 20pg/mL). 
80pL of each matrix, fibronectin, poly-L-Lysine, and PBS (negative control to 
check the cells do not adhere directly to the tissue culture plate) were applied to 
3 wells of the lid of a 96 well plate. The lid was then carefully placed in a 
humidified chamber and left overnight at 4°C. The following day, each drop of 
matrix was aspirated, and the lid was flooded three times in PBS. The lid was 
dried by aspirating gently, before blocking at 37°C in the humidified chamber for
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3h using a PBS solution containing 1% BSA. The lid was then washed three times 
in PBS and dried by aspiration. Cells at 70% confluence, fed the day before, were 
spin down and re-suspended in Optimem medium (Gibco) only. A solution of 104 
cells/80jiL drop was prepared. Sixty pL of cells were plated and incubated at 37°C 
in the humidified chamber for 10 minutes and 30 minutes in absence or presence 
of ligand Semaphorin3A (4pg/mL) or Semaphorin3E (~4pg/mL in conditioned 
medium). After three PBS washes, the lid was dried by aspiration. Unattached 
cells were washed off with PBS. Cells were then fixed for 20 minutes at room 
temperature with 4% paraformaldehyde, washed three times in PBS, and stained 
with 1% methylene blue for lh  at room temperature. The lid was washed twice in 
distilled water and left to dry overnight. The absorbance was measured on a plate 
reader. Each experiment was performed in triplicate and the results presented are 
the mean of three independent repeats with standard errors of the mean (SEM). 
ANOVA statistical analysis has been performed using GraphPad software (refer to 
page 81).
5. Statistical analysis
a. Mean and Standard Error of the Mean (SEM)
Experimental results of in vitro assays presented in this thesis were calculated 
as means of three independent repeats (n=3) with standard error of the mean (± 
SEM). The SEM is a measure of how far a sample mean is likely to be from the 
true population mean. The SEM is calculated by this equation: SEM=SD/Vn, 
n=number of replicates. The standard deviation (SD) quantifies variability. 
S D = V [ I ( y r y mean)2/ N - l ] ,  ys=value i, ymean=average, N=sample size. The SD 
quantifies scatter, i.e. how much the values vary from one another. With in vitro 
system with no biological variability, the scatter can only result from experimental 
imprecision, which is why we chose to present the data as means ± SEM. The SEM 
quantifies how accurately the mean was assessed. Mean, SD and SEM were 
calculated using Excel or GraphPad software.
ANOVA and T-tests statistical analysis are used routinely in many fields of 
science because they work well even if the sample distribution is only 
approximately Gaussian, which is the case of many kinds of biological data 
following a bell-shaped distribution. In this thesis, we assume that we have 
sampled data from populations that follow a Gaussian bell-shaped distribution and 
therefore used standard paired T-tests and ANOVA statistical analysis to measure 
the significance of the differences observed.
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b. Paired T-test
Paired T-tests allow the comparison of two paired groups. Paired groups means 
that we are comparing two columns of matched data, i.e. repeated experiments. 
Paired T-tests calculate the difference between each set of pairs, and analyzes 
that list of differences. Two-tail pvalue were selected as they are usually more 
appropriate. Therefore, standard paired, two-tail T-test statistical analysis have 
been applied in this thesis using Excel or GraphPad software when comparing two 
groups for the same variable, for example the (q)RT-PCRs. Because of the small 
number of repeats (n=3), an effect was considered statistically significant at 
pvalue inferior to 0.05 (depicted as * in graphic presentations).
c. Analysis of Variance (tw o-w ay ANOVA)
Standard statistical two-way analysis of variance (two-way ANOVA) allows the 
comparison of three or more groups with data categorized in two ways. The two- 
way ANOVA determines how a response is affected by two factors, by comparing 
the differences among group means with the pooled standard deviations of the 
groups. Two-way ANOVA compares the means.
Two-way ANOVA has been applied using GraphPad software when testing the 
effects of 2 different conditions (± serum and ± Semaphorin4D) on the migration 
of cells (Cos or NIH3T3 cells transfected with wild-type or mutant forms of 
PlexinBl), or when testing the effects of different proteins (Semaphorin3E and 
Semaphorin3A) on the adhesion of cells transfected with different receptors 
(PlexinAl/Neuropilinl and with PlexinDl) on different substrates (Poly-L-Lysine, 
fibronectin). An effect was considered statistically significant at pvalue inferior to 
0.001.
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CHAPTER 3: RESULTS
Section 1: Expression profiling of semaphorins and their receptors in 
prostate cell lines and hypoxia-induced regulation of secreted 
___________________ semaphorins gene expression___________________
Semaphorins are chemotactic guidance cues playing crucial roles orchestrating 
cellular movement. Since the ir firs t identification in the early 90s' in the developing 
nervous system, semaphorins have been reported to be expressed in many other 
tissues and organs, including the immune and vascular systems, where they play 
major roles (fo r reviews see Bismuth and Boumsell, 2002; Moretti et al., 2006; 
Eichmann et al., 2005). Recently, semaphorins have also been implicated in tum our 
cell m igration and invasion, and in tum our angiogenesis by controlling integrin 
function (Serini et al., 2003; for reviews see Neufeld e t al., 2005; Chedotal, 2007; 
Pan et al., 2007).
Plexins and neuropilins are high a ffin ity receptors for semaphorins. Plexins are 
guidance receptors, signalling through interaction w ith small GTPases (Rho, Rac, 
Ras). Neuropilins are also co-receptors for vascular endothelial growth factors 
(VEGF-A isoforms), which control angiogenesis (Neufeld et al., 2002; Chen et al., 
2005). There are few studies which highlight the importance o f neuropilins and 
VEGFs in prostate cancer tissues and cell lines, by showing variation in expression 
levels of these molecules in tum our angiogenesis (Latil e t al., 2000; Miao et al., 
2000). However, there are no studies at present showing the presence o f secreted 
semaphorins and the ir receptors, in normal or diseased prostate. The aim o f this 
chapter is therefore to study the distribution o f semaphorins and the ir receptors in 
prostate cell lines.
Most human cancers become life threatening as a result o f metastasis, and 
although it is well documented tha t prostate cancer preferentially metastasises to the 
bone (Bubendorf et al., 2000; Rubin et al., 2000), it is still unclear how and why it 
occurs. The scatter factor receptor MET, a member o f the sema domain containing 
superfam ily which controls the invasive growth program, has been reported to be 
overexpressed in prostate cancer (Pisters et al., 1995). However, attem pts to link 
HGF/MET signalling to the metastatic abilities o f prostate tum our cells have not ye t 
been successful. The receptor for the chemokine CXCL12, CXCR4 has also been 
reported to be overexpressed in cells derived from prostate cancer metastases 
(Araya et al., 2004). CXCR4 controls the homing o f breast tum our cells to the bone 
(Kang et al., 2003). None o f the theories suggested, however, is sufficient on its own
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to explain the progression of prostate cancer and spread to o ther organs (Tantivejkul 
et al., 2004; Yin et al., 2005).
Moreover, regions o f decreased oxygenation are frequent w ith in solid tumours, 
and the transcription factor HIF1 (hypoxia inducible factor 1) is a key m ediator of 
hypoxic responses. Under normoxic conditions H IF la  (the subunit regulating HIF1 
transcriptional activ ity ) is subject to ubiquitination and proteosomal degradation, 
which are inhibited under hypoxic conditions (Semenza, 2001). Overexpression of 
H IF la  has been detected in many invasive cancers as well as in the ir regional and 
distant metastases, whereas normal tissues and non-invasive benign tum ours do not 
overexpress H IF la  (Zhong et al., 1999). In prostate, H IF la  has been reported to be 
overexpressed in high-grade PIN, primary tum ours and regional and distant lymph 
node and bone metastases, whereas normal prostate tissue and benign hyperplasic 
tissue (BPH) do not overexpress H IF la  (Du et al., 2003; Hao et al., 2004). HIF1 
activates the transcription o f genes promoting tum our cell growth (glucose 
transporters and glycolytic enzymes), adhesion, m igration, and organ specific 
metastasis (CXCR4 receptor), invasion (scatter factor receptor MET), and vasculature 
remodelling and neoangiogenesis (VEGF-As) (Pennacchietti et al., 2003, Staller et 
al., 2003; Kang et al., 2003 ; Ferrara et al., 2003). To date there are no studies 
showing tha t the transcription of secreted semaphorin genes is regulated by hypoxia 
in cancer and metastases. The aim of this chapter is to study the effects o f hypoxia 
on secreted semaphorins gene expression.
In  order to investigate the possible roles o f semaphorin signalling in normal 
prostate homeostasis, prostate cancer progression, metastasis and angiogenesis, the 
expression profiles of secreted semaphorins and the ir receptors, plexins and 
neuropilins, as well as those o f vascular endothelial growth factor (VEGF-A isoforms) 
have been studied by RT-PCR in prostate cell lines derived from  a benign hyperplasic 
(BPH) epithelia (Pre2.8) and stroma (S2.13), a prim ary tum our (1542CPTX or 42C), 
the matched non-neoplastic epithelium (1542NPTX or 42N) and stroma (1542FT or 
42F) and a metastasis to the bone (PC3), the brain (DU145) and the lymph node 
(LNCaP). RT-PCR products were verified by sequencing (refer to page 70); all were 
the correct sequence (see Appendix 1). Also, in order to assess whether hypoxia 
controls the transcription o f secreted semaphorin genes, the ir expression profiles 
have been studied in matched non-neoplastic and prim ary tum our derived prostate 
cell lines and in a colon cancer cell line following hypoxic conditions. The same
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am ount of RNA was used fo r all reactions and GAPDH control was used to ensure 
equal amounts o f RNA was analysed between samples.
1. Expression profiles o f sem aphorins in 10 prostate cell lines fo llow ing  
norm oxic conditions
The presence of messenger RNA for secreted semaphorins 3a, 3b, 3c, 3e, 3f, and 
for transmembrane semaphorin 4d have been assayed by RT-PCR in 10 prostate cell 
lines. Figure 19 is the presentation o f one representative agarose gel.
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Figure 1 9 : Sem aphorins mRNA expression pro files (R T-PCR) in 10  prostate  ceif lines, derived from 
primary tumours (1542CPTX or 42C, and 1532CPTX or 32C), the matched non-neoplastic "normal" eplthelia 
(1542NPTX or 42N and 1532NPTX or 32N) and stroma (1542FTX or 42F), metastases to the lymph node 
(LNCaP), the brain (DU145) and the bone (PC3), and benign hyperplastic epithelia (Pre2.8) and stroma 
(52.13). The Glycerol-3-phosphate dehydrogenase (GAPDH) housekeeping gene shows approximately equal 
levels of total RNA between samples.
RT-PCRs were performed in trip licate, on three different RNA extractions (from  
three consecutive passages) for each o f the 10 prostate cell lines. The results 
presented below are normalised means w ith standard errors o f the mean (SEM). 
Band intensities for each gene, obtained using the Syngene software, have moreover 
been normalised to  the expression levels found in the non-neoplastic ("norm al") 
prostate epithelial cell line (42N = 1). Expression levels found in the non-neoplastic 
prostate epithelial cell line 1542NPTX (42N) were chosen as a reference o f normal 
expression throughout. These non-neoplastic ("norm al") cells were isolated from  a
42C 42N 32C 32N GAPDH
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normal area o f the prostate o f a patien t w ith  localised carcinom a (B righ t et al., 
1997). Standard T -tes t sta tistica l analysis was applied using Excel software ( * :  
s ign ifican t= < 0 .05 ). The expression levels obtained fo r sem aphorin 4d are the results 
of one trip lica te  experim ent; no statistica l analysis was applicable. Moreover, 
semaphorin 4d PCR product was not sequenced, and thus it w ill not be discussed in 
this thesis.
The results in figure  19 (sum m arised in table 7) show tha t messenger RNA for 
semaphorins 3a, 3b, 3c, 3e, 3f, and 4d are ubiquitously synthesised, a lthough at 
various levels, in the 10 prostate cell lines tested.
Origin Matched non-neoplastic  ("n o rm a l")
Matched
primary
tum our
Benign 
hyperplastic  
prostate (BPH)
Metastasis to the
Derived cell 
line
Epithelia  
(1542N P TX  
or 42 N )
Strom a  
( 1542FTX  
or 42F)
Epithelia 
( 1542C P TX  
or 42C )
Semaphorin
3a
Semaphorin
3b
Semaphorin
3c
Semaphorin
3e
Semaphorin
3 f
0.4±0.1
0.5±0.1
,7±0.1
1±0.3
0.7±0.1
Epithelia
(P re2 .8 )
Stroma
(S 2 .1 3 )
0.4±0.2
0.3±0.3
0.8±0.4
1±0.4 1±0.4
0 .6± 0.2 Q.7±0.2
Lymph
node
(LNCaP)
Brain
(D U 145)
0.7±0.1
0.7±0.3 0.13:0.2
1±0.2 0.3±0.2
0.7±0.1 0.1±0.2
0.6±0.05 0 .6±0 .1
0.6±0.3
0.5±0.3
0.7±0.3
0 .6± 0.2
0 .8± 0.1
Bone
(PC 3)
1±0.4
0.3±0.2
0.7±0.3
1.1±0.4
1±0.3
Semaphorin
4d
N europ ilin l
Neuropilin2
P lex ina l
0.5 0.6 0.9
0 .8± 0.2 0.3±0.1 0.5±0.2 0 .8±0.1
0.3±0.2 0.3±0.1 0.5 0.1±0.05 0 .6±0.1
0.6±0.07 0.3±0.2 0 .2± 0 .2 0.3±0.3 0.1±0.05 0.6±0.05
0.2
i .i± o .3
0.7±0.1
1.1±0.2
Plexina2 0 . 2± 0.1 0.5±0.2 0.3±0.1 0.3±0.2 0 .1±0 .05 0.4±0.2 0.5±0.2
Plexina3 0.3±0.2 0.5±0.2 0.3±0.1 0.4±0.1 0 .4±0.05 1±0.2 0.8±0.3
P lex in b l 0.2±0.07 0.9±0.2 0 .5±0.1 0.3±0.1 0.5±0.1 0.8±0.2 0.7±0.05
Plexinb3 0 .4 ±0 .1 0.9±0.3 0.5±0.05 0.9±0.3  1.2±0.05
Table 7 : Fold change in semaphorins and their receptors, plexins and neuropilins, gene expression in 8 
prostate cell lines (RT-PCR). Expression levels found in the  non-neoplastic  ("n o rm a l") p ros ta te  ep ithe lia l cell line 
1542NPTX (42N ) w ere chosen as a re ference o f norm al expression (expression = 1, grey co lou r). The resu lts  presented are 
norm alised mean (to  42N expression levels) w ith  standard e rro r o f the  mean (± SEM). The green co lour Indicates a 
s ign ifican t decrease In expression leve l; the  s tronger the  shading the  s tronge r the  decrease. The red co lour indicates a 
s ign ifican t increase In expression leve l; the s tronger the  shading the  s tro nge r the  increase. When the  increase o r 
decrease was no t s ign ifican t, o r when the re  was no change in expression level o r when no s ta tis tica l analysis was 
perform ed, no co lou r was applied.
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The results in figure 20 show tha t in the fib rob last cell line 1542FTX (42F) derived 
from  non-neoplastic ("no rm a l") prostate, mRNA expression levels o f secreted 
semaphorins 3a, 3c, and 3e are increased by 1.3 fold, while those o f sem aphorin 3f 
are decreased by 0.7 fold, compared to the levels found in the epithe lia l coun terpart 
(42N). Sem aphorin 3b mRNA expression levels are not changed. The results suggest 
tha t expression levels o f most secreted semaphorins are higher in cells o f strom al 
origin than o f epithe lia l orig in in non-neoplastic ("no rm a l") prostate.
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Figure 2 0 : Sem aphorins mRNA expression profiles (RT-PCR) in prostate  cell lines derived from  a 
prim ary tum our (1542CPTX or 42C, blue) and the matched non-neoplastic ("n o rm a l") epithelia  
( 1542NPTX or 42N , purple) and stroma (1542FTX or 42F, ye llow ). Results are norm alised mean (to  42N 
expression levels) o f tree  independent experim ents w ith  s tandard e rro r o f the  m ean (SEM). S tandard T- te s t has 
been applied ( * :  s ign ifica n t change :<  0 .05).
In  the prostate  p rim ary tum our derived epithelia l cell line 1542CPTX (42C), mRNA 
expression levels o f semaphorins 3a, 3b, 3c, and 3f, are decreased by 1.4 to 2 fold, 
compared to expression levels found in the "no rm a l" prostate cell lines of epithelia l 
(42N) and strom al (42F) origins (figure  20). In  contrast, sem aphorin 3e mRNA 
expression levels in the  prim ary tum our derived cell line (42C) are not changed 
compared to  non-neoplastic "no rm a l" epithe lia l levels (42N). The results suggest tha t 
expression levels o f m ost secreted sem aphorins are decreased in the prim ary tum our 
cell line, except those of sem aphorin 3e, which remain s im ila r to  expression levels 
found in the non-neoplastic "no rm a l" prostate epithelia l cell line.
The results in figure 21 shows tha t in the prostate cancer cell line derived from  a 
lym ph node metastasis (LNCaP), mRNA expression levels o f all secreted sem aphorins 
are strong ly  decreased, compared to non-neoplastic "no rm a l" epithe lia l levels (42N). 
Expression levels o f semaphorins 3 f and 3c mRNA are decreased by respectively 1.6 
and 3 fold, and those o f semaphorins 3b and 3e are decreased by 10 fold. No mRNA 
could be detected fo r sem aphorin 3a. The results suggest tha t expression levels of 
secreted sem aphorins are s trong ly decreased in the prostate cancer cell line derived
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from  a lym ph node m etastasis, compared to "no rm a l" epithe lia l (42N) and strom al 
(42F) levels.
In  the prostate cancer cell line derived from  a brain m etastasis (DU145), mRNA 
expression levels o f transm em brane semaphorin 4d are s im ila r to  th a t found in the 
non-neoplastic "no rm a l" epithelia l cell line 42N (figure 21); while expression levels of 
secreted sem aphorins are decreased by 1.25 to 2 fold (a lthough it is not always 
sign ificant). The results suggest tha t expression levels o f secreted sem aphorins are 
decreased in the brain m etastasis derived cell line, like in the lym ph node m etastasis 
derived cell line, compared to non-neoplastic "no rm a l" epithelia l prostate levels 
(42N).
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Figure 2 1 : Sem aphorins mRNA expression profiles (RT-PCRs) in prostate cancer cell lines derived from a 
lymph node m etastasis (LNCaP), a brain metastasis (D U 1 4 5 ), and a bone m etastasis (PC 3). Results are 
norm alised mean ( to  42N expression levels) o f th ree  independent experim ents  w ith  standard  e rro r o f the  mean 
(SEM). S tandard T- te s t has been applied ( * :  s ign ifican t change :<  0 .05 ).
In the prostate cancer cell line derived from  a bone m etastasis (PC3), mRNA 
expression levels o f sem aphorins 3a, 3e and 3f remain s im ila r to  non-neoplastic 
"no rm a l" epithelia l levels (42N), while those o f semaphorin 3c are decreased by 1.4 
fold and those o f sem aphorin 3b are strong ly  decreased by 3 fold (figure  21). The 
results suggest tha t in the bone m etastasis derived cell line, expression levels of 
semaphorins 3a, 3e and 3f, unlike the o the r sem aphorins, remain s im ila r to non­
neoplastic "no rm a l" epithelia l levels (42N).
The results in figure 22 show tha t in the prostate epithe lia l cell line (Pre2.8) 
derived from  benign prostate hyperplasia (BPH), mRNA expression levels o f 
sem aphorins 3a, 3b, an 3 f are decreased by 1.2 to 3 fold, compared to non­
neoplastic "n o rm a l" epithelia l expression levels (42N). In  contrast, expression levels 
o f sem aphorins 3c and 3e remain equal to "no rm a l" epithe lia l levels (42N). The 
results suggest tha t expression levels of semaphorins, except those o f sem aphorins
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3c and 3e, are decreased in the epithelia l cell line derived from  BPH, compared to the 
epithelia l cell line derived from  non-neoplastic "no rm a l" prostate.
In  the prostate strom al cell line derived from  BPH (S 2.13), mRNA expression 
levels o f sem aphorins 3a, 3b, 3e, and 3 f are decreased by 1.4 to  1.6 fold, compared 
to the levels found in the non-neoplastic "no rm a l" epithelia l cell line 42N, while those 
of secreted sem aphorin 3c remain s im ila r to 42N levels (figu re  22). The results 
suggest tha t expression levels o f semaphorins, except those o f sem aphorin 3c, are 
decreased in the strom al cell line derived from  BPH, compared to  the epithelia l and 
strom al cell lines derived from  non-neoplastic "no rm a l" prostate.
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Figure 2 2 : Semaphorins mRNA expression profiles (RT-PCR) in benign hyperplasic 
prostate  (B PH ) cell lines of epithelial origin (P re 2 .8 ) and strom al origin (S 2 .1 3 ).
R esults are norm alised mean (to  42N expression levels) o f th ree  independen t experim ents 
w ith  s tandard e rro r o f the  mean (SEM). Standard T- te s t has been applied ( * :  s ign ifican t 
change :<  0 .0 5 ).
The results in figure  22 also show tha t semaphorins mRNA expression profiles in 
the strom al cell line (S2.13) derived from  BPH tend to be h igher than in the epithelia l 
counterpart (P re2.8), like in the cell lines derived from  non-neoplastic "no rm a l" 
prostate, except fo r sem aphorins 3e and 3f, which are more highly expressed in BPH 
derived epithelia l cells than in the ir strom al counterpart.
2 . E xpress ion  p ro file s  o f p le x in s  an d  n e u ro p ilin s  in 10  p ro s ta te  ce ll lin es  
fo llo w in g  n o rm o x ic  c o n d itio n s
Plexins and neuropilins are high a ffin ity  receptors fo r sem aphorins. The mRNA 
expression profiles o f plexins a l ,  a2, a3, b l  and b3 and neuropilins 1 and 2 have 
been assayed by RT-PCR in 10 prostate cell lines. Figure 23 is the presentation o f 
one representative  agarose gel.
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RT-PCRs were perform ed in trip lica te , on three consecutive RNA extractions (from  
three d iffe ren t passages) fo r each o f the 10 prostate cell lines. The results presented 
below are normalised means w ith  standard errors o f the mean (SEM). Thus, band 
intensities have been normalised fo r each gene to the expression levels found in the 
non-neoplastic ("no rm a l") prostate epithelia l cell line (42N = 1). Expression levels 
found in the non-neoplastic "no rm a l" prostate epithelia l cell line 1542NPTX (42N) 
were chosen as a reference o f normal expression throughout. Standard T -tes t 
statistica l analysis was applied using Excel software ( * :  s ig n ifican t= < 0 .0 5 ).
The results in figure  23 (sum m arised in table 7) show tha t messenger RNA fo r 
neuropilins 1 and 2, and fo r plexins a l ,  a2, a3, b l  and b3 are ubiqu itously 
synthesised, a lthough a t various levels, in the 10 prostate  cell lines tested.
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Figure 23 : Plexins and neuropilins mRNA expression profiles (RT-PCR) in 10 prostate cell lines, derived 
from  prim ary tum ours  (1542CPTX o r 42C, and 1532CPTX o r 32C), th e  matched non-neop lastic  "n o rm a l" ep ithe lia  
(1542NPTX o r 42N and 1532NPTX o r 32N) and s trom a (1542FTX o r 42F), m etastases to  the  lym ph node (LNCaP), 
the  brain (DU 145) and the  bone (PC3), and benign hyperp lasic ep ithe lia  (P re2.8) and strom a (S 2 .1 3 ). NP: 
neurop ilin ; Plx: plexin.
The results in figure 24 show tha t in the fib rob last cell line derived from  non­
neoplastic "n o rm a l" prostate (42F), mRNA expression levels o f neuropilins 1 and 2 
are increased by 1.4 and 1.6 fold, while those o f plexins class A ( a l ,  a2, a3) and 
class B ( b l ,  b3) are decreased by 1.6 to 5 fold, compared to  the levels found in the 
epithelia l coun te rpa rt (42N). The results suggest tha t, like sem aphorins, neuropilins 
expression levels are h igher in cells o f strom al orig in than o f epithe lia l orig in in non­
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neoplastic "norm al" prostate, whereas the contrary is observed for plexins expression 
levels, which are higher in normal epithelial cells than in stromal cells.
In the prostate primary tum our derived epithelial cell line (42C), mRNA expression 
levels of neuropilin 2 are decreased by 5 fold (figure 24), compared to "norm al" 
epithelial levels (42N). Expression levels of plexins class A (a l,  a2, a3) are also 
decreased by 2 to 3 fold, while those of class B (b l,  b3) remain equal to "norm al" 
levels (42N), and those of neuropilin 1 are not significantly changed. The results 
suggest that, unlike those of class B plexins, mRNA expression levels of class A 
plexins and neuropilin 2 are decreased in the prostate primary tum our derived cell 
line, compared to non-neoplastic derived cell line.
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F igure  2 4 : P lex in s  an d  n e u ro p ilin s  m RNA expression  pro files  (R T -P C R ) in p ro s ta te  cell lin es d erived  fro m  a 
p r im a ry  tu m o u r  (1 5 4 2 C P T X  or 42C , b lu e ) and th e  m atch ed  n o n -n e o p la s tic  (" n o rm a l" )  e p ith e lia  (1 5 4 2 N P T X  
or 4 2 N , p u rp le ) an d  s tro m a  (1 5 4 2 F T X  or 42 F , y e llo w ). Results are norm alised m eans ( to  42N expression levels) 
o f th ree  independen t experim en ts  w ith  standard e rro r o f the  mean (SEM). NRP: ne u rop ilin ; Plx: p lexin . S tandard T- 
te s t has been applied ( * :  s ign ifican t change :<  0 .05).
The results in figure 25 show that in the prostate cancer cell line derived from a 
lymph node metastasis (LNCaP), mRNA expression levels of neuropilin 2 are 
decreased by 10 fold, those of class A plexins (a l,  a2, a3) are decreased by 2.5 to 
10 fold, and those of plexin b l are decreased by 2 fold, compared to expression 
levels in 42N cells. In contrast, mRNA expression levels of plexin b3 are sim ilar to 
"normal" expression levels (42N), and primary tumour levels (42C), and those of 
neuropilin 1 are not significantly changed. The results suggest that, like in the 
primary tumour cell line, mRNA expression levels of class A plexins and neuropilin 2 
are decreased in the lymph node metastasis derived cell line, compared to non­
neoplastic "norm al" prostate epithelial levels (42N).
□ 42C
□ 42F
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Figure 2 5 : Plexins and neuropilins mRNA expression profiles (RT-PCR) in prostate cancer cell lines 
derived from  a lymph node m etastasis (LNCaP), a brain metastasis (D U 1 4 5 ), and a bone m etastasis  
(PC 3). Results are norm alised m eans ( to  42N expression levels) o f th ree  Independent experim en ts  w ith  standard 
e rro r o f the  mean (SEM). NRP: neu rop ilin ; Plx: plexin . S tandard T- te s t has been applied ( * :  s ign ifica n t change :<  
0 .05 ).
In the prostate cancer cell line derived from a brain metastasis (DU 145), mRNA 
expression levels of neuropilin 2 and plexins a l and a2 are decreased by 
approximately 2 fold (figure 25), while those of neuropilin 1, plexins a3, b l and b3 
remain sim ilar to or are not significantly changed compared to non-neoplastic 
"norm al" epithelial prostate levels (42N). The results suggest that, like in the primary 
tum our and the lymph node metastasis derived cell lines, mRNA expression levels of 
class A plexins and neuropilin 2 are decreased in the brain metastasis derived cell 
line, compared to non-neoplastic "norm al" levels (42N), except for plexin a3, whose 
levels are unchanged.
In the prostate cancer cell line derived from a bone metastasis (PC3), mRNA 
expression levels o f neuropilin 1 are increased by 1.5 fold (figure 25), while those of 
neuropilin 2 are decreased by 1.4 fold, compared to non-neoplastic "norm al" levels 
(42N). Plexins a2 and b l mRNA expression levels are also decreased by 1.2 to 1.5 
fold, while those of plexin a l  and a3 remain "normal", and those of plexin b3 are 
increased by 1.9 fold compared to the levels found in non-neoplastic "norm al" 
epithelial cells (42N). The results suggest that in the bone metastasis derived cell 
line, like in the cell lines derived from a primary tumour, a lymph node and a brain 
metastases, neuropilin 2 and plexin a2 mRNA expression levels are decreased, 
compared to non-neoplastic "norm al" epithelial levels. Interestingly, plexin a l  mRNA 
expression levels remain "norm al", and those of plexin a3 are not significantly 
changed. Moreover, neuropilin 1 and plexin b3 expression levels are increased in the 
bone metastasis derived cell line, compared to the other metastases derived cell 
lines (lymph node and brain), the primary tum our and the matched non-neoplastic 
"norm al" epithelial cell lines.
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Figure 2 6 : P lex in s  an d  n eu ro p ilin s  m RNA  expression  pro files  (R T -P C R ) in ben ign  h y p erp las ic  
p ro s ta te  (B P H ) cell lin es o f e p ith e lia l orig in  (P r e 2 .8 )  an d  s tro m a l o rig in  (S 2 .1 3 ) .  Results are 
norm alised means ( to  42N expression levels) o f th ree  Independent experim ents  w ith  s tandard e rro r o f the  
mean (SEM). NRP: neu rop ilin ; Plx: p lexin . S tandard T- te s t has been applied ( * :  s ign ifican t change :<  0 .05 ).
The results in figure 26 show that in the prostate epithelial cell line (Pre2.8) 
derived from benign prostate hyperplasia (BPH), as well as in the stromal 
counterpart (S2.13), mRNA expression levels of all plexins and neuropilins are 
strongly decreased by 2 to 5 fold, compared to non-neoplastic "norm al" epithelial 
levels (42N), except for plexin b3, whose levels remain sim ilar to "norm al" levels in 
S2.13 cells. In contrast to the levels found in stromal cells from non-neoplastic 
"norm al" prostate (42F), where expression levels of both neuropilins are increased 
by 1.5 fold, they are decreased by 2 fold in the BPH derived stromal cell line. 
Inversely, plexin b3 mRNA levels are strongly decreased in the stromal cell line 
derived from non-neoplastic "normal" prostate (42F), while they remain sim ilar to 
42N levels in the stromal cell line derived from BPH (S2.13). The results suggest that 
plexins and neuropilins mRNA expression profiles are strongly decreased in both 
epithelial and stromal cell lines derived from BPH.
3. E xpress ion  p ro file s  o f v a s c u la r  e n d o th e lia l g ro w th  fa c to r  (V E G F -A  
is o fo rm s ) in 10  p ro s ta te  cell lin es  fo llo w in g  n o rm o x ic  c o n d itio n s
The presence of mRNA for three isoforms of vascular endothelial growth factor A, 
vegf206 , veg fi89 and veg fi65, have been assayed by RT-PCR, in 10 prostate cell lines. 
Figure 27 is the presentation of one representative agarose gel. Band intensities 
were not measured as the aim of this experiment was to identify the different vegf 
isoforms present in prostate cell lines, as well as to see if vegf was expressed in 
prostate cancer cell lines before we could use it as a control in subsequent hypoxia 
experiments.
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Figure 2 7 : Vascular endothelia l g row th  fac tor A isoform s mRNA expression profiles (R T-PCR) in 10  
prostate  cell lines, derived from primary tumours (1542CPTX or 42C, and 1532CPTX or 32C), the matched non­
neoplastic ("normal") epithelia (1542NPTX or 42N and 1532NPTX or 32N) and stroma (1542FTX or 42F), 
metastases to the lymph node (LNCaP), the brain (DU145) and the bone (PC3), and benign hyperplasic epithelia 
(Pre2.8) and stroma (S2.13), as well as In total RNA prostate extract (Tot.P) and In a positive control provided by 
the manufacturer (+ve).
The results in figure 27 show that messenger RNA fo r vascular endothelial growth 
factor isoform VEGF2q6 is undetectable in the 10 prostate cell lines tested, which is 
consistent w ith the expression profile found in to ta l prostate RNA extract. In 
contrast, the o ther two vascular endothelial growth factor A isoforms, VEGFi 65 and 
VEGFieg, are synthesised by most prostate cell lines, although at various levels. Nine 
out o f the 10 prostate cell lines tested synthesise mRNA fo r the predominant isoform 
of vascular endothelial growth factor VEGFi 65, and 6 out of 10 synthesise mRNA for 
the other isoform VEGFi 89. Noticeably, in the prostate cancer cell line derived from  a 
brain metastasis (DU145), no messenger RNA for VEGF-A isoforms is detected.
Stromal cells, whether from non-neoplastic "norm al" prostate (42F) or benign 
prostate hyperplasia (BPH) (S2.13) do not synthesise mRNA fo r VEGFi 89 isoform, but 
do synthesise mRNA for the predominant isoform, VEGFi 65, although at much lower 
levels than in the ir respective epithelial counterparts (42N and Pre2.8). BPH derived 
epithelial cells (Pre2.8) only synthesise mRNA for the predom inant VEGFi 6s isoform, 
whereas non-neoplastic "norm al" epithelial cells (42N) express mRNA for both 
VEGFi 65 and VEGF189 isoforms.
Both prostate cell lines derived from two primary tum ours (42C and 32C) and 
the ir matched non-neoplastic "norm al" epithelia (42N and 32N) express both VEGFi 65 
and VEGF189 isoforms o f vascular endothelial growth factor-A. The predominant 
isoform in the prim ary tum our cell lines is VEGFi 65, while it is VEGFi 89 in the matched 
non-neoplastic "norm al" epithelial cell lines.
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Both VEGFies and VEGFi89 isoforms are detected in the lymph node metastasis 
(LNCaP) and bone metastasis (PC3) derived cell lines, and in both cases, VEGF165 is 
the predominant isoform. No messenger RNA, for any o f the three isoforms of VEGF 
tested, is detectable in the prostate cancer cell line derived from a brain metastasis 
(DU145).
The results suggest tha t the 10 prostate cell lines tested synthesise mRNA for 
vascular endothelial growth factor-A, except the cell line derived from a brain 
metastasis. In ail the cell lines tested, the predominant isoform of vascular 
endothelial growth factor-A detected is VEGFi65/ except in the non-neoplastic 
"norm al" epithelial cell lines, where the predominant isoform is VEGFisg. Additionally, 
benign hyperplastic prostate epithelial and stromal cell lines synthesise mRNA only 
fo r the predom inant isoform VEG F16s. Also, non-neoplastic "norm al" strom al prostate 
cells synthesise messenger RNA only for VEG F165, while the ir epithelial counterpart 
synthesise mRNA for the predominant isoform and also for V E G F i89 isoform. Finally, 
both isoforms VEG F165 and V E G Fi89 are synthesised by cells derived from a prostate 
prim ary tum our, a lymph node and a bone metastases.
4. Search fo r H IF-responsive elem ents (HRE) w ith in  th e  prom oter regions  
of secreted sem aphorin genes
In order to  assess the susceptibility o f secreted semaphorin genes to hypoxia, 
the ir genomic sequences have been screened for the presence o f HIF-responsive 
elements (HRE), whose consensus sequence is RCGTG (where R=A or G). A single 
HRE is necessary but not sufficient to efficiently activate gene transcription in 
response to hypoxia. A fu lly functional HRE thus usually contains neighbouring DNA 
sites for additional transcription factors, which may confer tissue-restricted activ ity to 
the HRE. Tandemly arrayed HREs can also form  functional HIF responsive elements 
(fo r a review see Wenger et al., 2005). Screened promoter sequences were obtained 
from  the NCBI website (refer to page 71).
The results in table 8 show tha t the vegf promoter region contains many HRE 
m otifs, 10 in to ta l, among which only one o f them has been shown to  be functional 
(Wenger e t al., 2005). Equally, secreted semaphorin genes contain several HRE 
motifs, although the ir functionality also needs to be confirmed. Surprisingly, among 
secreted semaphorins, only one gene, semaphorin 3d, does not exhib it any HIF 
responsive elements in the prom oter region. The semaphorin 3f gene possesses four
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HRE, semaphorins 3b and 3c genes five, and semaphorins 3a and 3e genes seven. 
Interestingly, semaphorin 3e gene presents two tandem ly arrayed HRE, which may 
form  functional HIF1 responsive elements. These prelim inary results raise the 
possibility tha t most secreted semaphorins may be sensitive to hypoxia-induced 
H IF l-dependent transcriptional activation.
Gene
Name
HREs number and location In tron 1
5'Flanking 5'UTR + Exon Intron 1 Total
length
Length
screenedgcgtg acgtc gcgtg acgtc gcgtg acgtc
Sema3a 3 0 0 0 3 1 19800bp All
Sema3b 2 0 0 0 2 1 777bp All
Sema3c 2 3 0 0 0 0 2000bp All
Sema3d 0 0 0 0 0 0 ? All
Sema3e 0 2 l 0 0 0 158,153bp 4900bp4 0 30,900bp
Sema3f 0 3 0 0 1 0 ? All
Vegf 2 2 2 0 4 0 3028bp All
Table 8 : N um ber and location o f H IF  responsive e lem ents (HREs) w ith in  secreted  sem aphorins (S em a3) and  
vascular endothelia l grow th  factor (V e g f) genes. HRE consensus sequence Is RCGTG (Wenger et al., 2005). The 
promoter regions screened ranged from 3,000bp upstream of the transcription start site, to exon 1, which Includes the 
5TJTR, and Intron 1. UTR: untranslated region. Sequences were obtained from NCBI, and screened using the search tool 
from Word software.
5. Expression profiles of secreted sem aphorins and vascular endothelial 
grow th fac to r (VEGF) in prostate and colon cell lines fo llow ing hypoxia for 
24h and 48h
The matched prostate prim ary tum our derived cell line 42C, and its non-neoplastic 
"norm al" counterpart, the epithelial cell line 42N, as well as the colon cancer cell line 
HT29 have been incubated in a hypoxic incubator for 24h and 48h. Subsequently, 
mRNA expression profiles o f secreted semaphorins 3a, 3b, 3c, 3e, and 3 f have been 
assayed by RT-PCR, Presented data (figure 28) are the results o f one representative 
RT-PCR. RT-PCRs were performed in trip licate, and repeated three tim es. The results 
presented below are normalised means w ith standard errors o f the mean (SEM). 
Thus, band intensities have been normalised for each gene to the expression levels 
found in the non-neoplastic ("norm al") prostate epithelial cell line a t Oh (4 2 N /0 h = l) , 
or for figure 32 to the levels found in the prim ary tum our cell line at Oh (4 2 C /0 h = l), 
and fo r figure 33 to the levels found in the colon cancer cell line a t Oh (H T 2 9 /0 h - l) .  
Standard T-Test statistical analysis was applied using Excel software ( * :  
s ign ificant=<0.05).
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0h/24h/48h: time under hypoxic c o n d it io n
HT29
F ig u re  2 8 : S ecre te d  sem ap h o rin s  and vascu la r e n d o th e lia l g ro w th  fa c to r  (V E G F ) mRNA  
e x p ress io n  p ro files  (R T -P C R ), in a colon cancer ce ll lin e  (H T 2 9 ) ,  an d  in p ro s ta te  ce ll lines  
d e riv e d  fro m  a p r im a ry  tu m o u r  (1 5 4 2 C P T X  o r 4 2 C ) , and th e  m atch ed  n o n -n e o p la s tic  " n o rm a l"  
e p ith e lia  (1 5 4 2 N P T X  o r 4 2 N ) ,  fo llo w in g  hypo xia  fo r  2 4 h  and 4 8 h .
The results in figure 28 show that, in the colon cancer cell line HT29, the levels of 
vascular endothelial growth factor (VEGF) mRNA increases after 24h and 48h of 
hypoxic conditions as expected, providing a positive control. The results also show 
that mRNA for secreted semaphorins 3a, 3b, 3c, 3e, and 3f are synthesised, in HT29 
cells, at much higher levels than those of VEGF, which is also observed in the 
prostate cell lines (42N and 42C). Generally, the results suggest that VEGF and 
secreted semaphorin expression levels are largely regulated by hypoxic conditions.
a . E xp ress io n  p ro file  o f VEGF in p ro s ta te  and co lon  ce ll lin e s  fo llo w in g  
h y p o x ia  fo r  2 4 h  and 4 8 h
The results in figure 29 and 30 (summarised in table 9) show that in normoxic 
conditions, VEGF mRNA expression levels are identical in both prostate and colon 
cancer cell lines and significantly lower than in the non-neoplastic "norm al" prostate 
cell line (42N). VEGF mRNA expression levels progressively increase, following
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hypoxic treatm ent for 24h and 48h, by 1.3 fold in the positive control cell line HT29, 
and by more than 2 fold in the prostate primary tum our derived cell line 42C, 
whereas there is a slight increase in the matched "norm al" prostate cell line 42N, 
which is not significant (1.1 fold) after 48h of hypoxia. Surprisingly, the hypoxia- 
induced transcriptional activation of VEGF observed after 48h of hypoxia in the 
prostate primary tum our cell line is twice that in the colon cancer cell line (positive 
control) and reach the levels observed in the matched non-neoplastic "norm al" 
prostate cell line.
■  H T 2 9
F igure  2 9 : V ascu lar en d o th e lia l g ro w th  fa c to r  (V E G F ) m R N A  expression  
p ro files  (R T -P C R ) in th e  colon cancer cell lin e  H T 2 9 , th e  p ro s ta te  p rim a ry  
tu m o u r  cell lin e  1542C P TX  (4 2 C ), and its  m atch ed  n o n -n e o p la s tic  "n o rm a l"  
p ro s ta te  e p ith e lia l cell line 15 42N P T X  (4 2 N ) ,  in n o rm o x ic  co n d itio n s  (O h ), 
an d  fo llo w in g  hypoxia fo r 24h  o r 4 8 h . Results are mean o f th ree  independen t 
exp erim e n ts  w ith  standard e rro r o f the  mean (SEM). Results w ere  no rm alised to  the 
leve ls found in the  non-neoplastic ("n o rm a l") p rosta te  ep ithe lia l cell line  a t Oh 
(4 2 N /0 h =  1). S tandard T -te s t has been applied ove r tim e  fo r  each cell line ( * :  
s ig n ifica n t change :<  0 .05 ).
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Figure 3 0 : VEGF m RN A expression  profiles (R T -P C R ) in th e  colon  
cancer cell lin e  H T 2 9 , th e  p ro s ta te  p rim a ry  tu m o u r ce ll lin e  1542C P TX  
(4 2 C ) , and its  m atch ed  n o n -n eo p las tic  "n o rm a l"  p ro s ta te  e p ith e lia l 
cell lin e  1 5 4 2 N P T X  (4 2 N ) ,  in no rm oxic  cond itions (O h ), an d  fo llo w in g  
hypo xia  fo r  24h  or 4 8 h . Results were norm alised to  the  leve ls found in the 
non-neoplastic  ("n o rm a l") p rosta te  ep ithelia l cell line a t Oh (4 2 N /0 h = l) .
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VEGF Hypoxia
Cell line 24h 48h
HT29
42N
42C
1.2
1.2
1.5
1.3
1.1
2.1
Table 9 : Fold change in VEGF mRNA expression  
levels (R T-PC R ) in the  colon cancer cell line H T29, 
th e  prostate  prim ary tum our cell line 42C, and Its 
m atched non-neoplastic "norm al" prostate  
ep ithe lia l cell line 42N , a fte r 24h  and 48h  o f 
hypoxia.
The results suggest tha t VEGF mRNA expression levels are regulated by hypoxia 
in prostate cancer derived cells, but not in "norm al" prostate cells, which is 
consistent w ith what had been described by o ther groups (Du et al., 2003; Hao et 
al., 2004).
b. Expression profiles of secreted sem aphorins in the  non-neoplastic  
"norm al" prostate ep ithelia l cell line 1542N PTX fo llow ing  hypoxia for 24h  
and 48h
The results in figure 31 (summarised in table 10) show tha t mRNA expression 
levels o f secreted semaphorins are regulated by hypoxia in the non-neoplastic 
"norm al" prostate epithelial cell line. The results show tha t a fte r 24h o f hypoxia, 
mRNA expression levels of secreted semaphorins 3a, 3b, 3c, 3e and 3 f are 
significantly increased by 1.2 to 1.4 fold, compared to normoxic levels (Oh). Over a 
period o f 48h under hypoxic conditions, expression levels of most secreted 
semaphorins are back to the levels observed under normoxic conditions, except 
those o f semaphorins 3b and 3e, which continue to significantly increase by 
respectively 1.6 fold and 1.3 fold. In teresting ly, semaphorin 3 f mRNA expression 
levels remain equal to  normoxic levels in normal prostate cells following hypoxia for 
24h and 48h.
The results suggest tha t in the non-neoplastic "norm al" prostate epithelial cells, 
gene expression of secreted semaphorins is either not regulated by hypoxia 
(semaphorin 3f), o r is regulated by hypoxia, either progressively and positively 
(semaphorins 3b and 3e), or following a biphasic pattern (semaphorins 3a and 3c).
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Finure 3 1 : Expression pro files  o f se cre ted  sem ap h o rin s  (R T -P C R ) in th e  n o n -n e o p la s tic  "n o rm a l"  
p ro s ta te  e p ith e lia l cell lin e  1 5 4 2 N P T X  (4 2 N ) ,  in no rm ox ic  cond itions (O h ), and fo llo w in g  hypo xia  fo r 24 h  
or 4 8 h . Results are mean o f th ree  independent experim ents w ith  s tandard e rro r o f the  mean (SEM). Results were 
norm alised to  the  levels found in the  non-neoplastic ("n o rm a l") p ros ta te  ep ithe lia l cell line a t Oh (4 2 N /0 h = l)  
Standard T -te s t has been applied fo r each sem aphorin ( * :  s ign ifican t change :<  0 .05 ).
Cell line 42N
Hypoxia 24h 48h
Sem a3a 1.3 1.1
Sem a3b 1.3 1.65
Sem a3c 1.4 1.0
Sem a3e 1.25 1.3
S em a3f 1.0 0.98
VEGF 1.2 1.1
Table  1 0 : Fold change in se c re te d  sem ap ho rin s  
expression levels in th e  n o n -n eo p las tic  "n o rm a l"  
p ro s ta te  e p ith e lia l cell lin e  4 2 N , a f te r  24h  and  
48 h  o f hypoxia.
c. E xp ress io n  p ro file s  o f s e c re te d  s e m a p h o rin s  in th e  p ro s ta te  p r im a ry  
tu m o u r  ce il lin e  1 5 4 2 C P T X  fo llo w in g  h y p o x ia  fo r  2 4 h  an d  4 8 h
The results in figure 32 (summarised in table 11) show that mRNA expression 
levels of secreted semaphorins are strongly regulated by hypoxia in the prostate 
primary tum our cell line. The results show that after 24h of hypoxia, mRNA 
expression levels of secreted semaphorins 3a and 3c are significantly increased by
1.4 and 1.6 fold, compared to normoxic levels (Oh), while those of semaphorins 3b 
and 3e are decreased by 1.1 and 1.3 fold respectively. Like in the non-neoplastic 
"norm al" prostate epithelial cell line, in the matched primary tumour cell line, 
expression levels of semaphorin 3f are not significantly changed at 24h of hypoxia, 
compared to normoxic levels. However, after 48h of hypoxia, expression levels of 
semaphorins 3b, 3c, and 3f are significantly increased by 1.3, 1.6 and 1.2 fold 
respectively, while those of semaphorins 3a and 3e are significantly decreased by 2 
and 3 fold respectively.
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Figure 3 2 : E xpression  p ro files  o f secre ted  sem ap ho rin s  (R T -P C R ) in th e  p ro s ta te  p rim a ry  
tu m o u r cell lin e  1542C P T X  (4 2 C ),  in no rm ox ic  co nd ition s (O h ), an d  fo llo w in g  h ypo xia  fo r  2 4 h  or 
4 8 h . Results are m ean o f th ree  independen t experim ents w ith  s tandard e rro r o f the  mean (SEM). Results 
were norm alised to  the  levels found in the  prosta te  prim ary tu m o u r cell line a t Oh (42C /0h = l )  S tandard T- 
te s t has been applied fo r  each sem aphorin ( * :  s ign ifican t change :<  0 .05)
□ Oh
□ 24h
Cell line 42C
Hypoxia 24h 4 8h
Sem a3a 1.4 0.5
Sem a3b 0.9 1.3
Sem a3c 1.6 1.65
Sem a3e 0.75 0.3
S em a3f 1.1 1.2
VEGF 1.5 2.1
Tab le  1 1 : Fold change in se cre ted  sem ap h o rin s  
expression  levels in th e  p ro s ta te  p r im a ry  tu m o u r  
cell line 42C , a fte r  24 h  an d 4 8 h  o f hypoxia.
The results suggest that in prostate primary tum our derived cells following 
hypoxia, semaphorins expression levels are strongly regulated either progressively 
and positively (semaphorins 3c and 3f), or progressively and negatively (semaphorin 
3e) or following a biphasic pattern (semaphorins 3a and 3b). The results also 
demonstrate that in the prostate primary tum our cells, semaphorins are regulated by 
hypoxia in a different fashion than in the non-neoplastic "norm al" prostate cells.
d. Expression  p ro file s  o f s e c re te d  s e m a p h o rin s  in th e  co lon  c a n c e r ce ll 
lin e  H T 2 9  fo llo w in g  h yp o x ia  fo r  2 4 h  an d  4 8 h
The results in figure 33 (summarised in table 12) show tha t mRNA expression 
levels of secreted semaphorins are also strongly regulated by hypoxia in the colon 
cancer cell line. The results show that after 24h of hypoxia, mRNA expression levels 
of all the secreted semaphorins tested are significantly decreased by 1.4 to 1.6 fold, 
compared to normoxic conditions. Over a 48h period of hypoxia, the expression 
levels of secreted semaphorins 3b and 3c are back to normoxic levels, while those of
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semaphorins 3e, 3a, and 3f are still significantly decreased by, respectively, 2.5 fold, 
25 fold, and 1.4 fold.
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Figure  3 3 : Expression  p ro files  o f secre ted  sem ap ho rin s  (R T -P C R ) in th e  colon cancer cell lin e  H T 29 , in 
no rm o x ic  co nd ition s  (O h ), and fo llo w in g  hypoxia fo r 2 4 h  or 4 8 h . Results are mean o f th ree  Independent 
experim en ts  w ith  s tandard e rro r o f the  mean (SEM). Results were norm alised to  the  levels found in the  colon 
cancer cell line a t Oh (H T 2 9 /0 h = l)  S tandard T -tes t has been applied fo r  each sem aphorin  ( * :  s ign ifican t change 
:<  0 .0 5 )
Cell line HT29
Hypoxia 24h 48h
Sem a3a 0.6 0.4
Sem a3b 0.6 1.1
Sem a3c 0.7 1.0
Sem a3e 0.6 0.04
S em a3f 0.6 0.7
VEGF 1.2 1.3
Tab le  1 2 : Fold ch ang e in secre ted  sem ap ho rin s  
exp ress io n  levels  in th e  colon cancer cell lin e  
H T 2 9 , a f te r  24h  and 4 8 h  o f hypoxia.
These results suggest that, after 24h o f hypoxia, the expression levels of all the 
secreted semaphorins tested are decreased in the colon cancer cells, whereas they 
are increased in the "norm al" prostate cells. Additionally, in colon cancer cells, like in 
prostate primary tum our cells, expression levels of semaphorins 3a and 3e are 
strongly and progressively (for semaphorin 3e) decreased by hypoxia.
e . E xp ress io n  p ro file  o f s e m a p h o rin  3a in p ro s ta te  an d  co lon  ce ll lin es  
fo llo w in g  h y p o x ia  fo r  2 4 h  and  4 8 h
The results in figures 34 and 35 show that in normoxic conditions, expression 
levels of semaphorin 3a are twice lower in the prostate primary tum our cell line 
(42C), while they are 1.3 times higher in the colon cancer cell line (HT29) than in the
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non-neoplastic "norm al" epithelial prostate cell line. In both cancer derived cell lines 
following hypoxia for 24h and 48h, expression levels of semaphorin 3a are 
significantly decreased, compared to non-neoplastic "norm al" prostate levels at the 
same time point, and thus by 1.7 fold at 24h and by 2 or more fold at 48h. 
Interestingly, semaphorin 3a expression levels follow a biphasic pattern in both, the 
prostate primary tum our cell line and its matched non-neoplastic "norm al" cell line, 
whereas in the colon cancer cells it is progressively decreased, which may suggest a 
prostate-specific pattern of expression.
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F igure  3 4 : S ecre ted  sem ap ho rin  3a expression  pro files  (R T -P C R ) in th e  colon  
c a n ce r cell lin e  H T29, th e  p ro s ta te  p rim a ry  tu m o u r cell lin e  15 42C P T X  (4 2 C ),  
and its  m atch ed  n o n-neo p las tic  "n o rm a l"  p ro s ta te  e p ith e lia l cell lin e  15 42N P T X  
( 4 2 N ) ,  in no rm ox ic  conditions (O h ), an d  fo llo w in g  hyp o x ia  fo r  2 4 h  o r 4 8 h .
Results are mean o f th ree  Independent experim ents  w ith  standard e rro r o f the  mean 
(SEM). Results were normalised to  the  levels found in the  non-neop las tic  ("n o rm a l") 
p ros ta te  ep ithe lia l cell line a t Oh (4 2 N /0 h = l) .  S tandard T -te s t has been applied fo r each 
tim e  po in t ( * :  s ign ifican t change :<  0 .05).
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Figure 3 5 : S ecre ted  se m ap h o rin  3a exp ress io n  profiles  (R T -P C R ) in th e  
colon cancer cell line H T 2 9 , th e  p ro s ta te  p rim ary  tu m o u r  cell lin e  
1542C P TX  (4 2 C ) ,  and its  m atch ed  n o n -n eo p las tic  "n o rm a l"  p ro s ta te  
e p ith e lia l cell lin e  1 5 4 2 N P T X  (4 2 N ) ,  in no rm oxic  cond itions (O h ), and  
fo llo w in g  hypoxia  fo r 24h  or 4 8 h . Results w ere norm alised to  the  levels found In 
th e  non-neop lastlc  ("n o rm a l") p ros ta te  ep ithe lia l cell line a t Oh (4 2 N /0 h = l) .
The results suggest that semaphorin 3a mRNA expression levels are regulated by 
hypoxia in the same manner in the matched "normal" and primary tum our prostate 
cells. In the prostate and colon cancer cell lines following hypoxia for 48h, expression
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levels of semaphorin 3a are decreased, while they are unchanged in the non­
neoplastic "norm al" prostate cell line.
f. E xp ress io n  p ro file  o f  s e m a p h o rin  3b  in p ro s ta te  an d  co lon  ce ll lin es  
fo llo w in g  h y p o x ia  fo r  2 4 h  an d  4 8 h
The results in figures 36 and 37 show that in normoxic conditions, semaphorin 3b 
mRNA expression levels are identical in the matched non-neoplastic "norm al" and 
primary tum our prostate cell lines, while they are decreased by 1.4 fold in the colon 
cancer cell line. In both cancer derived cell lines (42C and HT29) following hypoxia 
for 24h and 48h, expression levels of semaphorin 3b are significantly decreased, 
compared to non-neoplastic "normal" prostate levels at the same time point. 
Expression levels are decreased by 1.4 fold in the primary tum our derived cells and 
by more than 2 fold in the colon cancer cells. Interestingly, in the prostate cancer 
cell line, semaphorin 3b mRNA expression follows a biphasic pattern, while it follows 
a progressive pattern in the matched non-neoplastic "norm al" prostate cell line. 
Additionally, in the other cancer cell line studied (colon), the pattern of expression of 
semaphorin 3b is also biphasic, which may suggest a cancer-related behaviour of 
semaphorin 3b transcription.
■  HT29
Oh 24h 48h
Figure  3 6 : S ecre te d  s e m ap h o rin  3b  exp ress io n  pro files  (R T -P C R ) in th e  co lon cancer  
cell line H T 2 9 , th e  p ro s ta te  p r im a ry  tu m o u r  cell lin e  15 42C P T X  (4 2 C ) ,  and its  
m atch ed  n o n -n eo p las tic  " n o rm a l"  p ro s ta te  e p ith e lia l cell lin e  1 5 4 2 N P T X  (4 2 N ) ,  in 
no rm ox ic  co nd ition s (O h ), an d  fo llo w in g  hypo xia  fo r 24 h  or 4 8 h . Results are mean o f 
th ree  independent experim en ts  w ith  s tandard e rro r o f the  m ean (SEM). Results were 
norm alised to the  leve ls  found in the  non-neoplastic  ("n o rm a l” ) p ros ta te  ep ithe lia l cell line at 
Oh (4 2 N /0 h = l) .  S tandard T - te s t has been applied fo r  each tim e  po in t ( * :  s ign ifica n t change 
:<  0 .0 5 ).
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Figure 3 7 : S ecre te d  se m ap h o rin  3b  ex p ress io n  p ro files  (R T -P C R ) in th e  colon  
cancer cell lin e  H T 2 9 , th e  p ro s ta te  p r im a ry  tu m o u r  cell lin e  15 42C P T X  (4 2 C ),  
and its  m atch ed  n o n -n eo p las tic  " n o rm a l"  p ro s ta te  e p ith e lia l cell line  
15 4 2 N P T X  (4 2 N ) ,  in n o rm o x ic  cond itions (O h ), and fo llo w in g  hypo xia  fo r  24 h  
o r 4 8 h . Results w ere norm alised to  the levels found In the  non-neoplastlc  ("n o rm a l") 
p ros ta te  ep ithe lia l cell line a t Oh (4 2 N /0 h = l) .
The results suggest that semaphorin 3b mRNA expression levels are regulated by 
hypoxia in both prostate primary tumour cells and non-neoplastic "norm al" prostate 
cells, and that after 48h of hypoxia, semaphorin 3b mRNA expression levels in the 
cancer cells are decreased, compared to the levels in non-neoplastic "norm al" 
prostate cells.
g. E xp ress io n  p ro file  o f s e m a p h o rin  3c  in p ro s ta te  an d  co lon  ce ll lin e s  
fo llo w in g  h y p o x ia  fo r  2 4 h  and 4 8 h
The results in figures 38 and 39 show that in normoxic conditions, semaphorin 3c 
mRNA expression levels are not significantly different in the matched non-neoplastic 
and primary tum our prostate cell lines, as well as in the colon cancer cell line. In 
primary tum our prostate cells (42C) following hypoxia for 24h, expression levels of 
semaphorin 3c are not significantly changed, compared to non-neoplastic "norm al" 
levels at the same tim e point. In contrast, expression levels of semaphorin 3c are 
significantly decreased by more than 2 fold in the colon cancer cell line (HT29), 
compared to non-neoplastic "norm al" prostate levels at the same time point. 
Inversely, In primary tum our prostate cells following hypoxia for 48h, expression 
levels of semaphorin 3c are significantly increased by 1.5 fold, while they are not 
significantly changed in the colon cancer cells, compared to the levels found in the 
non-neoplastic "norm al" prostate cells at the same time point. Interestingly, in the 
primary tum our prostate cells, semaphorin 3c expression is progressively regulated 
by hypoxia, whereas in non-neoplastic "norm al" prostate cells and in colon cancer 
cells, its expression follows a biphasic pattern.
106
2 . 0  -
■  H T 2 9
Oh 2 4 h 48h
F igure  3 8 : S ecre te d  s e m a p h o rin  3c  express ion  p ro files  (R T -P C R ) in th e  colon ca n ce r cell 
lin e  H T 2 9 , th e  p ro s ta te  p r im a ry  tu m o u r ce ll lin e  15 42C P T X  (4 2 C ) ,  and  its m atch ed  non­
n e o p las tic  " n o rm a l"  p ro s ta te  e p ith e lia l ce ll lin e  1 5 4 2 N P T X  (4 2 N ) ,  in n o rm o x ic  co nd ition s  
(O h ), an d  fo llo w in g  h ypo xia  fo r 24h  o r 4 8 h . R esults are mean o f th re e  Independent 
e xperim en ts  w ith  s tandard e rro r o f the  mean (SEM). Results were norm alised to  the  levels found 
in the  non-neop las tic  ("n o rm a l'')  p ros ta te  ep ithe lia l cell line  a t Oh (4 2 N /0 h = l) .  S tandard T - te s t has 
been applied fo r  each tim e  po in t ( * :  s ign ifican t change :<  0 .0 5 ).
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F ig u re  3 9 : S ecre te d  sem ap ho rin  3c exp ress io n  pro files  (R T -P C R ) in th e  colon cancer  
cell lin e  H T 2 9 , th e  p ro s ta te  p r im a ry  tu m o u r  cell lin e  1 5 4 2 C P T X  (4 2 C ) ,  and its  
m a tc h e d  n o n -n eo p las tic  "n o rm a l"  p ro s ta te  e p ith e lia l cell lin e  1 5 4 2 N P T X  (4 2 N ) ,  in 
n o rm o x ic  co n d itio n s  (O h ), and fo llo w in g  h ypo xia  fo r 2 4 h  o r 4 8 h . Results were 
no rm alised  to  th e  levels found in the  non-neop las tic  ("n o rm a l") p ros ta te  ep ithe lia l cell line a t 
Oh (4 2 N /0 h = l) .
The results suggest that the pattern of expression of semaphorin 3c mRNA in 
prostate cells following hypoxia for 48h is progressively increased in primary tum our 
cells, while it is unchanged in "norm al" cells (and in colon cancer cells), which may 
suggest a prostate cancer-related behaviour of semaphorin 3c transcription.
h. E xp ress io n  p ro file  o f s e m a p h o rin  3 e  in p ro s ta te  a n d  co lon  ce ll lin e s  
fo llo w in g  h y p o x ia  fo r  2 4 h  and  4 8 h
The results in figures 40 and 41 show that in normoxic conditions, semaphorin 3e 
mRNA expression levels are not significantly different in the matched non-neoplastic 
and primary tum our prostate cell lines, and in the colon cancer cell line (HT29). In 
prostate and colon cancer cells following hypoxia for 24h and 48h, expression levels 
of semaphorin 3e are strongly decreased by 1.5 and 3.5 fold in the prostate cells and
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by 2.5 and more than 14 fold in the colon cancer cells, compared to non-neoplastic 
"no rm a l" prostate levels at the same tim e point. In  contrast, expression levels o f 
semaphorin 3e are increased by 1.3 fold in cells derived from  non-neoplastic prostate 
follow ing hypoxia fo r 24h and 48h. The pattern o f expression o f sem aphorin 3e 
mRNA is progressive in the prostate and colon cell lines.
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Figure 4 0 : S ecre ted  sem ap ho rin  3e  expression  p ro files  (R T -P C R ) in th e  colon cancer cell 
lin e  H T 2 9 , th e  p ro s ta te  p rim ary  tu m o u r ce ll lin e  15 42C P T X  (4 2 C ),  and its m atch ed  non­
neo p las tic  "n o rm a l"  p ro s ta te  e p ith e lia l cell lin e  1 5 4 2 N P T X  (4 2 N ) ,  in no rm ox ic  co nd ition s  
(O h ), an d  fo llo w in g  hypoxia fo r 24h  o r 4 8 h . Results are m ean o f th ree  independent 
experim ents  w ith  standard e rro r o f the  mean (SEM). Results were norm alised to  the  levels found 
in the  non-neoplastic  ("n o rm a l") prosta te  ep ithe lia l cell line a t Oh (4 2N /0h  = l ) .  S tandard T -te s t has 
been applied fo r each tim e po in t ( * :  s ign ifican t change :<  0 .0 5 ).
(A
C<u
T3
CCfl
CO
2.0
5
0
5
0.0
24hOh 48h
HT29
Figure  4 1 : S ecre ted  se m ap h o rin  3e  ex p ress io n  pro files  (R T -P C R ) in th e  colon cancer  
cell lin e  H T 2 9 , th e  p ro s ta te  p rim a ry  tu m o u r cell lin e  1542C P TX  (4 2 C ),  and its  m atch ed  
n o n -n eo p las tic  "n o rm a l"  p ro s ta te  e p ith e lia l cell line 15 42N P T X  (4 2 N ) ,  in no rm ox ic  
cond itions (O h ), and fo llo w in g  h y p o x ia  fo r  24 h  or 4 8 h . Results were norm alised to  the 
levels found in the  non-neoplastic ("n o rm a l") prosta te  ep ithelia l cell line a t Oh (4 2 N /0 h = l) .
The results suggest tha t hypoxia tu rns o ff semaphorin 3e transcrip tion  in both 
prostate and colon cancer cell lines, while it s lightly increases its transcrip tion  in the 
cells derived from  non-neoplastic "no rm a l" prostate a fte r 48h o f hypoxia. The results 
may suggest tha t there  is a cancer-related behaviour o f semaphorin 3e transcrip tion .
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i. E xp ress io n  p ro file  o f s e m a p h o rin  3 f  in p ro s ta te  an d  co lon  ce ll lin e s  
fo llo w in g  h y p o x ia  fo r  2 4 h  and  4 8 h
The results in figures 42 and 43 show tha t in norm oxic conditions sem aphorin 3f 
mRNA expression levels are not sign ificantly d iffe ren t in the matched non-neoplastic 
and prim ary tum our prostate cells, while it is decreased in the colon cancer cells 
compared to non-neoplastic "no rm a l" prostate levels. In te res ting ly , sem aphorin 3f 
mRNA transcrip tion  is not regulated by hypoxia neither in the non-neoplastic 
"no rm a l" prostate cells nor in the matched prim ary tum our cells. In  contrast, 
semaphorin 3f mRNA transcrip tion  is decreased by 2 fold in the colon cancer cell line 
follow ing hypoxia fo r 24h and 48h, compared to non-neoplastic "no rm a l" prostate 
levels a t the same tim e  point.
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Figure  4 2 : S ecre te d  sem ap ho rin  3 f expression  p ro files  (R T -P C R ) in th e  colon cancer cell 
lin e  H T 2 9 , th e  p ro s ta te  p rim ary  tu m o u r cell lin e  1542C P TX  (4 2 C ) , an d  its  m atch ed  non­
neo p las tic  " n o rm a l"  p ro s ta te  e p ith e lia l cell lin e  1 5 4 2 N P T X  (4 2 N ) ,  in n o rm o x ic  cond itions  
(O h ), an d  fo llo w in g  hypoxia  fo r  2 4 h  or 4 8 h . Results are mean o f th ree  independent 
experim ents  w ith  s tandard e rro r o f the  mean (SEM ). Results were norm alised to  the  levels found 
in the  non-neop las tic  ("n o rm a l") prosta te  ep ithe lia l cell line a t Oh (42N /0h  = l ) .  S tandard T - te s t has 
been applied fo r each tim e  po in t ( * :  s ign ifican t change : < 0 .05).
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F igure  4 3 : S ecre te d  se m ap h o rin  3 f  expression  pro files  (R T -P C R ) in th e  colon cancer  
cell lin e  H T 2 9 , th e  p ro s ta te  p rim a ry  tu m o u r cell lin e  1542C P T X  (4 2 C ),  and its  
m atch ed  n o n -n eo p las tic  "n o rm a l"  p ro s ta te  e p ith e lia l cell lin e  1 5 4 2 N P T X  (4 2 N ) ,  in 
n o rm o x ic  co nd ition s (O h ), and fo llo w in g  hypoxia fo r  2 4 h  or 4 8 h . Results were 
norm alised to  the levels found In the  non-neoplastic ("n o rm a l") p ros ta te  ep ithe lia l cell line  at 
Oh (4 2 N /0 h = l) .
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The results suggest tha t hypoxia does not regulate semaphorin 3 f transcription in 
in the matched non-neoplastic "norm al" prostate cells and prim ary tum our cells, 
whereas its expression is progressively regulated by hypoxia over a 48h period in 
colon cancer derived cells.
j. Relative expression levels o f secreted sem aphorin genes in the prostate  
prim ary tum our cell line 1542CPTX fo llow ing hypoxia for 24h and 48h , 
com pared to the  m atched non-neoplastic cell line 1542NPTX
The results in figure 44 confirm the results obtained under normoxic conditions, 
which have been discussed previously. Namely, mRNA expression profiles o f secreted 
semaphorins are reduced in the prostate prim ary tum our derived cell line 42C, 
compared to the matched non-neoplastic "norm al" prostate derived cell line 42N, 
except for semaphorin 3e, which is slightly overexpressed in the prim ary tum our cell 
line, and semaphorin 3b, whose expression levels are sim ilar in "norm al" and 
primary tum our derived cells. After 48h o f hypoxia, expression levels o f semaphorin 
3c and VEGF are increased in the prostate prim ary tum our cell line, compared to the 
levels in the matched non-neoplastic "norm al" prostate cell line. In contrast, those of 
semaphorins 3a and 3e are decreased afte r 48h of hypoxia in the prostate primary 
tum our derived cells, so much so tha t the ir levels become much lower than those 
found in the matched "norm al" prostate cells. For the other semaphorins, although 
the ir expression levels are variable, they remain expressed at higher levels in the 
non-neoplastic "norm al" prostate derived cell line than in the matched prim ary 
tum our derived cell line following hypoxia.
The results suggest tha t semaphorins 3a and 3e transcription is strongly down- 
regulated by hypoxia, while this of semaphorin 3c is strongly up-regulated in 
prostate prim ary tum our derived cells, compared to non-neoplastic "norm al" prostate 
derived cells.
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Figure  4 4 : R e la tiv e  ex p ress io n  leve ls  o f secre ted  se m ap h o rin  g en es  in th e  p ro s ta te  p r im a ry  tu m o u r  
cell lin e  15 42C P T X  (4 2 C ) ,  co m p ared  to  th e  m atch ed  n o n -n e o p la s tic  ce ll lin e  15 4 2 N P T X  (4 2 N ) ,  
fo llo w in g  hy p o x ia  fo r  2 4 h  and 4 8 h .
6 . D iscussion
In  th is section, we report the firs t expression profiles study o f sem aphorins and 
the ir receptors, as well as vascular endothelial grow th  factors (VEGF-A isoform s), in 
cell lines derived from  non-neoplastic "norm a l" prostate, benign prosta te  hyperplasia 
(BPH), prostate  p rim a ry  tum our, and metastases to  the bone, the brain, and the 
lymph node.
The results show th a t messenger RNA for secreted and transm em brane 
semaphorins (3a, 3b, 3c, 3e, 3f, and 4d), as well as fo r the ir high a ffin ity  receptors, 
plexins (a l ,  a2, a3, b l ,  and b3) and neuropilins (n p l and np2) are w idely expressed, 
although at various levels, in epithe lia l and strom al cells derived from  a non­
neoplastic "no rm a l" prostate  (42N and 42F), epithelia l and strom al cells derived from  
a benign prostate hyperplasia (Pre2.8 and S2.13), epithe lia l cells derived from  a 
prostate prim ary tum ou r (42C), and epithe lia l cells derived from  m etastases to  the 
lym ph node (LNCaP), the  brain (DU 145), and the bone (PC3).
Particularly, the results accentuate the  differences in expression levels between 
strom al and ep ithe lia l cell types in non-neoplastic "no rm a l" prostate and benign 
hyperplasic prostate  (BPH). In  non-neoplastic "no rm a l" prostate, class 3 (secreted) 
semaphorins and neuropilin  receptors are pre fe ren tia lly  synthesised by strom al cells, 
while epithe lia l cells p re fe ren tia lly  synthesise mRNA for plexin receptors. This patte rn
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of expression is reminiscent of scatter factor HGF, also preferentially synthesised by 
stromal cells, while its receptor MET is expressed by epithelial cells (Humphrey et al., 
1995). In BPH, a non-cancerous enlargement of the prostate, in both epithelial and 
stromal cell types, expression levels of secreted semaphorins and the ir receptors are 
strongly decreased, compared to non-neoplastic "norm al" prostate levels, except for 
semaphorins 3c and 3e. Semaphorin 3c expression levels remain equivalent to 
"norm al" prostate levels (42N) in both BPH derived cell types. However, the balance 
strom al/epithelia l is maintained in the BPH derived cells; i.e. semaphorins mRNA 
expression levels are higher in the stromal cells than in the epithelial counterpart, 
except for semaphorin 3e. Interestingly, semaphorin 3e transcription is stronger in 
the BPH derived epithelial cell line than in the strom al counterpart. These variations 
in semaphorins and receptors expression levels are expected to affect the 
interactions between stromal and epithelial cells o f the prostate, which will most 
probably reflect on the architecture o f the tissue. Further experiments, such as co­
culture experiments, are necessary to investigate th is further.
The results also highlight the differences in expression levels between cells 
derived from a primary tumour, three metastases and non-neoplastic "norm al" 
prostate. They show tha t in the prostate cell lines derived from  a primary tum our 
and two o f the three metastases (brain and lymph node), the transcription o f 
secreted semaphorins, class A plexins and neuropilin 2 are strongly decreased, while 
this of neuropilin 1 and plexin b3 remain "norm al".
Noticeably, plexin b3 expression levels are comparable to o r stronger than normal 
epithelial prostate levels in derived cells from the prim ary tum our, the three 
metastases, and the stromal BPH. Plexin b3 expression levels are only significantly 
reduced in strom al cells derived from normal prostate and in epithelial cells derived 
from BPH. I t  is only recently tha t PlexinB3 ligand Semaphorin5A has been identified 
(Artigiani et al., 2005). These results may suggest im portant roles for SemaphorinSA 
signalling in prostate carcinogenesis and metastasis. I t  would be interesting to 
determ ine semaphorin 5a expression profile in prostate cell lines and tissue.
In teresting ly, in the prostate cells derived from a bone metastasis, the mRNA 
expression levels o f semaphorins 3a, 3e, 3f, plexins a l and a3 remain sim ilar to non­
neoplastic levels, and those of neuropilin 1 are increased, compared to the prim ary 
tum our or the o ther metastases derived cells. Semaphorin3A and 3F proteins bind to 
both PlexinAl and A3 receptors, and to both Neuropilins w ith varying affin ities. These
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results suggest an autocrine type o f regulation of Semaphorin3A and/or 3F signalling 
pathway in cells derived from prostate cancer metastases to the bone. Additionally, 
in the prostate cells derived from a bone metastasis, the mRNA expression levels of 
semaphorin 3b, the other tum our suppressor semaphorin, are strongly decreased 
compared to non-neoplastic "norm al" levels, which may indicate d istinct roles for 
Semaphorin3B and 3F proteins in prostate cancer and metastasis.
At the time these experiments were performed, the receptor fo r Semaphorin3E 
protein was still unknown. I t  was generally accepted tha t secreted semaphorin 
receptors were a complex made of a homo- or hetero-dim er of neuropilins and a 
monomer o f class A plexin (mostly plexin a l ) ;  and tha t the specificity of semaphorin 
signalling depended on the combination o f neuropilins and plexin present. I t  would 
now be interesting to evaluate plexin d l  mRNA expression levels in the 10 prostate 
cell lines to check whether there may be an autocrine regulation o f Semaphorin3E 
signalling in prostate cancer and metastases. Moreover, semaphorin 3e expression 
levels also remain "norm al" in the prostate prim ary tum our cell line and in the BPH 
derived epithelial cells, whereas all the other secreted semaphorins are strongly 
downregulated. An overexpression of semaphorin 3e, which is known mainly as a 
repellent cue, has also been reported in metastatic cell lines derived from mice 
mammary carcinoma (Christensen et al., 1998). A ltogether, these results may 
suggest an im portan t role fo r Semaphorin3E protein in prostate cancer progression 
and metastasis.
Altogether, these expression profiling results suggest an autocrine or paracrine 
type o f semaphorin signalling in prostate, as most cell lines express the ligands and 
the ir receptors. However, it is still unclear what controls semaphorin expression. As 
intratum oral hypoxia is frequently found in advanced cancers, and hypoxia inducible 
fa c to r- la  is markedly overexpressed in prostate cancers and metastases (Zhong et 
al., 1999), we sought to  determ ine whether secreted semaphorin mRNA expression 
levels would be regulated by hypoxia in prostate cell lines. First, secreted 
semaphorins prom oter regions were screened for the presence of HIF-responsive 
elements (HREs). The results show tha t all secreted semaphorins, but semaphorin 3d 
promoter, exibit 4 to 7 HREs. Interestingly, semaphorin 3e prom oter presents two 
tandemly arrayed HREs, which can also form functional HIF responsive elements 
(Wenger et al., 2005). These prelim inary results suggest tha t most secreted 
semaphorins may be sensitive to  hypoxia-induced H IF l-dependent transcriptional 
activation.
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Expression profiling experiments demonstrate that, overall, the expression of 
secreted semaphorins is hypoxia-regulated, and together w ith the dem onstration of 
HRE, suggest tha t semaphorin regulation may be dependent on HIF1. Cancer-specific 
and tissue-specific patterns o f expression following hypoxia can be observed. For 
example, a tissue-specific behaviour (prostate vs. colon) exists for semaphorin 3f, 
whose mRNA expression levels are unchanged in the cells derived from non­
neoplastic "norm al" prostate, and the matched prim ary tum our, compared to 
normoxic levels, while they are strongly decreased in the colon cancer cells, following 
hypoxia for 48h. In contrast, a cancer-specific expression pattern is observed for 
semaphorin 3e, whose transcription is strongly and progressively down-regulated in 
both cancer cells (prostate and colon) following hypoxia, compared to normoxic 
levels, and contrary to the transcriptional activation seen in the non-neoplastic 
"norm al" prostate cells. Altogether, these results suggest tha t a prostate cancer- 
specific expression pattern o f secreted semaphorins may be detectable after 48h of 
hypoxia, which can be defined in this case (1542CPTX and 1542NPTX cells), by a 
strong transcriptional activation of semaphorin 3c, and a strong transcriptional 
inhibition o f semaphorins 3a and 3e. Similarly, a colon cancer-specific expression 
pattern o f secreted semaphorins after 48h of hypoxia may be detected, which can be 
defined, in the HT29 cells, by a strong transcriptional inhibition o f semaphorins 3a 
and 3e, and also 3f.
Of particular in terest is the transcriptional behaviour o f secreted semaphorin 3e in 
the cancer cells following hypoxia, which may be the result o f an indirect inhibition 
(HIF could increase the expression o f an inhibitor o f semaphorin 3e transcription). To 
our knowledge, this study is the firs t study reporting an hypoxia-induced 
transcriptional inhibition. Further experiments are necessary nonetheless to confirm 
those results. Future work would include semaphorin prom oter reporter constructs in 
order to study the effects o f the presence and absence of H IF la  on the reporter 
expression.
Finally, these expression profiling results suggest tha t all secreted semaphorins 
may play roles in normal prostate homeostasis as well as in prostate cancer 
transform ation, progression and maybe neo-angiogenesis, as all secreted 
semaphorins and the ir receptors are synthesised by prostate cell lines, and as 
secreted semaphorin genes expression is regulated by hypoxia, which is frequently 
encountered in in tratum oral areas, and defined as a trigger fo r neo-angiogenesis.
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However, there are lim itations to this study, which need to be addressed by 
further work. I t  would be o f interest to assess the distribution o f semaphorins and 
receptors in more prostate cell lines, and to perform im m unohistochem istry 
experiments of secreted semaphorin proteins in prostate tissues, which would 
involve developing antibodies to some of the semaphorins, as not all o f them are 
commercially available. Further experiments to study the roles of semaphorins in 
prostate would include in vivo experiments to look at the effect on tum our form ation 
in mice, using normal prostate cell lines stably transfected and overexpressing 
Semaphorin3A, 3C or 3E proteins for example.
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Section 2: Role of PlexinBl mutations and PlexinBl/Semaphorin4D  
__________ signalling in prostate cancer and metastases__________
PlexinBl is the functional receptor for transmembrane semaphorin 4D in non 
lymphoid tissues (nervous system), while it is CD72 in lymphoid tissues (im mune 
system). Semaphorin4D signalling has been extensively studied in the immune 
system where it has been shown to regulate humoral and cellular immune responses, 
as well as the in flam m atory response. In the nervous system, Semaphorin4D 
signalling, through P lexinB l, regulates axonal growth cone guidance. Semaphorin4D 
signalling, through P lexinB l, has also been implicated in invasive growth, through 
interaction w ith the scatter factor receptor MET (Giordano et al., 2002), and recently 
in angiogenesis (Basile et al., 2006). However, a t present, there are no studies 
showing the roles o f P lexinB l/Sem aphorin4D signalling in normal and diseased 
prostate.
Previous work in the laboratory has identified 13 somatic missense mutations in 
the cytoplasmic domain o f plexin b l  gene. Mutations were found in 89% (8 /9 ) of 
prostate cancer bone metastases, 41%  (7 /17) o f lymph node metastases and 46% 
(41/89) o f prim ary cancers. Over 40%  o f prostate cancers contained the same 
mutation, A5653G. Overexpression o f the P lexinBl protein was found in the m ajority 
of prim ary tum ours (Wong et al., 2007). Three mutations were studied here, two of 
the most common m utations found in prostate cancer A5653G and T5714C and the 
one found in LNCaP (A5359G). These three m utations are single nucleotide changes. 
The nucleotide change A5653G leads to a Thrl795A la  amino acid change, which has 
been identified in 38 prim ary tum ours and 9 metastases. The nucleotide change 
T5714C leads to a Leu l815Pro am ino acid change, which has been identified in 2 
prim ary tum ours and 3 metastases. And finally, the nucleotide change A5359G leads 
to a Thr 1697 Ala am ino acid change, which is heterozygous in LNCaP cells.
The high frequency o f m utation and overexpression o f P lexinBl suggests tha t 
PlexinBl has a role in prostate cancer progression. A higher frequency of m utations 
was found in the metastases suggesting tha t the m utations may contribute to 
invasion and metastasis. An increase in cell m otility  is a phenotype associated w ith 
invasion and metastasis. P lexinB l has been shown to affect cell m igration (Barberis 
et al., 2004; Basile et al., 2005; Oinuma et al., 2006). To test the hypothesis tha t 
the m utations found in plexin b l  gene have an effect on cell m igration, transwell 
m igration assays were performed in the presence and absence o f Semaphorin4D
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ligand. Plexin b l expression levels were assessed in prostate cell lines and tissues by 
quantitative RT-PCR. Those of semaphorin 4d were assessed by RT-PCR in the 
previous chapter.
1. Q u a n t ita t iv e  e x p re s s io n  leve ls  o f p le x in  b l  in p ro s ta te  ce ll lin e s  and  
tissu es
Plexin b l mRNA expression levels have been quantified by real-time RT-PCR (qRT- 
PCR) in 8 prostate cell lines previously described, as well as in six paired non­
neoplastic and carcinoma prostate tissue samples, originating from patients with well 
and moderately differentiated tumours, confined within the prostate, and with no 
regional lymph node metastases detected. Quantitative RT-PCRs were performed in 
triplicate, and on three different RNA extractions (from three consecutive passages). 
The results presented are normalised means (refer to page 71) with standard errors 
of the mean (SEM). Normalisation has also been performed to the expression levels 
found in the non-neoplastic ("normal") prostate epithelial cell line (42N = 1), used as 
a reference. Standard T-test statistical analysis has been applied using GraphPad 
software.
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Figure 4 5 : Plexin b l  mRNA expression profiles (qRT-PCR) in 8 prostate cell lines, derived 
from  a p rim ary  tu m o u r (1542CPTX o r 42C), the matched non-neop lastlc  "n o rm a l" ep ithelia  
(1542NPTX o r 42N ) and s trom a (1542FTX o r 42F), m etastases to  the  lym ph node (LNCaP), the  
brain (DU 145) and the  bone (PC3), and benign hyperplaslc ep ithelia (P re2.8) and strom a (S 2 .13 ). 
Results are mean o f th ree  rep lica tes, norm alised to  42N expression levels, w ith  standard e rro r o f 
the  mean (SEM). S tandard T - te s t has been applied ( * :  s ign ifican t change :<  0 .05 ).
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Cell lines Relative expression levels
42C 2.7
42N 1
42F 3.0
LNCaP 6.75
Dul45 0.5
PC3 0.3
Pre2.8 27.3
S2.13 0.9
T a b le  1 3 : R e la tiv e  expression  levels  o f p lex in  
b l  m R N A  (q R T -P C R ) in 8  p ro s ta te  ce ll lines.
The results in figu re  45 (sum m arised in table 13) show th a t p lexin b l  mRNA 
expression levels are s ign ifican tly  higher in the prostate  p rim ary  tum ou r derived cell 
line (42C), com pared to  the levels found in the matched non-neoplastic "no rm a l" 
coun terpart (42N ). A dd itiona lly , plexin b l  mRNA levels are also s trong ly  (m ore than 
6 fo ld) and s ign ifican tly  increased in the cell line derived from  a lym ph node 
m etastasis (LNCaP), while  they are significantly decreased in the o the r two cell lines 
derived from  the brain (DU145) and the bone (PC3) m etastases, compared to  the 
levels in non-neoplastic "no rm a l" prostate cell line (42N). Results show th a t p lexin b l  
mRNA expression levels are s ign ificantly increased (3 fo ld) in the  s trom al cell line 
(42F) derived from  the non-neoplastic "norm a l" prostate, com pared to  the levels 
found in the ep ithe lia l coun te rpa rt (42N). In contrast, in the BPH derived cell lines, 
plexin b l  mRNA expression levels are strong ly and s ign ifican tly  increased (27 fo ld) in 
the epithe lia l coun te rpa rt (P re2.8) and not s ign ificantly decreased in the s trom al 
coun terpart (S 2 .13 ), than in 42N.
The results in figure  46 (sum m arised in table 14) show th a t in the paired prostate  
tissue samples, p lexin b l  mRNA expression levels are between 1.2 to 2.7 tim es 
h igher w ith in  the cancer than in the surrounding non-neoplastic tissue, in 5 out o f 6 
paired samples. I t  appears th a t p rim ary cancer synthesises h igher levels o f plexin b l  
mRNA than the non-neop lastic tissue. These results are consisten t w ith  those 
obtained w ith  the cell lines (i.e . plexin b l  mRNA expression levels are on average 3 
tim es h igher in the p rim ary  tu m o u r derived cells than in the m atched non-neoplastic 
prosta te  epithelia l cells). However, no association could be established between 
plexin b l  mRNA expression pro file  and the stage or Gleason score o f the tum our.
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Figure  4 6 : P lex in  b l  m R N A  ex p ress io n  pro files  (q R T -P C R ) in 6 p a ire d  n o n -n e o p la s tic /c a rc in o m a  p ro s ta te  
tis su e  sam p les . Results are mean of three replicates from one experiment. No statistical analysis has been applied.
Tissue sample Relative expression levels PT GSC
C l 27.0 3a 5B2 27.5
C3 2.5 2c 6
B4 0.9
C5 7.7 2c 6
B6 6.3
C7 11.2 3a 6
B8 4.3
C9 2.0 2c 5
BIO 1.0
C l l 9.6 2c 7
B12 4.4
T a b le  1 4 : R e la tiv e  exp ress io n  levels  o f p lex in  b l  m R N A  (q R T -  
PCR) in 6  p a ire d  p ro s ta te  tis su e  sam ples. Tumour stage (pT) and 
Gleason score (GSC) are listed. A Gleason grade between 5 and 7 
describes well and moderately differentiated tumours. Tumours are 
either confined within the prostate but involving both lobes (2c) or 
with extracapsular extension (3a).
Surprisingly, the results obtained with the quantitative RT-PCR technique do not 
match the results obtained w ith the semi-quantitative RT-PCR method (refer to 
figures on pages 92 and 93). As quantitative RT-PCR results are more accurate, 
ideally, the expression levels for all semaphorins should be quantitated by this 
method. However, unfortunately this was prohibitively expensive to do. The variation 
in expression levels for plexin b l mRNA in between RT-PCR and real tim e PCRs may 
be explained by the fact that the primers used for both techniques are d ifferent and 
not located at the same region of plexin b l gene. I t  is possible tha t the regions are 
spliced differently, which would explain the difference in expression pattern seen.
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2. D e te c tio n  o f P le x in B l p ro te in  in m a m m a lia n  ce lls  e x p re s s in g  w ild  ty p e  
an d  m u ta n t  fo rm s
NIH3T3 and Cos-1 cells have been stably transfected (by my colleagues) with 
plexin b l expression vectors either bearing the w ild-type gene or the three most 
frequently found mutations of plexin b l in prostate cancers and metastases (Wong et 
al., 2007). In order to estimate the expression levels of P lexinBl transgenic proteins 
in the stably transfected cells, a series of western blotting experiments have been 
performed. Below is presented one representative blot.
2 5 0
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F ig u re  4 7 : W e s te rn  b lo t o f w ild -ty p e  and m u ta n t fo rm s  o f P le x in B l
p ro te in  in s ta b ly  tra n s fe c te d  N 1H 3T3 ce lls . V: vecto r con tro l, WT: w ild -typ e
P le x in B l, D: A5359G  m u ta n t fo rm  o f P lex inB l, F: A45 m u ta n t fo rm  o f P le x in B l,
G: T5714C  m u ta n t fo rm  o f P le x in B l, T: NIH3T3 un transfected cells. HT: HT29 
ce lls, pos itive  con tro l. IC 2a an tibody  provided by L. Tam agnone (A rtig ia n i e t a l.,
2003 ). Expected band a t approx im a te ly  lOOKDa.
The results in figure 47 show tha t the polyclonal anti-P lexinB l antibody supplied 
by L. Tamagnone (Artigiani et al., 2003) stains many non-specific bands in addition 
to the approximately 100kDa band of interest (truncated form of PlexinBl, 
transmembrane p-chain, after cleavage by proprotein convertase). A band of the 
correct size is found in the positive control HT29 cells (HT) and is absent from the
negative controls (expression vector only (V) and untransfected cells (T)). This band
is also present in the NIH3T3 stable cells, which suggest that the stable cell lines 
express PlexinBl protein.
These results, together w ith the RT-PCR results (M. Williamson, personal 
communication), show that the stable clones express w ild-type and m utant forms of 
P lexinBl, therefore they were used for the following m igration experiments.
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3. Migration assays in modified Boyden chambers
a. T e c h n iq u e  o p tim is a tio n  an d  p r im a ry  re s u lts
To assess whether any of the selected single nucleotide mutations of plexin b l 
gene has any effect on cell movement, m igration assays have been performed in 
modified Boyden Chambers. The technique was optimised according to the number of 
cells in the upper chamber, the time of incubation at 37°C, and the presence or 
absence of serum. The best results were obtained when plating 4 x l0 4 cells in the 
upper chamber with an incubation time of 3h at 37°C. Up to 10s cells could be plated 
in the upper chamber, but it was harder to count the cells because they clumped at 
the periphery and in the centre of the filter.
In order to measure the effects of serum concentration in the incubating medium, 
Cos-1 and NIH3T3 cells stably transfected with vector only, w ild-type PlexinBl, and 
mutants T5714C-PlexinBl and A5359G-PlexinBl respectively, have been incubated in 
completed medium (8%  serum), and in medium containing 0.1%  serum. The results 
in figure 48 and 49 show that serum concentration has no significant effect on Cos-1 
cell m igration (p value=0.353), whereas a high concentration of serum has a 
significant effect on NIH3T3 cell migration (p value<0.001), which migrate faster in 
complete medium. All later experiments have therefore been performed using 
NIH3T3 cells and medium containing 0.1% serum.
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F igure  4 8 : M ig ra tio n  assay  o f C os-1  ce lls  s ta b ly  tra n s fe c te d  w ith  pcD N A 3 v e c to r  on ly , w ild -  
ty p e  P le x in B l (W T - P lx B l)  and m u ta n t T 5 7 1 4 C -P le x in B l. Presence o f serum  (RPM I1640 
m edium  com ple ted  w ith  8%  FBS) o r absence o f serum  (0 .1 %  FBS) has no s ign ifica n t e ffec t on cell 
m ig ra tion . The e ffe c t o f T5714C m u ta tion  is s ign ifican t in Cos-1 cells, P va lue = 0 .00 19 . Results are 
mean o f th re e  independen t exp erim e n ts  w ith  s tandard e rro r o f the  mean (SEM). ANOVA sta tis tica l 
analysis has been applied using GraphPad softw are, which showed th a t the  e ffects  o f serum  are no t 
s ig n ifica n t (p va lue  =  0 .3 5 3 ), w h ile  the  e ffects o f m u ta tion  are s ign ifica n t (p  va lue  < 0 .0 0 1 ).
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F igure  4 9 : M ig ra tio n  as say  o f N IH 3 T 3  cells s tab ly  tra n s fe c te d  w ith  p cD N A 3 v e c to r  on ly, 
w ild -ty p e  P le x in B l (W T - P lx B l)  and m u ta n t A 5 3 5 9 G -P le x in B l. The presence o f serum  (DMEM 
m edium  com p le ted  w ith  8%  NCS) has a s ign ifican t e ffect on cell m ig ra tion . The e ffe c t o f A5359G 
m u ta tion  Is s ig n ifica n t in N IH3T3 cells, P va lue=0 .0044 . Results are mean o f th re e  independen t 
experim en ts  w ith  standard  e rro r o f the  mean (SEM). ANOVA s ta tis tica l analysis has been applied 
using GraphPad so ftw a re , w hich showed th a t the  effects o f serum  and m u ta tion  are s ign ifica n t (p  
va lues < 0 .0 0 1 ).
The results show tha t in Cos-1 stably transfected cells (figure 48), like in NIH3T3 
stably transfected cells (figure 49), overexpression of w ild-type PlexinBl inhibits cell 
m igration. I t  has previously been shown that overexpression o f PlexinBl protein 
mimics ligand binding, which explains why there is an effect on m igration in the 
absence of ligand (Giordano et al., 2002). In contrast, an overexpression of mutants 
T5714C-PlexinBl and A5359G-PlexinBl prevents the expected inhibition of 
m igration, thus bringing the percentage of migrating cells to slightly higher levels 
than control levels (vector only). The single nucleotide A5359G mutation of PlexinBl 
is found in LNCaP cells. The single nucleotide T5714C mutation of P lexinBl is found 
in 3 prostate metastases. These prelim inary results suggest tha t an enhanced cell 
m igration (due to P lexinBl m utation) is associated with prostate metastasis.
These optim isation experiments were performed using the w ild-type and 2 m utant 
forms of PlexinBl, expressed by two different cell types, which allowed us to 
determine the roles o f these mutations, as well as the conditions to use in fu rther 
experiments.
b. O p tim is a tio n  o f th e  c o n c e n tra tio n  o f S e m a p h o r in 4 D  p ro te in  n e c e s s a ry  
to  d e te c t  an  e f fe c t  on ce ll m ig ra t io n
In order to determine the concentration of Semaphorin4D ligand to use for fu rther 
experiments, optim isation assays were performed using w ild-type PlexinBl and one
1 2 2
m utant form of PlexinBl found in LNCaP cells. Other groups o f reference working 
with Semaphorin4D and PlexinBl proteins were using a concentration o f 50ng/m L for 
their assays (Giordano et al., 2002). The effects of concentrations of ligand varying 
from lO ng/m L to 200ng/mL were therefore tested on the m igration o f NIH3T3 cells 
stably transfected w ith w ild-type PlexinBl and the m utant A5359G-PlexinBl. Only 
one o f the three m utant forms of PlexinBl was used here as the aim was to define 
the optimal concentration o f ligand to use in fu rther assays.
As shown in figures 48 and 49, expression of P lexinBl in Cos-1 or NIH3T3 cells 
inhibits cell m igration relative to cells not expressing P lexinB l, probably because of 
clustering and/or overexpression o f the receptor tha t m imic ligand binding. Figures 
50 and 51 show tha t addition o f 10 or 25ng/mL of Semaphorin4D ligand fu rthe r 
inhibits cell m igration. At 50ng/mL, the cell m igration of cells expressing w ild-type 
PlexinBl is at a rate sim ilar to  that seen in the absence of Semaphorin4D protein. 
Figure 49 shows tha t m igration of NIH3T3 cells expressing m utant A5359G-PlexinBl 
is enhanced relative to cells expressing no PlexinBl or w ild-type PlexinB l. As figure 
50 shows, m igration is also further reduced following addition o f 10 or 25ng/m L of 
Semaphorin4D protein but increased following addition of 50ng/m L relative to tha t 
seen in the absence of Semaphorin4D protein.
Other concentrations o f Semaphorin4D protein were tested (results not shown), 
which showed tha t m igration was further increased using lOOng/mL o f ligand, while 
at 200ng/mL, m igration was slighly decreased for both the w ild-type and the m utant 
form A5359G-PlexinB l, compared to lOOng/mL. At 200ng/mL of Semaphorin4D, the 
m igration o f the m utant form  o f PlexinBl was still enhanced compared to the wild 
type.
Because cell m igration was increased when using a concentration o f 
Semaphorin4D equal or superior to 50ng/mL, and as other groups of reference were 
using this same concentration, 50ng/mL of ligand were then used to subsequently 
test the effects of the three m utations on cell m otility, in presence or absence of 
ligand.
Altogether, these results suggest tha t Semaphorin4D ligand has a biphasic effect 
on P lexinBl signalling. Mutation o f P lexinBl and addition o f a high concentration of 
Semaphorin4D ligand (50ng/m L) synergise to enhance cell m igration.
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Figure  5 0 : E ffe c t o f  d if fe re n t  co n ce n tra tio n s  o f S em ap h o rin 4 D  on ce ll m ig ra tio n . NIH3T3 cells 
s tab ly transfec ted  w ith  w ild -typ e  P lex inB l (W T -P lxB l) and m u ta n t A 535 9G -P lex lnB l. Various 
concentra tions o f S em a4D  ligand were tested (0 to  50ng /m L). The m u ta tion  A5359G o f P le x in B l has no 
e ffec t on ligand b ind ing . C oncentra tions o f S em a4D <50ng/m L fu r th e r in h ib it cell m ig ra tion , whereas a 
concentra tion  o f 5 0 n g /m L  increases cell m ig ra tion  adding to  the  e ffects  o f m u ta tion  A5359G o f P lex inB l. 
Results are m ean o f th re e  independen t experim ents w ith  standard e rro r o f the  mean (SEM). ANOVA 
sta tis tica l analysis has been applied using GraphPad softw are, which showed th a t the  e ffects o f the  
m u ta tion  and o f th e  presence o f ligand in the  medium  are s ign ifican t (p  va lues < 0 .0 0 1 ).
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Figure 5 1 : E ffec t o f  d if fe re n t c o n c e n tra tio n s  o f S em ap h o rin 4 D  p ro te in  on th e  m ig ra tio n  o f 
N IH 3 T 3  ce lls  s ta b ly  tra n s fe c te d  w ith  A 5 3 5 9 G -P le x in B l m u ta n t ( x D ) .  C oncentra tions o f 
Ong/mL, lO ng /m L , 2 5 n g /m L  and 5 0 ng /m L  o f Sema4D ligand w ere tes ted . Four random  fie lds  were 
counted under a m icroscope a t m agn ifica tion
4 . E ffec ts  o f th r e e  m u ta t io n s  o f P le x in B l on ce ll m ig ra tio n
Three replicated m ig ra tion  assay experim ents have then been perform ed to  
measure the  effects o f p lexin b l  m utations on cell m ovem ent.
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The results in figure  52 show th a t expression o f w ild -type  P lex inB l pro te in  inh ib its 
cell m igra tion, re la tive to cells not expressing exogenous P lex inB l (vec to r only, 
contro l). Expression o f the  A5359G m utan t form  o f P lex inB l (found in LNCaP) 
increases m igra tion  re la tive  to  w ild -type  P lexinB l in the  absence o f Sem aphorin4D, 
and fu rthe r increases m igra tion  in the presence o f Sem aphorin4D. Expression o f the 
T5714C m u tan t form  of P lex inB l also increases m igration re la tive  to  w ild -type  
P lexinB l and vecto r contro l in the  absence o f Sem aphorin4D, and in the  presence o f 
Sem aphorin4D m igra tion  is s ligh tly  increased fu rthe r. Expression o f the  A5653
m utant form  o f P lex inB l (the  m ost frequent in prosta te  p rim ary tum ours and
m etastases) s trong ly  increases m igration re lative to w ild -type  P lex inB l and vecto r 
contro l in the absence o f Sem aphorin4D, and in the presence o f 50ng /m L of 
Sem aphorin4D m igra tion  is reduced but still increased re la tive to  w ild -type  P lexinB l 
and vector contro l.
I I NO Ligand 
41 f~~1 +Sema4D:50ng/mL
Vector WT A5359G T5714C A5653G
F igure  5 2 : E ffe c t o f  th re e  m u ta tio n s  o f P le x in B l pro te in  and presence o f lig and  
S e m a p h o rin 4 D  on ce ll m ig ra tio n . NIH3T3 cells stab ly  transfected  w ith  w ild -typ e  
P le x in B l (W T -P lxB l) and P le x in B l m u tan ts  A5359G, T5714C and A5653G. A concentra tion  
o f 50ng /m L  o f S em aphorin4D  ligand was added. Results are mean o f th ree  independent 
experim ents  w ith  s tandard  e r ro r  o f th e  mean (SEM). ANOVA sta tis tica l analysis has been 
applied, w hich showed th a t th e  e ffects o f ligand and m uta tion  are s ign ifica n t (p  va lues <
0 .0 0 1 ).
5 . D iscussion
In  th is section, we report the  f irs t s tudy o f P lexinB l and Sem aphorin4D signalling 
in prostate cells and toge the r the  results suggest tha t P lexinB l has a role in p rosta te  
cancer.
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We show by quantita tive RT-PCR tha t plexin b l  mRNA is overexpressed in a 
prostate prim ary tum our cell line and a bone metastasis derived cell line and tha t 
overexpression in NIH3T3 cells o f w ild-type P lexinB l, activated either by clustering 
or low concentrations o f Semaphorin4D/ inhibits cell m igration, whereas high 
Semaphorin4D concentrations (50ng/m L in this model) increase cell m igration. Two 
other groups confirmed tha t PlexinBl activation inhibits cell m igration in NIH3T3 and 
Cos-7 cells (Barberis et al., 2004; Oinuma et al., 2006). However, two other groups 
have shown tha t PlexinBl activation can increase cell m igration in MLP29 cells and in 
endothelial ceils (Giordano et al., 2002; Basile et al., 2005). The effect of activation 
of P lexinBl on cell m igration therefore appears to be dependent on cell type and the 
signalling pathways expressed.
We also report tha t the three m utant forms of PlexinBl tested have an effect on 
cell m igration. Two mutations (A5653G and T5714C) are the most frequent 
mutations of plexin b l gene found in prostate primary tumours and metastases. The 
other mutation (A5359G) is found in LNCaP (Wong et al., 2007). These three 
mutations increase m igration o f cells overexpressing them in absence of 
Semaphorin4D. Two of the three plexin b l mutations (T5714C and A5359G) fu rthe r 
increase cell m igration in presence o f Semaphorin4D (50ng/mL).
In the laboratory, it has recently been shown that these three mutations hinder Rac 
and R-Ras binding and R-RasGAP activ ity  resulting in an increase in cell m otility , 
adhesion and lamellipodia extension. W ild-type PlexinBl binds RacGTP and 
sequesters it from downstream pathways (Vikis et al., 2000 and 2002). The active 
form  of Rac (RacGTP) controls lamellipodia formation and is therefore required fo r 
cell m igration. Thus, w ild-type PlexinB l protein prevents lamellipodia form ation and 
subsequent cell m igration by sequestering the active form of Rac. The m utant form s 
of PlexinBl do not bind RacGTP (O. Wong, personal communication), so expression 
o f the mutant forms of PlexinBl would be predicted to enhance cell m igration relative 
to  the w ild-type form . The increase in m igration o f cells expressing m utant forms of 
PlexinBl relative to w ild-type PlexinBl is therefore consistent w ith a loss of RacGTP 
binding and is consistent w ith the results presented. Oinuma and colleagues have 
shown tha t w ild-type PlexinBl binds R-RasGTP and acts as a GTPase activating 
protein (GAP), resulting in the conversion of R-RasGTP to its inactive GDP bound 
form (Oinuma et al., 2004). They have recently shown tha t R-RasGTP activates 
integrins (Oinuma et al., 2006). In tegrin  activation is required fo r cell m igration and 
inhibition o f R-Ras inhibits m igration. Mutant forms of PlexinBl do not bind R-RasGTP
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(Wong et al., 2007), and therefore do not inactivate R-Ras and do not inhibit the R- 
Ras/integrin pathway. This finding explains the loss of inhib itory function of the 
m utant forms of P lexinBl but not the gain of function (i.e. does not explain the 
increase o f m igration over vector control). Further experiments to explain gain o f 
function are required.
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Section 3: Cloning of semaphorin 3e gene and roles of Semaphorin3E 
______________protein on cell phenotype and behaviour______________
Until a recent and im portant finding (Gu et al., 2005), little  was known of 
Semaphorin3E protein, its receptor and its role. This group recently identified 
P lexinDl as a functional receptor for Semaphorin3E protein in endothelial cells, 
inducing the inhibition o f vessels form ation and repulsion of surrounding vessels. 
Before this finding, it was thought that, like all secreted semaphorins (class 3), the 
receptor fo r Semaphorin3E would be a complex made of a class A plexin and a dimer 
of neuropilins. This theory had never been proved, but it had been shown that 
Semaphorin3E protein binds to Neuropilin l (Feiner et al., 1997). Gu and colleagues, 
however, dem onstrate tha t Semaphorin3E protein does not bind to neuropilins (1 or 
2), but d irectly to class D PlexinDl.
We have shown in section 1 of this chapter tha t semaphorin 3e mRNA is 
synthesised by many prostate cell lines. Semaphorin 3e mRNA is expressed in the 
cell lines derived from two primary tum ours and the matched non-neoplastic 
"norm al" prostate epithelia and stroma (w ith a higher expression in the stromal cells 
than in the epithelial counterpart). Semaphorin 3e mRNA is expressed in three cell 
lines derived from metastases, with a strong expression in the bone metastasis 
derived cells. Semaphorin 3e mRNA is also expressed in cells derived from benign 
hyperplasic prostate (BPH), with a strong expression in the epithelial cell line 
compared to the matched stromal cell line. We have also shown tha t semaphorin 3e 
expression was under the control o f hypoxia in one of the matched primary tum our 
and non-neoplastic "norm al" cell lines, as well as in one colon cancer cell line. 
Semaphorin 3e mRNA expression levels were increased by hypoxia in the "norm al" 
prostate epithelial cells, while they were strongly decreased in the matched prim ary 
tum our cells and in the colon cancer cell line.
We studied semaphorin 3e mRNA expression profile in six paired non-neoplastic 
and carcinoma prostate tissue samples by real-tim e RT-PCR (qRT-PCR), w ith the aim 
o f determ ining if semaphorin 3e gene is d ifferentia lly expressed in prostate cancer. 
The complete coding sequence of semaphorin 3e gene was cloned into a mammalian 
expression vector and the protein produced. Subsequently, the effects of 
Semaphorin3E protein on cell behaviour and phenotype were studied by means of 
immunostaining and adhesion assays.
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1. Q u a n t ita t iv e  e x p re s s io n  le v e ls  o f s e m a p h o rin  3 e  m R N A  in p ro s ta te  ce ll 
lin es  an d  tis s u e s
Semaphorin 3e mRNA expression levels have been quantified by real-tim e RT-PCR 
(qRT-PCR) in 8 prostate cell lines and six tissue samples previously described. 
Quantitative RT-PCRs were performed in triplicate, and on three different RNA 
extractions (from three consecutive passages). The results presented are normalised 
means (refer to page 71) w ith standard errors o f the mean (SEM). Normalisation has 
also been performed to the expression levels found in the non-neoplastic ("norm al") 
prostate epithelial cell line (42N=1), used as a reference. Standard T-test statistical 
analysis has been applied using GraphPad software.
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Figure  5 3 : S em ap h o rin  3e  m RN A  express ion  p ro files  (q R T -P C R ) in 8 p ro s ta te  ce ll lin es , derived 
from  a p rim a ry  tu m o u r (1542CPTX o r 42C), the  m atched non-neop las tic  "n o rm a l"  ep ithe lia  (1542NPTX o r 
42N ) and s trom a (1542FTX o r 42F), m etastases to  th e  lym ph  node (LNCaP), th e  bra in  (D U 145) and the  bone 
(PC3), and benign hyperp las tic  ep ithe lia  (P re2.8) and s trom a (S 2 .1 3 ). Results are m ean o f th ree  replicates 
no rm alised to  42N expression levels, w ith  standard e rro r o f th e  mean (SEM). S tandard T- te s t has been 
applied ( * :  s ign ifica n t change :<  0 .05 ).
Cell lines Relative expression levels
42C 0.8
42N 1
42F 1.2
LNCaP 0.1
Dul45 0.3
PC3 3.2
Pre2.8 3.4
S2.13 0.1
T a b le  1 5 : R e la tiv e  exp ress io n  lev e ls  o f  
se m ap h o rin  3 e  m RN A  (q R T -P C R ) in 8 
p ro s ta te  cell lines.
The results in figure 53 (summarised in table 15) show the same trend as the RT- 
PCR results detailed in section 1 of this chapter (refer to pages 88 to 90).
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Semaphorin 3e mRNA expression levels are slightly higher in the stromal cells 
derived from normal prostate (42F) compared to the levels observed in epithelial 
cells (42N). The results also confirm that there is no significant difference in the 
levels of expression of semaphorin 3e between primary tum our derived prostate cells 
(42C) and the matched non-neoplastic "norm al" cells (42N). Also, the results show 
that semaphorin 3e expression levels are extremely low (10 fold decrease) in a cell 
line derived from a lymph node metastasis (LNCaP) and in stromal cells derived from 
BPH (S2.13), very low (more than 3 fold decrease) in cells derived from a brain 
metastasis (DU145) whereas they are strongly increased (more than 3 fold) in cells 
derived from a bone metastasis (PC3) and in epithelial cells derived from BPH 
(Pre2.8).
I I Carcinoma
I I Non-neoplastic
C 1/B2 C3/B4 C5/B6 C7 / B8 C9/B10 C11 /B12
Figure 5 4 : S e m a p h o rin  3 e  m RNA expression  p ro file s  (q R T -P C R ) in 6 p a ire d  n o n -n e o p la s tic /c a rc in o m a  
p ro s ta te  tis su e  sa m p le s . Results are mean o f th ree  rep licates fro m  one experim en t. No s ta tis tica l analysis has been 
applied. ________________________________________________________ ______________
Tissue Sample Relative expression levels PT GSC
C l 2.1 3a crB2 10.5 j
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T a b le  1 6 : R e la tiv e  expression  levels  o f sem ap ho rin  3e  m RNA  
(q R T -P C R ) In 6 pa ired  p ro s ta te  tis su e  sam p les . Tum our stage 
(pT) and Gleason score (GSC) are listed. A Gleason grade betw een 5 
and 7 describes w ell and m odera te ly  d iffe ren tia ted  tum ours . Tum ours 
are e ith e r con fined w ith in  the  prosta te  bu t Invo lv ing both lobes (2c) o r 
w ith  ex tracapsu la r extension (3a).
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The results in figure 54 and table 16 show tha t semaphorin 3e mRNA expression 
levels are 3 to 5 times higher in non-neoplastic tissue, compared to the carcinoma 
counterpart, and thus in 5 out of 6 paired samples. This may reflect the higher 
proportion o f stromal cells seen in normal prostate tissue compared to cancer, as 
higher semaphorin 3e expression was found qRT-PCR and RT-PCR in the stromal cell 
line (42F). These tissue samples are paired non-neoplastic and cancer regions of well 
and moderately differentiated prostate tum ours w ith no regional lymph node 
metastases. However, no association was seen between semaphorin 3e mRNA 
expression profile and the stage or Gleason score of the tumour.
2. Cloning o f sem aphorin 3e gene and production of Sem aphorin3E  
protein
Semaphorin3E protein is not commercially available. Thus, in order to produce 
Semaphorin3E protein, its complete cDNA sequence was amplified from the 
KIAA0331/pBLUESCRIPT phagemid, kindly provided by Tanaka (refer to page 60), by 
means of a PCR using specific primers (Inv itrogen), manually designed to contain the 
restriction sites o f K pn l and N o tl enzymes at the 3' and 5' ends. PCR products were 
then digested by the enzymes (Invitrogen, refer to page 56) and purified from the 
agarose gel using a gel extraction kit from  Qiagen (refer to page 57). The purified 
products (sema3e transgenes) were dephosphorylated by the CIAP enzyme (Gibco) 
before being ligated into the pEF6 mammalian expression vector (Invitrogen, figure 
55) using the T4 DNA ligase (Invitrogen) (re fer to  pages 73 to 75).
The recombinant vector containing the transgene, pEF6-Se/na3e-Myc/His was 
subsequently used to  transform  Escherichia Coli host strains (refer to page 65). The 
presence of the insert was checked in several colonies by PCR using the specific 
semaphorin 3e primers in order to elim inate false positives (figure 56). The insertion 
of the transgene was fu rther checked by PCR in two of those positive colonies (figure 
58), using primers located at the overlap transgene-vector (P I, P2, P3, P4, 
Invitrogen, refer to page 63) (figure 57). The cloned semaphorin 3e complete coding 
sequence was then verified by sequencing using specific and overlapping primers. 
The sequence of the transgene was checked using BLAST tool from the NCBI website 
(h ttp ://w w w ,ncb i.n im .n ih .aov/l . No m utations had been inserted during the cloning 
(figure 59).
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5.9 kb
Figure  5 5 : S chem atic  re p re s e n ta tio n  o f th e  m a m m a lia n  
exp ress io n  v e c to r p E F 6 /M y c -H ls  (ve rs ion  B, In v itro g e n ), w ith  
se m ap h o rin  3e  gene in serted  b e tw e e n  K p n l an d  N o t l  s ites .
F igure  5 6 : D ire c t PCR o f E.Coli co lon ies tra n s fo rm e d  w ith  p E F 6 -S e m a 3 e -M y c -H is . Some 
colonies ( fo r  exam ple  1 to  6) are positive  fo r  th e  presence o f th e  transgene (S em aphorin  3e), and 
some are negative.
1581
1661
1734
1800
1866
3'«f»d of hE F-1 .. Intron 1
GTTTGGATCT TGGTTCATTC TCAAGCCTCA GACAGTGGTT CAAAGTTTTT TTCTTCCATT TCAGGTGTCG TGAGGAATTA 
 ^  5 ' end o f hEF-1« Exon 2
T 7 pfCHnotof.frritning site A sp 7 1 8 l
GCTTGGTAtfT AATACGACTC ACTATAGGG^ GACCCAAGCT GGCTAG TTA AGC TTG' Gt |
L eu  S e r  L eu  Vi Insert
Sema3E
. .m y p i t o p *
GGG1GCC GCT CGA 
A la  /A la  A la  A rg
B s B  I
 TE  t t c
H is  P r o  P h e
Po<yh»stidifwi tag
GAA CAA AAA CTC ATC TCA GAA GAG GAT CTG AAT ATG CAT ACC GGT CAT CAT CAC CAT CAC CAT TGA 
G lu  G in  L y s  L eu  l i e  S e r  G lu  G lu  A sp  L eu  A sn M et H is  T h r  G ly  H i s  H is  H is  H is  H i s  H is  ***
P m e  I pcONATt-I.BGH revefse prim ing a te
GTTTA AACCCGCTGA TCA 3CCTCGA CTGTGCCTTC T? 3TTGCCAG CCATCTGTTG TTTGCCCCTC CCCCGTGCCT
1941 TCCTTGACCC TGGAAGGTGC CACTCCCACT GTCCTTTCCT AATAAAATGA GGAAATTGCA TCGCATTGTC
Figure 5 7 : S ch e m a tic  re p re s e n ta tio n  o f th e  m u ltip le  cloning s ite  o f p E F 6 -S e m a 3 e -M y c -H is . In  pu rp le , the  
fo rw ard  T7 p ro m o te r/p rim in g  site  p r im e r (P 1-T7) and the  reverse BGH-reverse prim ing  s ite  (P4-BGH). The black arrow s 
represent the  reverse P2-Sem a3e p r im e r located w ith in  exon 1 o f sem aphorin  3e gene, and th e  fo rw a rd  P3-Sem a3e 
p rim e r located in exon 17.
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Figure  5 8 : PCR o f DNA m in ip re p a ra tio n s  o f tw o  p o s itive  E.Coli colonies  
fo r  se m a p h o rin  3 e  tra n s g e n e . The fo llow ing  sets o f p rim ers w ere used: P l-  
T 7 /P 2 -E xo n l (expected band a t 65 0bp), P 3-E xon l7 /P 4-B G H  (expected band a t 
310bp). Colony 9 Is a tru e  positive  (presence o f both bands a t th e  expected 
size), w hereas co lony 4 is a false positive (o n ly  one band a t the  expected size).
M M M l
*A « C A  G C C C G A  A f t  A G A G ftA C C t C C  A CG 6  r, A GA A S r . r ,» C 4 A r , - C A  A C T  G ' S t C
ema3E insertlExon 1Vector
Fig u re  59 : S equ en cing  o f th e  re c o m b in a n t v e c to r  p E F 6-S em a3e -M yc -H is . The plasm id DNA was sequenced using 
the  fo rw ard  p rim e r P l-T 7 -p ro m o te r/p r im in g  s ite , located a t the  5 'end o f the  vec to r and th e  reverse p rim er P2-Sem a3e- 
E x o n l, located w ith in  the  f irs t exon o f th e  sem aphorin  3e gene.
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Cos-7 cells were then transfected with the recombinant mammalian expression 
vector pEF6-Sema3e-Myc/His to produce the protein. Several Cos colonies were 
checked for the presence of the transgene (figure 60). A positive colony was chosen 
for subsequent protein production. The recombinant Semaphorin3E protein is 
coupled to a Myc epitope and a His-Tag, which allow its detection and purification on 
a nickel column. Untransfected and mock transfected Cos-7 cells do not 
endogenously synthesise semaphorin 3e mRNA (results not shown).
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F ig u re  6 0 : RT-PCR  o f C os -7  ce lls  tra n s fe c te d  w ith  th e  e x p re s s io n  v e c to r  p E F 6 -S e m a 3 e -M y c -H is . Several clones 
expressed th e  sem aphorin  3e transgene. For each clone, a con tro l w ith  no reverse transcrip tase  enzym e has been 
pe rfo rm ed. Cos-7 cells and mock transfec ted  cells do no t express any sem aphorin  3e mRNA ( resu ltsno t shown).
After 72h incubation, the medium was collected and the presence of the secreted 
recombinant protein Sema3E-Myc/His was detected by western blotting (figure 61), 
using the 9E10 mouse anti-Myc antibody from  Santa Cruz Biotechnology (refer to 
page 64). The results show that Semaphorin3E protein is not detectable in the 
medium collected 72h after the transfection of Cos-7 cells by the recombinant 
mammalian expression vector pEF6-Sema3e-Myc/His (figure 61, lane D) w ithout 
concentration.
f
W I
Claudel
Figure 6 1 : W e s te rn  b lo t o f th e  m ed iu m  fro m  
tra n s fe c te d  C os -7  ce lls; d e tec tio n  o f th e  presence  
o f th e  re c o m b in a n t S e m a 3 E -M y c -H is  p ro te in  using  
Myc a n tib o d y . M edium  was concentra ted by u ltra - 
f iltra tio n . C: concentra ted  fra c tion  a fte r u ltra -filtra tio n , 
E: e lu ted fra c tio n , W1 and W 2: frac tions collected a fte r 
the  f irs t ( W l)  and second (W 2) washes. D: m edium  not 
concentra ted .
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In order to detect the recombinant protein produced by the transfected Cos cells, 
the medium had to be concentrated by u ltra filtra tion (Amicon Ultra Centrifugal Filter 
Device PL30, Millipore, refer to page 75). The results show tha t the presence of the 
recombinant Sema3E-Myc/His protein was then detectable in the concentrated 
fraction o f the collected medium (figure 61, lane C).
I t  has been shown tha t the activ ity of class 3 semaphorins is modulated by furin 
(Adams et al., 1997; Christensen et al., 2005). Furin is a proprotein convertase 
which has been shown to cleave various latent precursor proteins into the ir 
biologically active products, and whose cleavage recognition sequence is RX(K/R)R 
(figure 62). Im portan tly , the putative furin recognition sequence of Semaphorin3E 
protein is located between the sema domain and the immunoglobulin-like domain 
(figure 62). The presence o f furin protease in the medium of transfected Cos-7 cells 
could elim inate the Myc epitope and His-Tag of the recombinant Sema3E-Myc/His 
protein, which are both added at the 3'end of the protein, thus preventing its 
detection by western blotting. At first, we thought tha t the protein was undetectable 
in the collected medium because of a probable cleavage by furin  protease. Thus, in 
parallel, the recombinant protein was re-expressed in Cos-7 cells treated by an 
inh ib itor o f the furin protease (decanoyl-RVKR-chloromethylketone, Clontech, refer to 
page 75).
The results confirm tha t furin proprotein convertase cleaves the recombinant 
Sema3E-Myc/His protein, as we detect more protein in the medium treated w ith furin 
inhib itor than in the medium not treated w ith  the inhib itor (figure 63). Also, the 
presence o f the recombinant protein is undetectable in non-concentrated fraction, 
whether treated or not with furin inhib itor. Further experiments were therefore 
performed using concentrated aliquots o f collected medium containing the 
recombinant Semaphorin3E protein produced by Cos-7 cells in presence of furin 
protease inhibitor.
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MASAGHIITEEEWGYLLELWTGGHTADTTHPRERLSHKELENEN  
RTSIFHSPFGFEDLHTMLLDEYQERLFVGGRDLVYSLSLERISDGY 
KEIH WPSTALKMEECIMKGKDAGECAN YVRVLHHYNRTHLLTC  
GTGAFDPVCAFIRVGYHLEDPLFHLESPRSERGRGRCPFDPSSSFIS 
TLIGSBLFAGLYSDY WSRDAAIFRSMGRLAI1IRTBHDDERLLKEPK 
FVGSYMIPDNEDRDDNKVYFFFTEK A L.EAENN All AIYTRVGRLCV  
ND VGGQR II.VNK W STFLKARI.VCS VPGMNGIDTYFDF.LED VFEEP 
TRDHKNPVIFGLFNTTSNIFRGHAICVYHMSSIRAAFNGPYAHKEG  
PEYHWSVYEGKVPYPRPGSCASKVNGGRYGT 1KDYPDDAIRFARS 
F1PLM YQAIKPAHKKPILVK TDGK YNLKQIAVDRVEAEDGQYDVLF  
1GTDNGIVLK VITIYNQEMESMEEV1LEEEQIFK DP VP1ISM E1SSKRQ 
Ql.YIGSAS AVAQ VRFFIHCDM YGSACADCCLARDPYCAWDGISCSR 
YYPTGTHAKRRFRRQDVRHGNAAQQCFGQQFVGDALDKTEEHLA  
YGIENNSTLLECTPRSLQAKVIWFVQKGRETRKEEVKTDDRVVKM  
DLGLLFLRLHKSDAGTYFCQTVEHSFVHTVRK ITLEVVEEEK VPiDM 
FNKDDEEDRHHRMPCPAQSS1SQGAKP W YKEFLQL1G YSNFQRVEE 
Y( 1 KVW(  IDUKRKKLKMSPSKWKYANPQEKKLRSKPEHYRLPRH
TEDS
F igure  6 2 : T h e  fu r in  p ro te a s e  reco gn ition  sequence o f S e m a p h o rin 3 E  p ro te in . The sema dom ain 
o f Sem aphorln3E  p ro te in  Is h igh ligh ted  In ye llow , and spans 300 am ino acids (2 4 1 -5 4 0 ), the  
im m unog lobu lin  dom ain is h igh ligh ted  In p ink and spans 90 am ino  acids (6 4 7 -7 3 6 ). The fu rin  protease 
cleavage recogn ition  sequence Is located between these tw o  dom ains, in red (consensus sequence is 
RX(K/R)R).
Sema3E + Antt-Furin protease Sema3E - Anti Furin protease Vector + Anti-Furin protease
105
. I S * * *
, 50
•35
C D E W  C D E W  C D E W
Figure 6 3 : W e s te rn  b lo t o f th e  m ed iu m  o f C os -7  ce lls  tra n s fe c te d  w ith  th e  exp ress io n  v e c to r  pE F6- 
S e m a 3 e -M y c -H is  o r th e  v e c to r  on ly , an d  tr e a te d  o r n o t tre a te d  w ith  fu rin  in h ib ito r . Medium was 
concentra ted by u ltra -f iltra tio n . C: concentra ted  fra c tio n  a fte r u ltra -f iltra tio n , D: m edium  no t filte red , i.e. no t 
concentra ted , E: e lu ted  fra c tion , W: fra c tion  collected a fte r th e  f irs t w ash. The con tro l V ector -  A n ti- fu rin  protease is 
also negative (n o t show n).
Altogether, these results show th a t sem aphorin  3e cloning and production were 
successful. In  contrast, purifica tion  o f the  prote in using a nickel column was 
unsuccessful, probably because the  His tag was cleaved o r hidden (re fe r to  pages 75 
and 76). However, to tes t the  e ffects o f Sem aphorin3E prote in, it is not necessary to 
have it purified on a nickel colum n and it was therefore concentrated but not 
purified. Protein concentration was measured using the Lowry method (S igma, re fer 
to page 76) and estim ated by w estern b lo tting  (re fe r to  page 77), using the anti-M yc 
antibody (Santa Cruz B iotechnology, re fer to  page 64) (results not shown).
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3. Effects of Sem aphorin3A and Sem aphorin3E on the  m orphology and 
interactions of Cos-7 cells overexpressing P lex in A l and N e u ro p ilin l 
receptors or P le x in D l receptor
a. Actin m icro filam ent distribution in Cos-7 cells overexpressing P lex in A l 
and N eu ro p ilin l receptors or P lex in D l receptor
To test the effects of Semaphorin3E protein on cell phenotype and behaviour, 
Cos-7 cells have been transfected with expression vectors for PlexinAl/M yc and 
Neuropilin l/H A (Semaphorin3A receptors), or PlexinDl/VSV (Semaphorin3E 
receptor). Their expression was verified 48h a fte r transfection by immunostaining 
using prim ary antibodies against the ir tags (Myc, HA or VSV) and secondary 
antibodies conjugated with fluorescent green (FITC) or red (TRITC) dyes (refer to 
pages 64 and 79). Actin microfilaments were stained w ith phalloidin conjugated to a 
red dye (TRITC) and nuclei were stained in blue (DAPI). Cells were further treated 
for 30 minutes w ith or w ithout Semaphorin3A protein (4^g/m L) and w ith or w ithout 
Semaphorin3E (~4ng/ml_).
The results in figure 64 show that Cos-7 cells express the PlexinAl and 
Neuropilin l receptors (e, f, g), which co-localise at the plasma membrane (as shown 
by the yellow staining in e) or are expressed on d iffe rent cells. They also show that 
Cos-7 cells express P lexinDl receptor (h). However, not all the cells have been 
transfected with the receptors, as the transfection efficiency was less than 100%. 
Nonetheless, RT-PCR showed tha t Cos-7 cells endogenously express high levels of all 
three receptors (results not shown). Therefore, even if all cells are not transfected, 
we can still expect to see some effect w ith  Semaphorin3A and Semaphorin3E 
proteins.
The results in figure 65 show tha t actin m icrofilament distribution is different 
between Cos-7 cells transfected w ith P lexinD l receptor and those transfected w ith 
P lexinAl and Neuropilin l receptors. No stress fibers are observed in the cells 
transfected w ith PlexinDl receptor (g, h), whereas the cells transfected with PlexinAl 
and Neuropilin l present stress fibers (e, f). Addition o f the ligands, Semaphorin3A 
(a, b) o r Semaphorin3E (c) inhibits the form ation o f stress fibers in cells transfected 
with PlexinAl and N europ ilin l, which suggest that Semaphorin3E may bind 
N europilin l in our cellular system, as shown by Feiner and colleagues (Feiner et al.,
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1997). Addition of Semaphorin3E protein (d) does not induce stress fibers form ation 
in cells transfected w ith PlexinD l.
Altogether these results suggest that an overexpression of Semaphorin3A 
receptors, P lexinAl and N europilin l, lead to stress fibers form ation, which is 
inhibited by addition o f its specific ligand, Semaphorin3A, but as well by 
Semaphorin3E. In contrast, cell transfected by Semaphorin3E specific receptor, 
P lexinD l, do not show any stress fiber form ation, which may suggest that stress 
fiber formation is activated by Neuropilins rather than Plexins.
b. Effects o f Sem aphorin3A  and Sem aphorin3E on p i-in teg rin  activation in 
Cos-7 cells overexpressing P lex inA l and N e u ro p ilin l receptors or P lex in D l 
receptor
The effects of Semaphorin3A and Semaphorin3E proteins in cells overexpressing 
the receptors P lexinAl and Neuropilin l, or P lexinD l were also visualised by 
immunostaining using an antibody directed against active conformations o f human 
p l-in te g rin . Cell adhesion is mediated by integrins, which are transmembrane 
receptors interacting w ith the extracellular m atrix. For instance, a5p l-in tegrin  is the 
typical fibronectin receptor involved in m atrix attachm ent (Wu et al., 1993; Zhang et 
al., 1993; Danen et al., 2002).
The results in figure 66 show that Cos-7 cells overexpressing PlexinAl and 
N europilin l receptors stain for active p i-in te g rin  (d, e) in the cytoplasm. When 
treated with Semaphorin3E (b) or Semaphorin3A (a), these cells still stain for active 
p l-in tegrin . However, a sparse distribution o f the cells is observed when treated w ith 
Semaphorin3A, which would support the claim tha t Semaphorin3A protein inhibits 
p i-in tegrin  adhesion, as shown by Serini and colleagues (Serini et al., 2003). The 
effect of Semaphorin3A protein on active conformations of p l-in tegrins is less 
obvious under a microscope at a 40X magnification (figure 67, a and d). The results 
in figure 66 also show that Cos-7 cells overexpressing PlexinDl receptor stain for 
active p l-in teg rin  (f), but trea tm ent w ith Semaphorin3E strongly inhibits active p l-  
integrin staining (c). Even at a 40X magnification (figure 67, c and f), the effect of 
Semaphorin3E protein on p l-in te g rins  is visible, which suggests that the inhib itory 
effect o f Semaphorin3E is stronger than the inhibitory effect observed w ith 
Semaphorin3A.
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Altogether, these results confirm tha t PlexinAl and Neuropilin l receptors are not 
functional receptors for Semaphorin3E protein, as no effect is observed in cells 
overexpressing P lexinA l and N europ ilin l receptors and treated by Semaphorin3E. In 
contrast, P lexinAl and N europ ilin l are functional receptors for Semaphorin3A in Cos 
cells. The results confirm  tha t P lexinD l is a functional receptor fo r Semaphorin3E in 
Cos cells, which suggest tha t it m ight be the case in many other cellular systems, as 
already shown in endothelial cells by Gu and colleagues (Gu et al., 2005). The results 
also show tha t Semaphorin3E protein strongly reduces active p l-in tegrins  
immunostaining of cells overexpressing its functional receptor PlexinD l, suggesting 
that Semaphorin3E inhibits cell-m atrix adhesion, more strongly than Semaphorin3A 
does.
c. Effects o f Sem aphorin3A and Sem aphorin3E on vinculin in Cos-7 cells 
overexpressing P lex inA l and N e u ro p ilin l receptors or P lex in D l receptor
The effects o f Semaphorin3A and Semaphorin3E proteins in cells overexpressing 
the receptors PlexinAl and N europ ilin l, or P lexinD l were visualised by 
immunostaining using an antibody directed against vinculin. Vinculin is an actin- 
binding protein tha t links integrins to the actin cytoskeleton, modulating focal 
adhesion (FA) structure and function. Vinculin is ubiquitously expressed and is 
traditionally used as a marker fo r focal adhesion form ation, which has a punctate 
appearance by immunostaining (Zam ir and Geiger, 2001).
The results in figure 68 indicate tha t Cos-7 cells overexpressing p lexinA l and 
N europilin l receptors do not stain fo r vinculin at focal adhesions (e, f, g) because the 
marked typical punctate staining is detectable only when the cells were treated with 
Semaphorin3A protein (a, b). The results also show tha t Semaphorin3E protein does 
not lead to the form ation o f focal adhesions by Cos-7 cells overexpressing PlexinAl 
and Neuropilin l receptors (c), whereas it does in Cos-7 cells overexpressing P lexinDl 
receptor (d). Altogether, these results show tha t activation o f PlexinAl and 
N europilin l receptors by Semaphorin3A ligand, and activation o f P lexinDl receptor 
by Semaphorin3E ligand activate vinculin-mediated formation of focal adhesions.
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Figure 64 : Im m u n o s ta in in g  o f C os-7 ce lls  tra n s fe c te d  w ith  sem ap h o rin  recep to rs  P le x in A l/M y c  and N e u ro p il in l /H A  (a ,  c, e, f, and g ) o r P le x in D l/V S V  
(b , d, h ) (1 0 0 X  m ag n ific a tio n ), a: no p rim ary  an tibody, secondary rabb it an ti-m ouse FITC-conjugated. b: no p rim ary  an tibody, secondary goat an ti-ra b b it TRITC- 
con jugated. c, d: phallo id in-TR ITC -conjugated. A rrows po in t a t stress fibers, e, f, g: p rim ary  mouse an ti-M yc and rabb it an ti-H A  antibodies and secondary rabb it 
an ti-m ouse FITC-conjugated and goat a n ti-ra b b it TR ITC-conjugated. h: p rim ary  rabb it antl-VSV antibodies and secondary goat an ti-ra b b it TR ITC-conjugated.
1 ...   ...   (,         .
Figure 6 5 : P h a llo id in -T R IT C  im m u n o sta in in g  o f ac tin  m ic ro filam e n ts  (1 0 0 X  m ag n ific a tio n ). Cos-7 cells transfected  w ith  sem aphorin receptors P lex inA l and 
N e u ro p ilin l (a , b, c, e, f) o r P lex inD l (d , g, h) and trea ted  w ith  Sem aphorin3A prote in (a, b) o r Sem aphorin3E prote in  (c, d ). Cos-7 cells overexpressing P lex inA l and 
N e u ro p ilin l receptors present stress fibe rs  (a rrow s, e, f) ,  bu t none when they have been trea ted  w ith  Sem aphorin3A (a, b) o r Semaphorin3E (c). Cos-7 cells 
overexpressing P lex inD l do no t p resent stress fibers, w he the r trea ted  (d ) o r no t trea ted  w ith  Sem aphorin3E (g , h).
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F igure 6 6 : Im m u n o s ta in in g  o f p l- in te g r in  ac tive  co n fo rm atio n s  (1 0 0 X  m ag n ific a tio n ). Cos-7 cells transfected 
w ith  sem aphorin receptors P lex inA l and N e u ro p ilin l (a, b, d, e) o r P lex inD l (c, f)  and trea ted  w ith  Sem aphorin3A (a ) or 
Sem aphorin3E (b , c) prote ins. Cells expressing receptors P lex inA l and N e u ro p ilin l receptors stain fo r  active p l- in te g r in  
w he ther un trea ted  (d, e) or trea ted  w ith  Sem aphorin3A (a ) o r Sem aphorin3E prote in  (b ). Cells expressing P lex inD l 
recepto r s ta in fo r active p i- in te g r in  when un trea ted ( f) whereas tre a tm e n t w ith  Semaphorin3E prote in (c ) s trong ly  
inh ib its  p i- in te g r in  im m unosta in ing
cFigure 6 7 : Im m u n o s ta in in g  o f p l- in te g r in  ac tive  co n fo rm atio n s  (4 0 X  m ag n ific a tio n ). Cos-7 cells transfected  
w ith  sem aphorin receptors P lex inA l and N e u ro p ilin l (a , b, d, e) o r P lex inD l (c, f)  and trea ted  w ith  Sem aphorin3A (a ) o r 
Sem aphorln3E (b , c) prote ins. Cells expressing receptors P lex inA l and N e u ro p ilin l receptors s ta in fo r active p l- in te g r in  
w he ther un trea ted  (d, e) or tre a ted  w ith Sem aphorin3A (a ) o r Semaphorin3E prote in  (b ). Cells expressing P lex inD l 
recepto r stain fo r ac tive  p l- in te g r in  when un trea ted ( f) , whereas tre a tm e n t w ith  Semaphorin3E prote in (c ) Inh ib its p i -  
in tegrin  im m unosta in ing.
Figure 6$ : V incu lin  im m u n o sta in in g  (1 0 0 X  o r 4 0  X  m a g n ific a tio n s ). Cos-7 cells transfected w ith  sem aphorin receptors P lex inA l and N e u ro p ilin l (a , b, c, e, f, g ) o r 
P lex inD l (d , h) and trea ted  w ith  Sem aphorin3A (a, b) and Semaphorin3E pro te ins c, d). Cells expressing receptors P lex inA l and N e u ro p ilin l (e , f, g ) and trea ted  w ith  
Semaphorin3E prote in  (c ) do no t stain fo r v incu lin , w hereas those trea ted  w ith  Sem aphorin3A (a, b) do (do tted  s ta in ing). Cells expressing P lex inD l recepto r do no t stain fo r 
v incu lin  (h ) unless tre a ted  w ith  Sem aphorin3E prote in  (d ) (puncta te  sta in ing).
4. Effects o f Sem aphorin3A  and Sem aphorin3E on cell adhesion of 
HEK293 cells overexpressing P lex in A l and N eu ro p ilin l receptors or 
P lex in D l receptor
The adhesion o f ceils overexpressing PlexinAl and Neuropilin l receptors, and 
PlexinDl receptor was tested on two different substrates, over tim e (10 and 30 
minutes), and in presence or absence o f ligands (refer to pages 59, 67, and 80). 
HEK293 cells were chosen and th is  assay was optimised by us. Adhesion assays were 
performed on the lid of a 96 well plate (refer to page 80), coated w ith fibronectin, 
which mediates an integrin based adhesion, or poly-L-lysine, which mediates a non- 
integrin based adhesion. Adhesion was measured by absorbance (methylene blue 
staining of adhered cells) on a plate reader. Assays were performed in triplicate, and 
repeated three times independently. ANOVA statistical analysis has been applied 
using Graph Pad software.
a. Effect o f m atrix  and tim e on cell adhesion o f HEK293 cells
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Fioure 6 9 : Adhesion assay on tw o  d iffe ren t substrates, poly-L-lysine and fibronectin. HEK293 cells 
tra ns fec ted  w ith  th e  con tro l v e c to r pcDN A3. Results are mean o f th re e  Independent experim ents , w ith  s tandard  e rro r 
o f th e  mean (SEM). ANOVA s ta tis tica l ana lys is  has been app lied, w hich showed th a t th e  effects o f  m a trices and tim e  
are s ig n ifica n t (p  va lue  <  0 .0 0 1 ).
The results in figure 69 show tha t HEK293 cells mock transfected do not adhere to 
the plastic (PBS) nor to  poly-L-lysine substrate, whether in presence (lower panels) 
or absence (top panels) o f ligands, Semaphorin3A (right panels) or 3E (le ft panels).
145
Similarly, cells overexpressing PlexinAl and Neuropilin l receptors, or P lexinD l 
receptor do not adhere to plastic (PBS) nor to poly-L-lysine substrate whether in the 
presence or absence o f ligands (results not shown).
In contrast, HEK293 cells mock transfected adhere to fibronectin in presence 
(lower panels) or absence (top panels) of ligands, Semaphorin3A (righ t panels) or 3E 
(le ft panels), which suggest tha t HEK293 cells endogenously express the integrins 
which bind to fibronectin and th a t cell adhesion is mediated by integrins. 
Additionally, a significant increase in cell adhesion is observed over time (p value 
<0.001), which suggest tha t cell adhesion increases with tim e with or w ithout ligand.
b. E ffe c t o f S e m a p h o r in 3 A  a n d  S e m a p h o r in 3 E  on  ce ll a d h e s io n  o f  H E K 2 9 3  
c e lls  o v e re x p re s s in g  P le x in A l  a n d  N e u r o p i l in l  re c e p to rs  o r  P le x in D l  
re c e p to r
The results presented are normalised means w ith standard errors of the mean 
(SEM) (refer to page 81). Normalisation has been performed to the absorbance 
found in the mock transfected cells untreated by ligand (M o ck= l).
Mock
PlexinD l
PlexinAl/Np-1
M ock P le x in D l
10'-/+3 A
PlexinAl/Np-1 PlexinD l
30 -/+3A
PlexinA1/Np-1
Mock PlexinDl P!exinA1/Np-1 Mock PlexinDl PlexlnA1/Np-1
10'-/+3E 30V+3E
F igure  7 0 : A dh esio n  as s a y  o f H E K 2 9 3  c e lls  tra n s fe c te d  w ith  P le x in A l an d  N e u ro p ilin l recep to rs  
( P le x in A l /N p - 1 )  o r  P le x in D l r e c e p to r  a n d  t r e a te d  w ith  S e m a p h o rin 3 A  o r S e m a p h o rin 3 E  fo r  1 0  m in u te s  
and 3 0  m in u te s . Results are  m ean o f th re e  inde pen den t exp erim e n ts , w ith  s tandard e rro r o f th e  mean (SEM). 
ANOVA s ta tis tica l ana lys is  has been ap p lied , w h ich  showed th a t th e  effects  o f recepto r, ligand, and tim e  are 
s ig n ifica n t (p  va lue  < 0 .0 0 1 ).
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The results in figure 70 show tha t cell adhesion to fibronectin o f untransfected 
HEK293 cells is reduced by approximately 2 fold following incubation w ith 
Semaphorin3A (top panels), whereas in the presence of Semaphorin3E protein cell 
adhesion of HEK293 cells is not significantly changed (lower panels). HEK293 cells 
express low levels of P lexinA l and NP1 (M. Williamson, personal communication) and 
so the decrease in adhesion observed in untransfected HEK293 cells in response to 
Semaphorin3A is likely to be a result of activation of the endogenous receptors. In 
contrast, HEK293 cells express undetectable levels of p lex inD l, accounting for the 
minimal response of untransfected HEK293 cells to Semaphorin3E.
The results also show tha t cell adhesion to fibronectin o f HEK293 cells 
overexpressing PlexinAl and N europ ilin l receptors or PlexinDl receptor is reduced 
by approximately 2 fold relative to vector controls, whether in the presence or 
absence of the ir respective ligands, Semaphorin3A and Semaphorin3E (figure 70). I t  
has previously been shown tha t overexpression of certain plexins results in receptor 
clustering and mimics ligand binding (Giordano et al., 2002). Plexins are indeed 
activated by clustering of the ir ligands. Our results suggest tha t overexpression of 
PlexinAl and N europ ilin l or P lexinD l may act sim ilarly, by clustering thus mimicking 
ligand binding, the receptors are activated and the signal is transduced, in this case 
inhibition of cell adhesion to fibronectin. Adhesion to fibronectin is mediated by 
integrins, suggesting tha t activation o f these receptors results in the inhibition of 
integrin activity. Previously, we have shown tha t Semaphorin3E inhibits p i-in teg rin  
immunostaining o f Cos-7 cells overexpressing P lexinD l receptor, and Semaphorin3A 
also, although to a lesser extent, inhibits ac tiva ted-p i-in tegrin  immunostaining of 
Cos-7 cells overexpressing PlexinAl and N europ ilin l receptors.
Altogether, these results show tha t both Semaphorin3A and 3E strongly inhibits 
p l-in tegrin-m edia ted cell adhesion to  fibronectin through the ir functional receptors.
5. Discussion
In this section, we report the expression profiling o f semaphorin 3e mRNA in 
prostate cell lines and tissue samples, as well as the cloning and production of 
Semaphorin3E protein, and the study of its effects on cell morphology and 
behaviour.
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Expression levels o f semaphorin 3e mRNA were assessed by quantita tive RT-PCR 
in the same 8 prostate cell lines as previously described, as well as in the six paired 
non-neoplastic and carcinoma prostate tissue samples. The results confirm the RT- 
PCR results from section 1, i.e. semaphorin 3e mRNA expression levels are higher in 
the non-neoplastic "norm al" prostate stromal cell line than in the epithelial 
counterpart. In  contrast, in benign hyperplasic prostate (BPH), there is a stronger 
expression of semaphorin 3e in the derived epithelial cell line than in the stromal 
counterpart, which may suggest roles for Semaphorin3E protein in BPH development. 
Further experiments could include immunostaining of normal prostate and BPH 
tissues with antibodies directed against Semaphorin3E protein and its receptor 
PlexinD l, to appreciate the ir d istribution in situ. BPH is a benign enlargement of the 
prostate tha t originates w ithin the transition zone of the gland, whereas the 
peripheral zone is a most frequent site o f cancer. Interestingly, semaphorin 3e 
expression levels found in six non-neoplastic tissues surrounding cancers (graded 5 
to 7) were 3 to 5 times higher than w ith in  the tumours themselves. This may reflect 
the (q)RT-PCR results obtained w ith  the cell lines, i.e. prostate primary tum our and 
matched non-neoplastic epithelial cell lines express sim ilar levels of semaphorin 3e 
mRNA, whereas the matched non-neoplastic stromal cell line and normal prostate 
tissue, which has more stroma express higher levels than the epithelial counterpart. 
I t  would be o f interest to appreciate the distribution o f Semaphorin3E and its 
receptor by immunostaining in situ.
In the prostate cancer cell line derived from  a bone metastasis, mRNA expression 
levels o f semaphorin 3e are higher than in the non-neoplastic "norm al" prostate cell 
line. In contrast, they are much lower in the other two prostate cancer cell lines 
derived from a lymph node and brain metastases, which may suggest that 
Semaphorin3E may be involved d iffe ren tly  in prostate metastasis depending on the 
secondary sites invaded. Further experiments to understand the roles of 
Semaphorin3E in cancer metastasis could include orthotopic xenografts of PC3 cells 
(derived from a bone metastasis) in mice, w ith or w ithout siRNA to Semaphorin3E to 
determine the effects o f Semaphorin3E knockdown on metastasis formation to the 
bone. In  addition, the effects o f overexpressing Semaphorin3E in non-neoplastic 
"norm al" prostate cells xenografts on tum our formation could be investigated.
To elucidate the roles o f Semaphorin3E protein on cell morphology and behaviour 
in general, its complete cDNA sequence was cloned into a mammalian expression 
vector (pEF6/Myc/His), the protein produced, and used to assess integrin and focal
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adhesion form ation by immunostaining o f active p l-in te g rin  and vinculin, and 
adhesion to  fibronectin by adhesion assays.
The results show tha t P lexinA l and Neuropilin l are functional receptors fo r 
Semaphorin3A and th a t P lexinD l is a functional receptor for Semaphorin3E protein, 
which support findings in endothelial cells (Gu et al., 2005). In  addition, the results 
show that overexpression o f P lexinA l and Neuropilin l receptors by Cos-7 cells leads 
to stress fiber form ation, whereas no stress fibers were observed w ith 
overexpression of P lexinD l. Addition o f Semaphorin3A or Semaphorin3E ligands 
inhibited stress fiber form ation in cells overexpressing PlexinAl and Neuropilin l 
receptors. I t  has previously been shown tha t RhoAGTPAse is implicated in stress fiber 
formation and cell-m atrix adhesion (Ridley and Hall, 1992; Rottner et al., 1999). 
Thus we may hypothesise tha t overexpression of P lexinAl and/or Neuropilin l may 
activate RhoAGTPases, while the addition o f ligand reduces their activity. We could 
go fu rther and suggest tha t RhoAGTPase activation may be activated only by 
Neuropilin l, as results showed tha t Semaphorin3E also reduces stress fiber 
formation in ceils overexpressing P lexinA l and/or N europ ilin l. I t  has already been 
shown that Semaphorin3E binds to N europ ilin l (Feiner et al., 1997), however, it has 
never been shown tha t Semaphorin3E binds to P lexinAl, in presence or absence of 
Neuropilins. Thus, these results may confirm  tha t Semaphorin3E and Neuropilin l 
interact, and tha t the result of such interaction is a reduction in RhoAGTPase activity. 
This may suggest that N europ ilin l is able to affect RhoA activ ity via a co-receptor 
w ith sufficient cytoplasmic domain. Further experiments to understand the 
downstream effects o f neuropilin activation by semaphorins in prostate cancer cells 
are required.
Moreover, the results confirm  tha t Semaphorin3A protein reduces active p l-  
integrins immunostaining o f cells overexpressing its functional receptors, as already 
suggested by Serini and colleagues (Serini et al., 2003). Additionally, we show that 
Semaphorin3E also reduces active p l-in teg rins  immunostaining of cells 
overexpressing its functional receptor, and thus with a stronger effect than 
Semaphorin3A. In te resting ly, Semaphorin3E through Neuropilin l has no effect on 
active p l-in teg rins  im m unostaining o f cells overexpressing PlexinAl and/or 
Neuropilin l, whereas an effect on stress fiber formation was observed. These results 
may suggest tha t stress fiber form ation and cell adhesion are regulated by d ifferent 
pathways. The reduction in stress fiber formation may come from a reduction in Rho 
activity, whereas the reduction in integrin activity would be through some other
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pathway. In tegrin  activ ity  and avidity is controlled by many pathways (called inside- 
out signalling) including PI3K and via RAP1, RhoA, DOCK2 and R-Ras (Kinashi, 
2005). Further experiments to  decipher which pathways may be involved in these 
processes are required.
Also, the results show tha t both Semaphorin3A and Semaphorin3E ligands 
activate vinculin specific punctate staining, which suggest tha t both semaphorins 
modulate focal adhesion form ation. Vinculin plays a key role in cell m igration by 
strengthening focal adhesions and promoting cell spreading and lamellipodia 
extension (Xu et al., 1998). Thus, our results would suggest that both semaphorins 
play roles in cell m igration. Vinculin regulates cytoskeletal dynamics, promoting actin 
polymerization and recru itm ent o f cytoskeletal proteins. Racl stimulates the 
formation of lamellipodia (Nobes and Hall, 1995). Further experiments, such as 
m igration assays, or lamellipodia form ation are necessary to study the roles of 
Semaphorin3A and 3E on the various steps of cell m igration.
The adhesion assays results show tha t activation of P lexinAl and/or Neuropilin l 
receptors, and activation o f P lex inD l, e ither by clustering or by addition of the ir 
respective ligands, inhibits ceil adhesion to fibronectin. Cell adhesion is mediated by 
integrins, which are cell surface proteins tha t bind and mediate adhesion to the 
extracellular m atrix (ECM), organise the cytoskeleton and activate intracellular 
signalling pathways small GTPases o f the Rho fam ily (Schwartz and Shattil, 2000). 
Each integrin is formed of one a and one p subunit (18a and 8(3 subunits). Different 
combinations bind distinct ECM ligands. Integrins exist in an inactive and active 
form. Activation is required fo r ECM binding.
At firs t sight, the above results may appear contradictory, as adhesion to the ECM 
is mediated by focal adhesions and activation of integrins (part o f the focal 
adhesions). However, cell m ovem ent is a dynamic and complicated process which 
involves up to 50 d iffe rent proteins in the formation and maintenance of focal 
adhesion complexes. D ifferent types of integrins may be implicated at various stages 
of focal adhesion form ation. For instance, other p-integrins (p2- to p8-integrins for 
example), which do not form  the receptor for fibronectin (p i- in teg rin ), may be 
activated in focal adhesion form ation, cell-cell attachment, and lamellipodia 
form ation. Further experim ents to elucidate which integrins are involved in focal 
adhesion form ation o f cells activated by semaphorin signalling pathways could 
include adhesion experim ents to diverse substrates, such as collagen and vitronectin.
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Altogether, our results suggest tha t Semaphorin3A and Semaphorin3E inhib it 
integrin-mediated cell adhesion to a fibronectin m atrix and in itiate cell m otility, most 
probably through regulation o f small GTPases. Oinuma and colleagues have shown 
that PlexinBl acts as a RasGAP and inactivates R-Ras (Oinuma et al., 2004b), which 
is an activator o f integrins. Activation o f P lexinBl therefore inhibits integrins via R- 
Ras. PlexinDl could possibly operate via a sim ilar mechanism, although PlexinAl 
does not bind R-Ras. P lexinA l and /or N europ ilin l overexpression causes stress fiber 
formation, whereas P lexinD l overexpression does not. Further experiments to 
elucidate the mechanism o f action o f Semaphorin3E could include interaction 
experiments. For example, looking at the effects of Semaphorin3E on cells 
transfected w ith N europ ilin l only, and study Neuropilin l interaction with integrins. 
To understand the roles o f Semaphorin3E in tumourigenesis and/or metastasis, the 
effect of semaphorin3E on cell m o tility  and lamellipodia formation could be 
investigated using transwell m igration and cell spread assays. Finally, to investigate 
the roles o f Semaphorin3E in prostate cells, it would be o f interest to overexpress 
Semaphorin3E in the matched non-neoplastic "norm al" and primary tum our cell 
lines, and measure the effects on in tegrin-m ediated cell adhesion to fibronectin, and 
cell m igration (m igration assays) fo r example.
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CHAPTER 4: CONCLUSIONS AND FUTURE WORK
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This thesis summarises the research work performed between Oct-2001 and Mar- 
2005, aiming at understanding the expression, regulation and roles of semaphorins 
and the ir receptors in normal prostate, prostate cancer and metastasis. Because of 
the ir roles as a ttractive and repulsive cues, semaphorins may contribute to tum our 
progression and metastasis, which depend on the ability of cancer cells to in itiate 
angiogenesis, m igrate, and invade. Angiogenesis is under the control of vascular 
endothelial growth factors (VEGFs), which are up-regulated by hypoxia. Invasion is 
under the control o f scatter factor HGF, whose receptor MET is a member of the 
sema domain containing superfam ily. Semaphorins control cellular movement in 
various tissues, including the nervous, immune, and vascular systems. We may 
therefore hypothesise tha t semaphorins also play key roles in prostate tum our 
progression and metastasis by controlling the movement of cancer cells.
Although semaphorins have been extensively studied in many tissues, there are 
no studies showing the ir expression in prostate. Expression profiling experiments 
were therefore performed in prostate cell lines and tissues, by (q)RT-PCR, showing 
that messenger RNAs for secreted semaphorins 3a, 3b, 3c, 3e, 3f, and the receptors 
plexins a l,  a2, a3, b l ,  b3, and neuropilins 1 and 2 are synthesised by most prostate 
cell lines and tissues. Differences were found in the expression profiles of secreted 
semaphorins and receptors between strom al and epithelial cell types and between 
celis derived from normal prostate, BPH, prim ary tum our and metastases. Expression 
profiling experiments were also performed under hypoxic conditions in matched non­
neoplastic and prim ary tum our prostate cell lines, which showed for the firs t time 
that the expression of secreted semaphorins is controlled by hypoxia.
In cells derived from normal prostate under normoxic conditions, semaphorins 3a, 
3c, and 3e, as well as neuropilins 1 and 2 are preferentially synthesised by stromal 
cells, whereas plexin receptors are significantly reduced compared to epithelial cells. 
These results may suggest a paracrine regulation o f semaphorin signalling in 
prostate. Further experim ents to  demonstrate this hypothesis would include co­
culture experiments w ith  prostate strom al cells expressing semaphorin and prostate 
epithelial cells expressing the receptor. I f  the semaphorin secreted repels the 
epithelial cells, islands o f epithelia l cells should form. Also, immunohistochemistry of 
plexin and semaphorin could be performed on prostate tissue sections.
In cells derived from  bone metastasis under normoxic conditions, expression 
levels of both semaphorin 3a and its functional receptors plexin a l  and neuropilin 1
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are maintained at high levels, whereas they are significantly reduced in prostate 
primary tum our cells. A ltogether, these results may suggest an autocrine regulation 
of Semaphorin3A signalling in prostate metastasis to the bone. Serini and colleagues 
have shown tha t Semaphorin3A is a potent inhib itor o f angiogenesis, as its autocrine 
signalling negatively regulate endothelial cells m igration and facilitate cell 
reorientation by inhibiting integrin function (Serini et al., 2003). In contrast, Muller 
and colleagues have recently shown tha t Semaphorin3A promotes migration and 
invasion of pancreatic cancer cells (Muller et al., 2007). Our results, obtained in Cos 
and HEK cellular systems, confirm  tha t Semaphorin3A inhibits integrin activ ity and 
integrin-mediated cell adhesion, while it possibly activates cell spreading (focal 
adhesion form ation). Furthermore, expression profiling experiments under hypoxic 
conditions showed tha t semaphorin 3a expression is strongly downreguiated by 
hypoxia in cancer cells (prostate and colon), but not in normal cells (at 48h). These 
results may suggest tha t Semaphorin3A could also function as an inhib itor of 
angiogenesis in prostate, and as an activator o f prostate metastasis to the bone. 
Further experiments to study the roles o f Semaphorin3A and its autocrine signalling 
in prostate tum our form ation, metastasis to the bone, and angiogenesis would 
include in vivo experiments in mice, using normal prostate cell lines overexpressing 
Semaphorin3A or siRNA to Semaphorin3A.
Interestingly, expression levels under normoxic conditions of semaphorins 3b and 
3f, two tum our suppressor genes, are not significantly different between stromal and 
epithelial cells derived from normal prostate. In contrast, they are reduced in stromal 
and epithelial cells derived from  BPH, a benign enlargement of the prostate, and in 
cells derived from prostate, prim ary tum our. The loss of expression and/or m utation 
of semaphorins 3b and 3 f genes have also been reported in lung cancer (Tomizawa 
et al., 2001; Kuroki e t al., 2003), nasopharyngeal carcinoma (Liu et al., 2003), 
melanoma (Bielenberg e t a l., 2004; Chabbert-de Ponat et al., 2006) and 
neuroblastoma (Nair e t al., 2007). Noticeably, semaphorins 3b and 3f genes are 
located on chromosome 3p21.3, which is frequently lost (LOH) in prostate cancer 
(Dahiya et al., 1997). Additionally, our results show that expression levels o f 
semaphorin 3b are sign ificantly reduced in the three prostate metastases, and those 
of semaphorin 3 f are sign ificantly reduced in two out of three, the lymph node and 
brain metastases. In te resting ly , others have shown that Semaphorin3F is a potent 
metastasis inh ib itor th a t is markedly down-regulated in highly metastatic melanoma 
tum our cells (Kessler e t al., 2004; Bielenberg et al., 2004), where Semaphorin3F
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inhibits the form ation o f metastases in the lymph node and lung. By analogy, we 
could hypothesise tha t Semaphorin3F has a sim ilar role in prostate cancer metastasis 
to the lymph node. However, the cells derived from prostate metastases to the 
lymph node are not highly m etastatic in vivo. On the other hand, semaphorin 3 f 
expression levels are unchanged in prostate cells derived from bone metastases, 
which are highly m etastatic in vivo. This is contradictory w ith the findings in 
melanoma. Sim ilarly, we could hypothesise tha t Semaphorin3B play sim ilar inhib itory 
roles in prostate as its expression is significantly reduced in prostate cells derived 
from metastases. However, a group has recently demonstrated that Semaphorin3B, 
although inhibiting prim ary tum our growth, was increasing metastatic dissemination 
to the lung, by inducing the production o f In te rleukin 8 (IL8) by tum our cells, which 
results in the recruitm ent o f macrophages and metastasis (Rolny et al., 2008). 
Additionally, Semaphorin3F and 3B proteins have been shown to inhibit VEGF- 
induced endothelial cell pro life ra tion and angiogenesis (Kessler et al., 2004; Castro- 
Rivera et al., 2004). And Semaphorin3A and 3F have been shown to work together to 
repel endothelial cells and induce th e ir apoptosis (Guttmann-Raviv et al., 2007,). Our 
hypoxia results show tha t semaphorin 3f expression is not changed by hypoxia, 
neither in normal prostate cells nor in prim ary tum our cells. However, semaphorin 3f 
expression is decreased by hypoxia in another cancer cell line (colon), which 
suggests that its behaviour in prostate is specific. Also, the hypoxia results show tha t 
semaphorin 3b expression varies depending on the origin o f the cells and on the time 
spent under hypoxic conditions (biphasic expression in prostate).
Although contradictory, the above results may suggest that Semaphorins play 
different, even contradictory roles a t d iffe rent stages of tum our progression, and this 
would most probably depends on the strom al environment, i.e. on which molecules 
involved in the ir signalling are present (seed and soil theory, refer to page 28, 
Langley and Fidler, 2007). Some Semaphorins, like Semaphorin3B (Rolny et al., 
2008), may be able to foste r a pro-m etastatic environment, while still inhibiting 
tum our growth and angiogenesis. Others m ight have the opposite roles, like 
Semaphorin3C (see next paragraph). Such processes (tumourigenesis, metastasis, 
and angiogenesis) involve d iffe ren t signalling pathways. I t  would therefore be of 
great interest to study the pathways activated by secreted semaphorins signalling 
and investigate fu rthe r the roles o f the stromal environment on these signalling 
pathways. Further experim ents would also include in vivo experiments to look at the 
effect on tum our form ation and metastasis in mice, using normal prostate cell lines
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expressing siRNA to Semaphorin3B or 3F to knock down the expression of these 
proteins.
Expression profiling results under normoxic conditions showed tha t semaphorin 3c 
levels are not s ignificantly changed in prostate cancer and metastases cells, 
compared to normal levels, except in the cells derived from lymph node metastases, 
where they are reduced. Others have shown tha t Semaphorin3C is overexpressed in 
ovarian tum our cell lines w ith invasive and metastatic behaviour (Yamada et al., 
1997; Neufeld et al., 2005). And its expression was also found to be upregulated in 
metastatic lung adenocarcinoma cells, and in malignant melanoma cells, indicating 
that upregulation o f semaphorin 3c expression may be linked to tum our progression 
(Martin-Satue and Blanco, 1999; Rieger et al., 2003). Further experiments would 
therefore include qRt-PCR of semaphorin 3c mRNA and western blotting of the 
protein in prostate cell lines and tissues in order to see whether its expression is 
further enhanced in prostate cancer. Additionally, Semaphorin3C has also been 
shown to stimulate endothelial cell (EC) proliferation and survival, and enhance EC 
adhesion, directional m igration (increasing integrin activity, contrary to 
Semaphorin3A), and tube form ation in vitro (Banu et al., 2006). Expression profiling 
results under hypoxic conditions showed tha t hypoxia strongly upregulates 
semaphorin 3c expression in prostate prim ary tum our cells. We may therefore 
hypothesise that, in prostate, Semaphorin3C is likely to act as an angiogenic factor, 
and maybe have a s im ilar role to  VEGF. Its  role in cell m igration could be 
investigated using m igration assays. Further experiments would also include in vivo 
experiments to look a t the effect on tum our form ation, and metastasis in mice, using 
normal prostate cell lines stably transfected and overexpressing Semaphorin3C.
Expression profiling results under normoxic conditions revealed tha t expression 
levels of semaphorin 3e remain sim ilar to or are higher than normal prostate levels 
in cells derived from  BPH, prostate prim ary tum our, and bone metastases, while in 
cells derived from metastases at o ther sites (lymph node and brain), semaphorin 3e 
expression is significantly reduced. Semaphorin 3e expression has been positively 
correlated w ith the m etastatic ab ility  o f breast cancer cells, and it has been shown to 
promote metastasis grow th to  the lung (Christensen et al., 1998 and 2005). 
A ltogether these results suggest tha t Semaphorin3E may promote prostate cancer 
metastasis to the bone. Further experiments to look at the effects of Semaphorin3E 
on tum our form ation would include in vivo experiments. Christensen and colleagues 
suggest tha t Semaphorin3E paracrine stimulation promotes a local angiogenic
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response by stim ulating endothelial cells m igration, thus contributing to metastasis 
growth in the lung (Christensen et al., 2005). On the contrary, Gu and colleagues 
have shown th a t Semaphorin3E inhibits endothelial cell m igration in vivo (Gu et al., 
2005). Our results show tha t semaphorin 3e expression is strongly and progressively 
decreased in prostate cancer cells undergoing hypoxia, which would suggest that 
Semaphorin3E may act as an inh ib itor o f tum our angiogenesis, s im ilarly to 
Semaphorin3A, which is also downregulated by hypoxia in prostate cancer cells, and 
contrary to Semaphorin3C, known as a potent activator of angiogenesis, whose 
expression is strongly upregulated by hypoxia in prostate cancer cells. These results 
suggest tha t hypoxic regions w ith in prostate tumours, e ither directly downregulate 
semaphorin 3a and 3e transcrip tion (possibly through HIF1) or upregulate the 
expression o f an inhib itor, ye t to be determ ined, of semaphorin 3a or 3e expression. 
Further work would include prom oter reporter assay experiments to understand what 
downregulates semaphorin 3a and 3e, and upregulates semaphorin 3c transcription 
in hypoxic regions of cancer. In prostate, it has been shown tha t the metastatic 
potential o f cancer cells correlates w ith the expression of angiogenic factors 
(Aalinkeel et al., 2004). I t  would therefore be interesting to study how angiogenesis 
in prostate cancer is affected by secreted semaphorins.
Altogether, these expression profiling results under normoxic conditions suggest 
the presence o f autocrine and paracrine semaphorin signalling in normal prostate, 
BPH, prostate cancer and metastases, as most cell lines express the ligands and their 
receptors. Unfortunately a t the tim e these profiling experiments were performed, not 
all ligand and receptor complexes were elucidated (e.g. Semaphorin3E and PlexinD l, 
Semaphorin5A and PlexinB3), and thus not all ligands and receptors were screened. 
Further expression profiling experim ents, including the previously unknown receptors 
or ligands (e.g. plexin d l  and semaphorin 5a) would complete this sem i-quantitative 
analysis, and allow the selection o f some ligands and receptors whose expression 
levels are significantly changed in prostate, and to perform quantitative experiments 
(qRT-PCRs for example) on these selected molecules. Interestingly, PlexinDl 
receptor is also a functional receptor fo r Semaphorin3C in vivo. Sempahorin3C binds 
to P lexinAl, A2, and D l,  and also to both neuropilins (Banu et al., 2006). 
Semaphorin3A binds to  all three class A plexins and to Neuropilin l only. 
Semaphorin3F binds to P lexinA l and A3 and to both neuropilins. Semaphorin3B 
binds to both neuropilins and VEGF receptor 2. Semaphorin3E binds to P lexinDl and 
N europilin l, etc. The various ligand-receptor combinations probably activate different
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signalling pathways, and therefore have different effects on cell movement, tum our 
progression and angiogenesis. Studying semaphorin signalling would shed some light 
on the ir roles.
However, the main lim ita tions o f such expression profiling experiments are tha t it 
is only sem i-quantita tive  and it remains at a transcriptom ics level. Further 
experiments to confirm  these mRNA results a t the protein level would include looking 
at protein expression in the cell lines by western blotting and in prostate tissue 
sections by tissue m icroarray or im m unohistochem istry using antibodies to 
semaphorins and plexins. One o f the problems remains the availability of antibodies.
In order to understand the effects o f Semaphorin3E, whose protein is 
unfortunately not com m ercia lly available, we decided to clone its gene into a 
mammalian expression vector in order to obtain a recombinant protein that we could 
use in experiments aim ing a t understanding its roles in general (as not much was 
known about it), and, if  tim e allowed it, in prostate. The recombinant protein was 
produced in presence o f an ti-fu rin  protease to prevent Semaphorin3E cleavage and 
the loss o f the Myc and His tags, which allow its detection on a western blot. Furin 
modulates the repulsive ac tiv ity  o f semaphorins (Adams et al., 1997). For example, 
when Semaphorin3E is truncated a t its C-term inal m oiety by fu rin (-like) convertase, 
it converts the repelling signal into an inducer of invasive growth and lung 
metastasis, by mediating tum our-endothe lia l cells interaction, stim ulating lung 
endothelial cells m igration via E rk l/2  activation and thus contributing to a local 
angiogenic response (Christensen et a l., 2005). In our experiments, we used anti- 
furin protease inh ib itor to  avoid loosing the tags o f the recombinant Semaphorin3E 
protein, which may account fo r its repulsive activ ity  (inhibition of integrin function 
and cell adhesion). I t  would be o f in terest to study the effects o f the truncated form 
of Semaphorin3E on cell adhesion and spreading to complement this study.
Because Semaphorin3E purification on a nickel column failed when going to the 
large scale protocol, probably because of the cleavage o f the tag, and as other 
groups working on sem aphorins (fo r example 3F, Kessler et al., 2004) did not use 
purified proteins fo r th e ir biological assays, we decided to work w ith the conditioned 
medium also (using conditioned medium from untransfected cells as a control). As 
not much was known about Semaphorin3E protein signalling and roles, and as the 
prototype Semaphorin3A protein was well studied using simple cellular systems, we 
decided to use Semaphorin3A as a positive control for our experiments. I t  had jus t
158
been published tha t Semaphorin3A, and more generally secreted semaphorins 
control vascular morphogenesis by inhibiting integrin function (Serini et al., 2003). 
We therefore performed immunostaining experiments using commercially available 
anti-active-(31-integrin and anti-v inculin antibodies, as well as adhesion assays on 
various substrates, w ith  the aim to study the effects of Semaphorin3E on cell 
adhesion and m igration.
Immunostaining experim ents confirmed what others had shown, namely that 
PlexinAl and N europ ilin l are functional receptors for Semaphorin3A, and that 
PlexinDl is a functional receptor fo r Semaphorin3E (Takahashi et al., 1999, and Gu 
et al., 2005). The results also confirmed tha t Semaphorin3A inhibits active (31- 
integrin staining, as previously shown by Serini and Colleagues (Serini et al., 2003). 
Moreover, our results showed th a t Semaphorin3A activates vinculin staining, and 
tha t Semaphorin3E also inhib its active (31-integrin staining and activates vinculin 
staining. Additionally, adhesion assays showed tha t Semaphorin3A, or the 
overexpression of its receptors P lexinA l and N europ ilin l, inhibits integrin-mediated 
cell adhesion. Sim ilarly, Semaphorin3E, or the overexpression of its receptor 
PlexinD l, also inhibits in tegrin-m ediated cell adhesion. Altogether, these results 
suggest tha t Semaphorin3A and 3E may have sim ilar roles on cell movement, i.e. 
inhibiting ceil adhesion and activating focal adhesion form ation, suggesting a role in 
the initial steps o f cell spreading. Further experiments to study the effects of 
Semaphorin3E protein on cellu lar m ovem ent would include chemotaxis assays of 
prostate cancer cells to a gradient o f Semaphorin3E in Dunn chemotaxis chambers 
using tim e lapse video m icroscopy. This would allow the speed and direction of 
movement to be measured. The morphology would also be assessed and lamellipodia 
and stress fiber form ation m onitored. Then addition o f siRNA to p lexinD l receptor 
would allow us to study which signalling pathway is involved in prostate cancer.
Recently, Chauvet and colleagues have shown tha t gating of 
Semaphorin3E/PlexinD l signalling by N europ ilin l switches axonal repulsion to 
attraction during brain developm ent (Chauvet et al., 2007). They also show that 
PlexinDl is the predom inant binding partner fo r Semaphorin3E in the brain, and that 
Semaphorin3E binds N eu rop ilin l, which is in line w ith our results suggesting that 
Semaphorin3E binds N eu rop ilin l, thus inhibiting stress fiber form ation. Also, the 
authors have dem onstrated tha t Semaphorin3E acts as a bifunctional ligand in vivo, 
depending on the com position of the receptor complex; i.e. receptor is PlexinDl only, 
Semaphorin3E acts as a repellent; Neuropilin l in addition to P lexinDl switches
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Semaphorin3E signal from  repulsion to attraction. Additionally, Herman and Meadows 
have shown tha t cells derived from prostate metastases to the bone overexpressing 
Semaphorin3A or 3E exhib it an anti-invasive activ ity, i.e. inhibits adhesion and 
invasion, while in contrast, Semaphorin3C increase invasion and adhesion (Herman 
and Meadows, 2007a and 2007b). A ltogether, these results are in line w ith ours. 
Further experiments would include invasion and adhesion assays with cells 
overexpressing P lexinD l and N europ ilin l receptors to see whether Neuropilin l 
reverts the repulsive signal into an attractive  signal (enhanced adhesion). Herman 
and Meadows also showed th a t Semaphorin3E anti-invasive effect was reversible by 
regulating E-cadherin and p-catenin proteins, which suggest tha t semaphorins, 
cadherins, and catenins may in teract w ith each other during invasion. Along this 
line, Mol and colleagues have suggested tha t molecules controlling cell adhesion and 
m igration, such as E-cadherin, N-cadherin, p-catenin, integrins, focal adhesion 
kinase, connexins and m atrix  m etalloproteinases, may all be promising biological 
markers associated w ith the early stage m etastatic process in prostate cancer (Mol 
et al., 2007). A ltogether, these results may raise the possibility tha t Semaphorin3E 
could play m ajor roles in prostate metastasis and Semaphorins may be added to this 
list of biological markers in the near future. Further experiments could include 
overexpressing Semaphorin3E in normal prostate cells and studying the regulation of 
cadherins and catenins.
However, there are lim ita tions to these studies on Semaphorin3E tha t need to be 
addressed. For example, fo r the adhesion assay, it would be better to transfect less 
receptors DNA to lower the ir expression in order to obtain a ligand-dependant 
response. Also, d iffe rent substrates could be used, such as collagen, vitronectin, 
etc... Additionally, it would be interesting to knock down PlexinDl receptor to make 
sure that Semaphorin3E signals through PlexinD l to inhibit adhesion. Further 
experiment could also include a tim e course of integrin inactivation with 
Semaphorin3E treatm ent.
The invasive grow th program , which governs cancer cell invasion, is also under 
the control o f members o f the sema domain superfamily, the scatter factors receptor 
MET and its ligand HGF, and also the transmembrane Semaphorin4D protein and its 
receptor P lexinB l. P lexinB l and MET interact independently of the ir ligand, but 
activation o f P lexinB l by Semaphorin4D stimulates MET, which enhances invasive 
growth (Giordano et al., 2002). Interestingly, frequent missense mutations of plexin 
b l gene were detected in prostate tumours and metastases (Wong et al., 2007). Our
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migration assays results in cells overexpressing w ild-type PlexinBl showed that 
P lexinBl, activated either by clustering or low concentrations o f its ligand 
Semaphorin4D (<50ng/m L), inhibits cell m igration, whereas high Semaphorin4D 
concentrations (>50ng/m L) increase cell m igration. Three missense mutations of the 
plexin b l gene were studied using m igration assays. Two of the mutations studied 
(A5653G and T5714C) were the most common mutations found in prostate prim ary 
cancers and metastases. The o ther m utation (A5359G) was found in LNCaP, cells 
derived lymph node metastases. The results show tha t these three mutations of 
plexin b l  increase cell m igration in the absence of Semaphorin4D. Two of the three 
mutations (T5714C and A5359G) fu rthe r increase cell m igration in presence of 
Semaphorin4D (50ng/m L). We may therefore hypothesise tha t the control o f cell 
m igration by Semaphorin4D signalling pathway through PlexinBl may be harnessed 
by cancer cells during invasion and metastasis. To investigate which signalling 
pathways are required for the increase in m igration observed fo r the m utant forms of 
P lexinBl, the experiment needs to  be repeated in the presence or absence of 
inhibitors, for example to R-Ras, Rho, PI3K.
The main lim ita tion is tha t most o f the thesis is based on cell lines experiments in 
vitro. In  vivo experiments are more representative. To assess the expression of 
plexins and semaphorins, im m unohistochem istry experiments on prostate tissue 
sections would add to this study. And to assess tum our development and metastasis, 
in vivo experiments in mice should be performed.
The results obtained in th is thesis demonstrate tha t semaphorins and the ir 
receptors, plexins and neuropilins, are synthesised in prostate cells. They also 
suggest that the ir d istribution in normal prostate, prostate cancer and metastases, 
as well as in the benign enlargem ent (BPH) may play a role in the development of 
these diseases.
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APPENDIX 1
Semaphorin 3a:
- DU145 cell line:
TGKGGGGCTYTWRRWGMTGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGC
CCTTACTGCTATTT CM G C A AT G G AG CTTT CC ACTAAG C AG C A AC AACTATATATT G GTT C A AC
GGCTGGGGTTGCCCAGCTCCCrTTACACCGGTGTGATATTTACGGGAAAGCGTGTGCTGAG
TGTTGCCTCGCCCGAGACCCTTACTGTGCTTGGGATGGTTCTGCATGTTCTCGCTATTTTCCC
ACTGCAAAGAGACGCACAAGACGACAAGATATAAGAAATGGAGACCCACTGACTCACTGTTC
AGACTTACACCATGATAATCACCATGGCCACAGCCCTGAAGAGAGAATCATCTATGGTGTAG
AGAATAGTAGCACATTTTTGGAATGCAGTCCGAAGTCGCAGAGAGCGCTGGTCTATTGGCAA
TTCCAGAGGCGAAATGAAGAGCGAAAAGAAGAGATCAGAGTGGATGATCATATCATCAGGA
CAG AT CAAG G CCTT CTG CTACGTAGT CTACAACAG AAG GATT C AG G C AATTACCT CT G CCAT
G CGGT G G A AC AT G GGTT CATAC A AACT CTT CTTAAG GTAACCCT G G AAGT CATT G ACAC AG A
GCATTTGGAAGAACTTCTTCATAAAGATGATGATGGAGATGGCTCTAAGACCAAAGAAATGT
CC AAT AGC AT G AC ACCTAGCC AG AAG GT CT G GTAC AG AG ACTT CAT G CAG CT CAT CA ACC AC
CCC AAT CT CAACACA AT G G AT G AGTT CTGTG AAC AAGTTAAG G G CG AATT CC AG C AC ACTG G
CGGCCGTTACTAGTGGATCCGAGCTCGGTACCAAGCTTGATGCATAGCTTGAGTATTCTATA
GTGTCACCTAAATAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCC
GCTCACAATTCCACACACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGKGCCTAAT
GRGKGAGCTAACYCAMATTAAATTGSGTTGSGC
- 1542NPTX cell line:
TKSCCYYYWKWWKMAWGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGCCC
TTACT G CT ATTT CAG CAAT G G AG CTTT CC ACTAAG CAG CAACAACTATATATTGGTT CAACG G
CTGGGGTTGCCCAGCTCCCTTTACACCGGTGTGATATTTACGGGGAAGCACGTGCTGAGTG
TTGCCTCGCCCGAGACCCTTACTGTGCTTGGGATGGTTCTGCATGTTCTCGCTATTTTCCCAC
T GCAA AG AG ACGCAC AAG ACG ACAAG ATATAAG AAATGG AG ACCCACTG ACTC ACT GTT CA
GACTTACACCATGATAATCACCATGGCCACAGCCCTGAAAAGAGAATCATCTATGGTGTAGA
G AATAGTAG C ACATTTTT G G A AT G C AGT CCGAAGTCGCAGAGAGCGCTGGTCTATT G G CAAT
TCCAGAGGCGAAATGAAGAGCGAAAAGAAGAGATCAGAGTGGATGATCATATCATCAGGAC
AG AT CAAG G CCTT CTG CTACGTAGT CTAC AAC AG A AG GATT C AG G CAATTACCTCTG CCAT G
CGGTGGAACATGGGTTCATACAAACTCTTCTTAAGGTAACCCTGGAAGTCATTGACACAGAG
C ATTT GT A AG AACTT CTT CATAAAG ACG AT GATGGAGATGGCTCTAAG ACCA AAG AAATGT C
CAATAGCATGACACCTAGCCAGAAGGTCTGGTACAGAGACTTCATGCAGCTCATCAACCACC
CCAATCTCAACACAATGGATGAGTTCTGTGAACAAGTTAAGGGCGAATTCCAGCACACTGGC
GGCCGTTACTAGTGGATCCGAGCTCGGTACCAAGCTTGATGCATAGCTTGAGTATTCTATAG
TGTCACCTAAATAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCG
CTCACAATTCCACACAACATACGAGCCGGAAGCATAAGTGTAAAGCCTGGGTGCCTAATGAG
TGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAA
Semaphorin 3b:
- DU 145 cell line:
CSCMKCCSTGRMCGSST GTTT GT G G GT G CC RAG A ACCAT GT G G CCTCCCT C A ACCT G G AC A 
ACATCAGCAAGCGGGCCAAGAAGCTGGCCTGGCCGGCCCCTGTGGAATGGCGAGAGGAGT
180
GCAACTGGGCAGGGAAGGACATTGGTACTGAGTGCATGAACTTCGTGAAGTTGCTGCATGC
CTACAACCGCACCCATTTGCTGGCCTGTGGCACGGGAGCCTTCCACCCAACCTGTGCCTTTG
TGGAAGTGGGCCACCGGGCAGAGGAGCCCGTCCTCCGGCTGGACCCAGGAAGGATAGAGG
ATGGCAAGGGGAAGAGTCCTTATGACCCCAGGCATCGGGCTGCCTCCGTGCTGGKGGGGG
AGGAGCTATACTCAGGGGTGGCAGCAGACCTCATGGGACGAGACTTTACCATCTTTCGCAG
CCT AGG G CAACGTCCA AGT CT CCG AACAG AG A
- 1542NPTX cell line:
GTGGATTSTCGTGCKWAGTGGWGAGGAGCGTGGACGCCTGTTTGTGGGTGCCGAGAACCA
TGTGGCCTCCCTCAACCTGGACAACATCAGCAAGCGGGCCAAGAAGCTGGCCTGGCCGGCC
CCTGTGGAATGGCGAGAGGAGTGCAACTGGGCAGGGAAGGACATTGGTACTGAGTGCATG
AACTTCGTGAAGTTGCTGCATGCCTACAACCGCACCCATTTGCTGGCCTGTGGCACGGGAG
CCTT CCACCCA ACCT GTG CCTTT GTG G AAGTG G G CC ACCGGG CAG AG GAGCCCGTCCTCCG
GCTGGACCCAGGAAGGATAGAGGATGGCAAGGGGAAGAGTCCTTATGACCCCAGGCATCG
GGCTGCCTCCGTGCTGGTGGGGGAGGAGCTATACTCAGGGGTGGCAGCAGACCTCATGGG
ACGAGACTTTACCATCTTTCGCAGCCTAGGGCAACGTCCAAGTCTCSGGAACAGAGA
Semaphorin 3c:
- DU145 cell line:
CG SAGYAAG CACTKACKG W K W YAYYWTM Y W S A W YG ATRC AG AT CA RG ACCG G ATATAT GT 
G G G AAG CA AAG AT CAC ATT CTTT CCCT G AATATTAACAATATAAGTCAAG AAGCTTTG AGT GT 
TTT CTG G CC AGC AT CTAC AAT CAAAGTTG AAG AAT G C AA AAT G G CTG G C AAAG AT CCC AC AC 
ACGG CTGT GG G AACTTT GTCCGT GTAATT CAG ACTTT CAAT CG CAC ACATTT GTATGTCTGTG 
GGAGTGGCGCTTTCAGTCCTGTCTGTACTTACTTGAACAGAGGGAGGAGATCAGAGGACCA 
AGTTTT C ATG ATT G ACT CC AAGT GT G AAT CT G G AAA AG G ACG CTG CT CTTT C AACCCC A ACG 
TGAACACGGTGTCTGTTATGATCAATGAGGAGCI I I ICTCTGGAATGTATATAGATTTCATGG 
GGACAGATGCTGCTATTTTT CG A AGTTTAACC AAG AG G AAT G CG GT CAG AACTG AT CA AC AT 
AATT CCAAAT GG CTAAGT G AACCTAT GTTT GTAG AT G CAC AT GT CAT CCRAA W KG GTAC
- 1542NPTX cell line:
CCTWCCYTTRWSKACARGATTTTATTAATGGATGAAGATCAGGACCGGATATATGTGGGAA 
G C AAAG AT CAC ATT CTTT CCCT G AATATTAACAATATAAGTCAAG A AG CTTT G AGT GTTTT CT 
GGCCAGCATCTACAATCAAAGTTGAAGAATGCAAAATGGCTGGCAAAGATCCCACACACGG 
CT GT G G G A ACTTT GT CCGTGTAATT CAG ACTTT CAAT CG CAC ACATTT GTATGTCT GT G G G AG 
TGGCGCTTTCAGTCCTGTCTGTACTTACTTGAACAGAGGGAGGAGATCAGAGGACCAAGTTT 
TCATGATTGACTCCAAGTGTGAATCTGGAAAAGGACGCTGCTCTTTCAACCCCAACGTGAAC 
ACGGTGTCTGTTATGATCAATGAGGAGCI I I I CTCTGGAATGTATATAGATTTCATGGGGAC 
AGATGCTGCTAI I I I I CG A AGTTTAACCAAGAG G AAT G CGGT CAG AACT G ATC AACATAATT C 
CAAATGGCTAAGTGAACCTATGTTTGTAGATGCACATGTCATC
Semaphorin 3e:
- DU145 cell line:
181
CC M AGTYT G ACG ACT CATATTT CATAG CCCTTTT G G ATTT CTT G ATCT CCATAC A AT G CTG CT 
GGATGAATATCAAGAGAGGCTCTTCGTGGGAGGCAGGGACCTTGTATATTCCCTCAGCTTG 
GAGAGAATCAGTGACGGCTATAAAGAGATACACTGGCCGAGTACAGCTCTAAAAATGGAAG 
AATGC AT AAT G A AG G G AAA AG AT G CG G GT G A AT GT G C AA ATTAT GTT CG G GTTTT G C ATCAC 
TATA ACAG G ACAC ACCTT CTGACCTGTG GTACT G G AG CTTTT GATCC AGTTT GT G CCTT CAT C 
AGAGTTGGATATCATTTGGAGRATCCTCTGTTTCACCTGGAATCACCCAGATCTGAGAGAGG 
AAGGGGCAGATGTCCTTTTGACCCCASCTCCTCCTTCATCTCCACTTTAATTGGTAGTGAATT 
GTTTGCTGG ACTCTACAGTGACTACKG RAA
- 1542NPTX cell line:
CSAGAYTGACKCAMTSATATTTCATAGCCCTTTTGGAI I I Cl IGATCTCCATACAATGCTGCT 
GGATGAATATCAAGAGAGGCTCTTCGTGGGAGGCAGGGACCTTGTATATTCCCTCAGCTTG 
GAG AG A AT C AGT G ACG G CTATAAAG AG ATAC ACT GGCCGAGTAC AG CT CTAAA AAT G G A AG 
AATGCATAATGAAGGGAAAAGATGCGGGTGAATGTGCAAATTATGTTCGGGTTTTGCATCAC 
TATAACAG G ACACACCTT CT G ACCT GTGGTACT G G AG CTTTTG AT CC AGTTT GT G CCTT CAT C 
AGAGTTGGATATCATTTGGAGGATCCTCTGTTTCWCCTGGAATCACCCAKATCTGAKRGARG 
AAGGGGCAGATGTCCI I I TGACCCCAGCTCCTCCTTCATCTCCACTTTAATTGGTAGTGAATT 
GTTTGCTGG ACTCTACAGTRM CYTACTGGAA
Semaphorin 3f:
- DU145 cell line:
GGTMTCTGRSTGAKTTMGCATGGTCTTCAACGGGCCCTTWGCCCACRAMGAGGGGCCCAA 
CTACCAGTGGATGCCCWTCTCRKGSAASAYGCCCTACCCACSGSCGGGMMCRTGYCCTGGT 
G G A ACSTT C W M G CC ATSTRKG AAGT CC ACC AAG GATTATCCT G ATG AG GT GATCA ACYT CAT 
GCGCAKCCACCCACTCRTGTACCRSGCCKKGTACSCTCTRYRSMGGCGGCSCCTGGTARTC 
CGCACAGGTGCTCCCTACCGCCTTACCACTATTGCCGTGGACCAGGTGGATGCAGGCGAC
- 1542NPTX cell line:
AGCAGAGGTYTMTGGCTGWATTCGCATGGTCTTCACGGGCCCTTTGCCCACAAAGAGGGGC
CCAACTACCAGTGGATGCCCTTCTCAGGGAAGATGCCCTACCCACGGCCGGGCACGTGCCC
TGGTGGAACCTTCACGCCATCTATGAAGTCCACCAAGGATTATCCTGATGAGGTGATCAACT
TCATGCGCAGCCACCCACTCATGTACCAGGCCGTGTACCCTCTGCAGCGGCGGCCCCTGGT
AGTCCGCACAGGTGCTCCCTACCGCCTTACCACTATTGCCGTGGACCAGGTGGATGCAGGC
RMGTG
Plexin a l :
- 1542NPTX cell line:
TKKGGCTYYTWRAWKMWGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGCC
CTTTGCTGGACGCTGCCTACAAGGGCGTGCCCTACTCCCAGCGGCCCAAGGCCGCGGACAT
GGACCTGGAGTGGCGCCAGGGCCGCATGGCGCGCATCATCCTGCAGGACGAGGACGTCAC
CACCAAGATTGACAACGATTGGAAGAGGCTGAACACACTGGCTCACTACCAGGTGACAGAT
G GGT CCT CGGT G G CACT G GTG CCCA AG CAG ACGT CCG CCTAC AACAT CT CC AACT CCT CCA
CCTTCACCAAGTCCCTCAGCAGATACGAGAGCATGCTGCGCACGGCCAGCAGCCCCGACAG
182
CCTGCGCTCGCGCACGCCCATGATCACGCCCGACCTGGAGAGCGGCACCAAGCTGTGGCA
CCTGGTGAAGAACCACGACCACCTGGACCAGCGTGAGGGTGACCGCGGCAGCAAGATGGT
CTCGGAGATCTACTTGACACGGCTACTGGCCACCAAGGGCACACTGCAGAAGTTTGTGGAC
GACCTGTTTGAGACCATCTTCAGCACGGCACACCGGGGCTCAGCCCTGCCGCTGGCCATCA
AGTAC AT GTT CG ACTT CCTG G AT G AGC AG G CCG AC AAG CACCAG AT CCACG AT G CT G ACGT
GCGCCACACCTGGAAGAGCAACTGCCTGCAAGGGCGAATTCCAGCACACTGGCGGCCGTTA
CT AGT G G ATCCG AG CTCGGTACC AAG CTT G ATG CAT AG CTT G AGTATTCTATAGT GTC ACCT
AAATAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAAT
TCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGC
TAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGAAACCTGTCGTGCCAG
CTGCATTAATGAATCGGCCAACGCGCGGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCC
GCTT
Plexin a2:
- DU145 cell line:
TMWTTTWCTGGTGCTGTCACTCAACCCAATCCGAGGTCCCGAGTCARRARRSACTATGGTG
ACCATTACCGGCCATTACCWTGSGGCTRGGAGCAGCGTGGCAKTCTACCTGGGCAACCAGA
CCTG CG AGTT CTACGGG AG GT CAAT G AGTG AG AT CGT G YGT GT CT CACCCCC AT CAT C CAAT
GGCCTTGGCCCGGTCCCTGTTTCTGTGAGTGTCGACCGAGCCCATGTGGATAGCAACCTGC
AGTTTGAGTACATAGATGACCCTCGGGTCCAGCGCATCGAGCCAKAGTGGAKCATTGCCAG
TGGCCACACACCCCTGACCATCACAGGCTTCAACCTGGATGTCATTCAGGAGCCAAGGATCC
S AGTCA AATT CAAT G G C A AAK AAT CT GT CAAT GT GT G K A AAGTT GT G A AC AC AACC ACCCT C
ACCTGSCTGGSACCCTCTCTGACCACGGACTACCGCCCTGGCCTGGACACTGTGGAAMGCC
CAG AT G AGTTTGG ATTT GTCTTTA AC A ATGTCCAAT CCTT G CTAATTTACAACG ACACCAAGT
TTATCTACTACCCC AACCCG ACCTTTG AACTG CTTAG CCCTACT GG AGT CTT GG AT CAAAAG C
CAGGATCGCCCATCATTCTGAAGGGCAAAAACCTCTGCCCTCCTGCCTCTGGAGGGGCCAA
ACTCAAYTACACTGTGYTCAWCGGAGAGACCCCTTGTGCTGTCMCCGTATCTGAGACCCAG
CTA
- 1542NPTX cell line:
AMTACKATGAACCCTTCTGTGCTGTCACTCAACCCAATCCGAGGTCCCGAGTCAKGAGGCAC
TATGGTGACCATTACCGGCCATTACCTTGGGGCTGGGAGCAGCGTGGCAGTCTACCTGGGC
AACCAG ACCTGCG AGTT CTACG G G AG GT CAAT G AGT GAG AT CGT GTGT GTCTC ACCCCCAT
CAT CCAAT G G CCTTG G CCCG GT CCCT GTTT CT GT G AGT GT CG ACCG AGCCCAT GT G GATAG
CAACCTGCAGTTTGAGTACATAGATGACCCTCGGGTCCAGCGCATCGAGCCAGAGTGGAGC
ATT G CC AGTG GCCACACACCCCT G ACCAT CAC AGGCTTCAACCT G GAT GTCATT CAG G AGCC
AAGGATCCGAGTCAAATTCAATGGCAAAGAATCTGTCAATGTGTGTAAAGTTGTGAACACAA
CCACCCTCACCTGCCTGGCACCCTCTCTGACCACGGACTACCGCCCTGGCCTGGACACTGT
G G A ACGCCC AG AT G AGTTT G G ATTT GT CTTTAACAAT GTCCAATCCTT G CTA ATTTAC AACG A
CACCAAGTTTATCTACTACCCCAACCCGACCTTTGAACTGCTTAGCCCTACTGGAGTCTTGGA
TCAAAAGCCAGGATCGCCCATCATTCTGAAGGGCAAAAACCTCTGCCCTCCTGCCTCTGGAG
GGGCCAAACTCAACTACACTGTGCTCATCGGAGAGACCCCTTGTGCTGTCACCGTATCTGAG
AACCCAKMTATAAA
Plexin a3:
- DU145 cell line:
183
AMGTCTATGCCACGGGGCTGCTCAAGCAACTGCTGGCCGACCTCATCGAGAAKAACCTCKW
GAGCAAGAACCACCCCAAGCTGCTGCTACGCAKGACWGAGTCAGTGGCTRAGAAGATGCTT
ACCAACTGGTTCACGTTCCTGCTGCATAAGTTTCTGAAGGAGTGTGCTGGGGAGCCTCTCTT
CCTGCTTTACTGTGCCATCAAGCAGCAGATGGAGAAGGGCCCCATTGATGCCATCACGGGC
GAGGCACGATACTCCCTGAGCGAGGACAAGCTCATCCGTCAGCAGATCGACTACAAGACAC
TGACCCTTCACTGCGTGTGTCCGGAGAACGAGGGCAGCGCCCAGGTCCCAGTGAAGGTTCT
CAACTGTGACAGCATCACCCAGGCCAAAGATAAGCTGCTGGACACTGTGTACAAGGGCATT
CCGTACTCCCAGCGTCCCAAAGCTGAGGACATGGACCTGGAGTGGCGCCAGGGCCGCATG
ACTCGCTYCATCCTCC
- 1542NPTX cell line:
TGACTATGCCACGGGGCTGCTCAAGCAACTGCTGGCCGACCTCATCGAGAAGAACCTCGAG
AGCAAGAACCACCCCAAGCTGCTGCTACGCAKGACAGAGTCAGTGGCTRAGAAGATGCTTA
CCAACTGGTTCACGTTCCTGCTGCATAAGTTTCTGAAGGAGTGTGCTGGGGAGCCTCTCTTC
CTGCTTTACTGTGCCATCAAGCAGCAGATGGAGAAGGGCCCCATTGATGCCATCACGGGCG
AG G C ACG ATACT CCCT GAG CG AG G AC A AG CT CAT CCGT CAG CAG AT CG ACTAC AAG AC ACT
GACCCTTCACTGCGTGTGTCCGGAGAACGAGGGCAGCGCCCAGGTCCCAGTGAAGGTTCTC
AACTGTGACAGCATCACCCAGGCCAAAGATAAGCTGCTGGACACTGTGTACAAGGGCATTC
CGTACTCCCAGCGTCCCAAAGCTGAGGACATGGACCTGGAGTGGCGCCAGGGCCGCATGA
CTCGATYCMWTCCTCCC
Plexin b l:
- DU145 cell line:
AGMMGCTCWRGATGCATGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGCC
CTT G CT C ACCGT G S C ACT G CAT G G G AAG CTT G AGTATTT CACTG AC AT CCTCCGCACTCTGC
TCAGTGACCTGGTTGCCCAGTATGTGGCCAAGAACCCCAAGCTGATGCTGCGCAGGACAGA
GACTGTGGTGGRGAAGCYGCTCACCAACTGGATGTCCATCTGTCTGTATACCTTCGTGAGGG
ACTCCGTAGGGGAGCCTCTGTACATGCTCTTTCGAGGGATTAAGCACCAAGTGGATAAGGG
GCCAGTGGACAGTGTGACAGGCAAGGCCAAATACACCTTGAACGACAACCGCCTGCTCAGA
GAGGATGTGGAGTACCGTCCCCTGACCTTGAATGCACTATTGGCTGTGGGGCCTGGGGCAG
GAGAGGCCCAGGGCGTGCCCGTGAAGGTCCTAGACTGTGACACCATCTCCCAGGCAAAGG
AG AAG ATG CTG G ACC AG CTTTATA AAG G AGTG CCTCTC ACCCAG CG G CCAG ACCCTCG CAC
CCTTGATGTTGAGTGGCGGTCTGGAAGGGCGAATTCCAGCACACTGGCGGCCGTTACTAGT
GGATCCGAGCTCGGTACCAAGCTTGATGCATAGCTTGAGTATTCTATAGTGTCACCTAAATA
G CTT G GCGTAATC ATG GT CATAG CT GTTT C CT GT GT G AAATT GTTATCCG CT CAC AATTCC AC
ACAAC ATACG AG CCG G AAG CATA A AGTGTAA AG CCTG G G GTG CCTAATG AGTG AG CTA ACT
CACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGC
ATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTC
CTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGSGTATCAGCTCACTCAA
AG G CGGTATACGGTTAT CCAC AG A AT CAGGG G A W AACG CAG AAAG AACAT GT G ARC AAAG
G
Plexin b3:
- PC3 cell line:
184
GKSAGGCWRACCTAGTGGCAGCCTGCCCCCAGTTCCCTGACTGTGCCAGCTGCCTCCAGGC
CCAGGACCCGCTGTGTGGCTGGTGTGTCCTCCAGGGCAGGTGTACCCGGAAGGGCCAGTG
CGGGCGGGCAGGCCAGCTGAACCAGTGGCTGTGGAGTTATGAGGAGGACAGCCACTGCCT
GCACATCCAGAGCCTGCTGCCGGGCCACCACCCCCGCCAGGAGCAGGGCCAGGTCACTTT
GTCTGTCCCCCGGCTGCCCATCCTGGATGCAGATGAATACTTCCWTTGTGCGTTCGGGGAC
TATGACAGCTTGGCTCATGTGGAAGGGCCCCACGTGGCCTGTGTCACCCCTCCCCAAGACC
AGGTGCCACTTAACCCTCCAGGCACARACCACATCACTGTGCCCCTGGCCCTGATGTTCGAG
GACGTGACTGTGGCTGCCACCAACTTCTCCI I I IATGACTGCAGTGCCGTCCAGGCCTTGGA
GGCGGCTGCCCCGTGTCGCGCTTGCGTGGGCAGCATCTGGCGGTGTCACTGGTGCCCGCA
GAGTAGCCACTGCGTGTACGGAGAGCACTGCCCAGAGGGCGAGAGGACCATCTACAGCGC
CCAGGAGGTGGACATCCAGGTGCGTGGCCCAGGGGCTTGCCCACAGGTCGAARGYKKGSC
MRGGWY
Neuropilin 1:
- DU145 cell line:
GWSGWCAYCGACTACGAAACACATGGTGCAGGATTTTCCATACGTTATGAAATTTTCAAGA
GAGGTCCTGAATGTTCCCAGAACTACACAACACCTAGTGGAGTGATAAAGTCCCCCGGATTC
CCT G AAAAATATCCC AAC AG CCTT G AAT G CACTTATATT GT CTTT G CGCC AA AG AT GT CAG AG
ATTATCCTGGAATTTGAAAGCTTTGACCTGGAGCCTGACTCAAATCCTCCAGGGGGGATGTT
CTGTCGCTACGACCGGCTAGAAATCTGGGATGGATTCCCTGATGTTGGCCCTCACATTGGGC
GTTACTGTGGACAGAAAACACCAGGTCGAATCCGATCCTCATCGGGCATTCTCTCCATGGTT
TTTTACACCGACAGCGCGATAGCAAAAGAAGGTTTCTCAGCAAACTACAGTGTCTTGCAGAG
CAGT GT CT CAG AAG ATTT C AAAT GTAT G G AAG CTCTGG G CAT G G A AT C AG G AG AAATT CATT
CTGACCAGATCACAGCTTCTTCCCAGTATAGCACCAACTGGTCTGARAARCGCTMA
- 1542NPTX cell line:
CKKKGTSRGWGRTMTMTRACTACGARCACATGGKGCAGGATTTTCCATACGTTATGAAATTT 
TCAAGAGAGGTCCTGAATGTTCCCAGAACTACACAACACCTAGTGGAGTGATAAAGTCCCCC 
GG ATT CCCT G AAAAATAT CCC A AC AG CCTT G AAT GCACTTATATT GTCTTTG CRCCAAAG AT G 
TCAGAGATTATCCTGGAATTTGAAAGCTTTGACCTGGAGCCTGACTCAAATCCTCCAGGGGG 
GATGTTCTGTCGCTACGACCGGCTAGAAATCTGGGATGGATTCCCTGATGTTGGCCCTCACA 
TTGGGCGTTACTGTGGACAGAAAACACCAGGTCGAATCCGATCCTCATCGGGCATTCTCTCC 
AT G GTTTTTTACACCG ACAGCG CG ATAG C AA AAG AAG GTTT CT CAS CAAACTAC AGT GT CTT 
G CAG AG CAGTGTCT CAG A AG ATTT C AAAT GTATG G AAG CTCT G G G CAT G G AAT CAG GAG A A 
ATT CATT CTG ACCAG AT CAC AG CTT CTT CCC AGTATAG CACC AACT G GT CTG AG AA
Neuropilin 2:
- DU145 cell line:
CGKKGGCTYCWGATGCWGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGCC
CTTCTACATCAAGTYCACCTCCGACTACGCCCGGCAGGGGGCAGGCTTCTCTCTGCGCTACG
AGATCTTCAAGACAGGCTCTGAAGATTGCTCAAAAAACTTCACAAGCCCCAACGGGACCATC
GAATCTCCTGGGTTTCCTGAGAAGTATCCACACAACTTGGACTGCACCTTTACCATCCTGGC
CAAACCCAAGATGGAGATCATCCTGCAGTTCCTGATCTTTGACCTGGAGCATGACCCTTTGC
AGGTGGGAGAGGGGGACTGCAAGTACGATTGGCTGGACATCTGGGATGGCATTCCACATGT
TGGCCCCCTGATTGGCAAGTACTGTGGGACCAAAACACCCTCTGAACTTCGTTCATCGACGG
185
GGATCCTCTCCCTGACCTTTCACACGGACATGGCGGTGGCCAAGGATGGCTTCTCTGCGCG
TTACTACCTGGTCCACCAAGAGCCACTAGAGAACTTTCAGTGCAATGTTCCTCTGGGCATGG
AGTCTGGCCGGATTGCTAATGAACAGATCAGTGCCTCATCTACCTACTCTGATGGGAGGTGG
ACCCCTCAACAAAGCCGGCTCCATGGTGATGACAATGGAAGGGCGAATTCCAGCACACTGG
CGGCCGTTACTAGTGGATCCGAGCTCGGTACC AAG CTT G ATG CATAG CTT G AGTATT CTATA
GTGTCACCTAAATAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCC
GCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAAT
GAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTG
TCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGC
G CTCTTCCG CTTCCTCG CTC ACTG
- 1542NPTX cell line:
186
ABSTRACT
Prostate cancer (PCa) has become a m ajor public health issue; it is the second 
most common cause o f cancer-related death in the UK. PCa preferentially 
metastasises to the bone. Semaphorins are an important fam ily of membrane bound 
or secreted signalling proteins, which control cell movement (or chemotaxis). They 
have a role in the nervous, immune and vascular systems, but have not previously 
been studied in prostate. To determ ine if semaphorins and the ir receptors are 
expressed in normal and pathological prostate, profiling experiments were performed 
by (q)RT-PCR in prostate cell lines and tissues. Results show that semaphorins and 
receptors are ubiquitously expressed, suggesting autocrine and paracrine regulation 
of semaphorin signalling in prostate; particularly an autocrine signalling of 
Semaphorin3A in bone metastasis derived cells. Results also show that expression of 
secreted semaphorins is strongly regulated by hypoxia; which strongly down- 
regulates semaphorin 3e in prim ary tum our derived cells, whereas semaphorin 3c is 
strongly up-regulated. Particular focus was brought on semaphorin 3e, whose 
expression is strongly increased in epithelial cells derived from benign prostate 
hyperplasia, non-neoplastic tissue, and bone metastasis derived cells. A 
Semaphorin3E expression construct was made and the protein produced in 
mammalian cells to study its effects on cell morphology and adhesion by 
immunocytochemistry and adhesion assays. Results show that Semaphorin3E inhibits 
integrin-mediated cell adhesion while it initiates vinculin-mediated focal adhesion 
formation, which suggest that Semaphorin3E may play im portant regulatory roles in 
prostate cancer metastasis. The effects on cell movement of frequent missense 
mutations of PlexinBl receptor, associated with prostate primary tumours and 
metastases, was studied by m igration assays. Results show that the three mutations 
of PlexinBl increase cell m igration in absence of ligand Semaphorin4D, and further 
increase migration in its presence. Together these results suggest that semaphorin 
signalling has a key role in prostate cancer progression.
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